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A B S T R A C T
Background
Depression is a recurrent illness with high rates of chronicity, treatment-resistance and significant economic impact. There is evidence
in the literature that S-adenosyl methionine (SAMe), a naturally occurring compound in the human body, has antidepressant efficacy.
This product may be an important addition to the armamentarium of antidepressant agents.
Objectives
To assess the effects of SAMe in comparison with placebo or antidepressants for the treatment of depression in adults.
Search methods
We searched the Cochrane Common Mental Disorders Group’s Specialised Register (CCMDCTR Studies and Reference Register),
MEDLINE, EMBASE, PsycINFO, international trial registers ClinicalTrials.gov and the World Health Organization trials portal
(ICTRP). We checked reference lists, performed handsearching and contacted experts in the field. The CCMDCTR literature search
was last updated on 5 February 2016.
Selection criteria
Randomised controlled trials comparing SAMe with placebo or antidepressants in adults with a diagnosis of major depression.
Data collection and analysis
Two authors independently performed extraction of data and assessment of risk of bias. We contacted trialists of included studies for
additional information.
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Main results
This systematic review included eight trials comparing SAMe with either placebo, imipramine, desipramine or escitalopram. We
accepted trials that used SAMe as monotherapy or as add-on therapy to selective serotonin reuptake inhibitors (SSRIs), and we accepted
both oral and parenteral administration. The review involved 934 adults, of both sexes, from inpatient and outpatient settings.
The trials were at low risk of reporting bias. We judged the risk of selection, performance, detection and attrition bias as unclear or
low, and one study was at high risk of attrition bias.
There was no strong evidence of a difference in terms of change in depressive symptoms from baseline to end of treatment between
SAMe and placebo as monotherapy (standardised mean difference (SMD) -0.54, 95% confidence interval (CI) -1.54 to 0.46; P = 0.29;
142 participants; 2 studies; very low quality evidence). There was also no strong evidence of a difference in terms of drop-out rates
due to any reason between SAMe and placebo, when used as monotherapy (risk ratio (RR) 0.88, 95% CI 0.61 to 1.29; P = 0.52; 142
participants; 2 studies; low quality evidence).
Low quality evidence showed that the change in depressive symptoms from baseline to end of treatment was similar between SAMe
and imipramine, both as monotherapy (SMD -0.04, 95% CI -0.34 to 0.27; P = 0.82; 619 participants; 4 studies). There was also no
strong evidence of a difference between SAMe and a tricyclic antidepressant in terms of drop-outs due to any reason (RR 0.61, 95%
CI 0.28 to 1.31; P = 0.2; 78 participants; 3 studies; very low quality evidence).
There was little evidence of a difference in terms of change in depressive symptoms from baseline to end of treatment between SAMe
and escitalopram, both as monotherapy (MD 0.12, 95% CI -2.75 to 2.99; P = 0.93; 129 participants; 1 study; low quality evidence).
There was no strong evidence of a difference between SAMe and escitalopram in terms of drop-outs due to any reason (RR 0.81, 95%
CI 0.57 to 1.16; P = 0.26; 129 participants; 1 study; low quality evidence).
There was low quality evidence that SAMe is superior to placebo as add-on to SSRIs in terms of change in depressive symptoms from
baseline to end of treatment (MD -3.90, 95% CI -6.93 to -0.87; P = 0.01; 73 participants; 1 study). There was no strong evidence of
a difference between SAMe and placebo as adjunctive therapy to an SSRI in terms of drop-outs due to any reason (RR 0.70, 95% CI
0.31 to 1.56; P = 0.38; 73 participants; 1 study; very low quality evidence).
For all comparisons, secondary outcomemeasures of response and remission rates were consistent with these primary outcomemeasures.
With regard to all extractable measures of the acceptability of SAMe, the quality of the evidence was low to very low. SAMe was not
different from placebo and established antidepressants. The exception was that compared to imipramine, fewer participants experienced
troublesome adverse effects when treated with parenteral SAMe.
The specific adverse effects were not detailed in most of the included studies. There were two reports of mania/hypomania recorded
for 441 participants in the SAMe arm.
Authors’ conclusions
Given the absence of high quality evidence and the inability to draw firm conclusions based on that evidence, the use of SAMe for
the treatment of depression in adults should be investigated further. Future trials should be in the form of large randomised controlled
clinical trials of high methodological quality, with particular attention given to randomisation, allocation concealment, blinding and
the handling of missing data. Comparator antidepressants from all classes should be used. Adverse events should be detailed for each
participant, bearing in mind that induction of mania is of particular interest.
P L A I N L A N G U A G E S U M M A R Y
S-adenosyl methionine for depression in adults
Description of the illness
Depression is a common, recurrent mood disorder. Usually, affected people experience symptoms such as lowmood and a loss of interest
or pleasure. People with depression also often experience some of the following symptoms: weight loss or gain; a decrease or increase in
appetite, insomnia or hypersomnia; restlessness or fatigue as well as excessive guilt; feelings of worthlessness, poor concentration and
indecisiveness; recurrent thoughts of death and suicidal thoughts. The medicines most often used in the treatment of depression are
antidepressants.
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Description of the medicine
S-adenosyl methionine (often referred to as SAMe) is naturally present in the human body and there is evidence that it is effective as
an antidepressant. SAMe has been marketed in some European countries since the mid-1980s for the treatment of depression and for
other medical conditions such as osteoarthritis (joint disease that causes joint pain and stiffness), fibromyalgia (widespread pain and
stiffness), liver disease and migraine headaches. However, SAMe is not formally approved in the UK for the treatment of depression,
and in the USA it is classified only as a dietary supplement.
Aim of the review
Given the extent of the burden of depression, the high rates of chronicity and the high number of people who do not respond to the
conventional treatments, there is an urgent need to examine alternative medications. In this review, we investigated the effectiveness of
SAMe in the treatment of depression.
Results
We searched scientific databases for all randomised controlled trials (clinical studies where people are randomly put into one of two
or more treatment groups) in adults with a diagnosis of major depression, where SAMe was compared to either placebo (a pretend
treatment) or other antidepressant medicines (e.g. imipramine and escitalopram) carried out before February 2016.
We included eight studies involving 934 people in this review. There was no strong evidence of a difference in effectiveness between
SAMe and imipramine or escitalopram when used alone. It was superior to placebo when used in combination with selective serotonin
reuptake inhibitor antidepressants, but this evidence was of low quality. There was no significant difference in terms of effectiveness
between SAMe and placebo alone, but again this evidence was of very low quality. The acceptability of SAMe did not differ from that
of antidepressants or placebo. The exception was that fewer participants experienced side effects when treated with SAMe compared
with imipramine. Though, the quality of the evidence for acceptability of SAMe was of low quality.
Limitations of this review were that not all the relevant data could be obtained despite efforts to contact the authors and some of the
included studies were of low quality.
What should happen next
It is not possible to draw any firm conclusions from this review and the evidence included is of limited quality. There is a need to
investigate the efficacy and acceptability of SAMe for the treatment of depression in adults further in larger and better planned trials.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
S-adenosyl methionine as monotherapy compared to placebo as monotherapy for depression in adults
Patient or population: adults with depression
Settings: inpat ient and outpat ient
Intervention: SAMe as monotherapy
Comparison: placebo as monotherapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo as monother-
apy
SAM e as monotherapy
Efficacy. Change in
scores from baseline to
end of treatment on the
depression rating scale
A larger negat ive SMD
indicates greater im-
provement in the SAMe
group
Follow-up: 3 to 12
weeks
- The mean change in
scores f rom baseline to
end of treatment on the
depression rat ing scale
in the SAMe groups was
0.54 standard devi-
ations greater (1.54
lower to 0.46 higher) in-
dicat ing more improve-
ment. However, this
was not stat ist ically
signif icant
- 142
(2 studies)
⊕©©©
very low1,2,3
SMD -0.54 (95% CI -1.
54 to 0.46)
Acceptability
Part icipants dropping
out of treatment during
the study period for any
reason
Follow-up: 3 to 12
weeks
M oderate RR 0.88
(0.61 to 1.29)
not stat ist ically signif i-
cant
142
(2 studies)
⊕⊕©©
low4,5
-
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37 per 100 32 per 100
(22 to 47)
Proportions of partic-
ipants responding to
treatment
≥ 50% reduct ion in
depression score f rom
baseline to end of treat-
ment
A larger RR indicates
greater response to
treatment in the SAMe
group
Follow-up: 3 to 12
weeks
M oderate RR 1.77
(0.51 to 6.13)
not stat ist ically signif i-
cant
142
(2 studies)
⊕⊕©©
low4,5,6
-
21 per 100 38 per 100
(11 to 100)
Proportions of partici-
pants achieving remis-
sion
Depression rat ing scale
score within the normal
range at the end of the
study
A larger RR indicates
greater response to
treatment in the SAMe
group
Follow-up: 12 weeks
M oderate RR 1.69
(0.85 to 3.36)
not stat ist ically signif i-
cant
124
(1 study)
⊕⊕©©
low4,5
-
17 per 100 28 per 100
(14 to 56)
Acceptability. Partic-
ipants experiencing
troublesome adverse
effects of any nature
No data - - - - -
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io; SAM e: S-adenosyl methionine; SM D: standardised mean dif ference.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 downgraded one point because of inconsistency caused by high level of heterogeneity (I2 = 72%; P = 0.06), related to the
dif ferent durat ion of the trials and sample size (3 weeks, 18 part icipants for Kagan 1990; 12 weeks, 124 part icipants for
M ischoulon 2014).
2 downgraded one point because of imprecision caused by small sample size, fewer than 400.
3 downgraded one point because of imprecision caused by a 95% conf idence interval that included no ef fect and the upper
and lower conf idence lim it crosses an ef fect size of 0.5 in either direct ion.
4 downgraded one point because of imprecision caused by a total number of events that was fewer than 300.
5 downgraded one point because of imprecision caused by a 95% conf idence interval that includes both no ef fect and
appreciable benef it and appreciable harm (the threshold for ’appreciable benef it ’ or ’appreciable harm’ was a relat ive risk
reduct ion (RRR) or relat ive risk increase (RRI) greater than 25%).
6 The two studies showed a non-signif icant heterogeneity (I2 = 49%; P = 0.16). This was due to the Kagan 1990 study where
the number of responder was bigger in the SAMe arm than the placebo arm, but it was not stat ist ically signif icant (RR 4.80,
95% CI 0.72 to 32.15; P = 0.11).
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B A C K G R O U N D
Description of the condition
Depression is a common recurrent illness with high rates of
chronicity. It ranks first among mental illnesses in the causes of
worldwide disability (Murray 1997). The main symptoms of de-
pression are low mood and a loss of interest or pleasure. Physi-
cal symptoms include weight loss or gain, a decrease or increase
in appetite, insomnia or hypersomnia, psychomotor agitation or
retardation and fatigue. Psychological symptoms such as excessive
guilt, feelings of worthlessness, poor concentration and indeci-
siveness occur. Recurrent thoughts of death and suicidal thoughts
and actions may also feature (APA 1994). Anxiety is common in
depression (Fawcett 1983), and its presence detrimentally affects
the treatment outcome (Goldberg 2012). In cases of severe depres-
sion, mood-congruent psychotic symptoms such as hallucinations
and delusions may develop.
Atypical depression may be a distinct subtype of depression. Its
atypical symptoms include reactivity of mood, increased sleep and
increased appetite. This type of depression may preferentially re-
spond to one particular class of antidepressants, monoamine oxi-
dase inhibitors (MAOIs) (Henkel 2006).
Treatment-resistant depression is a significant problem, with a 12-
month prevalence of 2% to 3% (Nemeroff 2007). Treatment resis-
tance has been defined as occurring when “at least two trials with
antidepressants from different pharmacologic classes (adequate in
terms of dosage, duration, and compliance) fail to produce a sig-
nificant clinical improvement” (Berlim 2007).
Depression has significant economic impact. It is associated with
significant occupational underperformance and low earnings. It is
also associated with an increased risk of chronic physical illnesses,
early mortality and suicide (Kessler 2012). In the USA, the eco-
nomic cost of depression was USD 83 billion in 2000; USD 26
billion were direct medical costs, USD 5.4 billion were suicide-
related mortality costs and USD 51.5 billion were workplace costs
(Greenberg 2003). In Europe, the total annual cost of depression
in 2004 was EUR 118 billion, approximately 1% of the gross do-
mestic product. Direct costs corresponded to EUR 22 billion for
outpatient care, EUR 10 billion for hospitalisation, while indi-
rect costs due to morbidity and mortality were EUR 76 billion
(Sobocki 2006). The total cost of services for depression in Eng-
land in 2007 was estimated to be GBP 1.7 billion; lost employ-
ment brought the total cost to GBP 7.5 billion. The projection
is that in 2026 the costs will increase to GBP 3 billion for total
cost of services and GBP 12.2 billion for lost employment (King’s
Fund 2008).
Description of the intervention
Currently the various major US and European guidelines for the
treatment of depression provide similar basic principles of treat-
ment, which include individualising the treatment plan, preparing
the person for potential long-term treatment, providing measure-
ment-based care and treating to remission. With regard to mild
depression, some, but not all, guidelines suggest that it may resolve
with exercise or watchful waiting, but psychotherapy or antide-
pressants could be used if initial efforts fail. First-line treatment
recommendations for moderate major depressive disorder include
antidepressant monotherapy, psychotherapy and the combination
of both (Davidson 2010). In contrast, a combination of depres-
sion-focused psychotherapy and pharmacotherapy is considered a
useful treatment choice for people with severe or chronic forms of
depression (APA 2010). With regard to drugs, normally a selec-
tive serotonin reuptake inhibitor (SSRI) is chosen because of its
favourable risk-benefit ratio. In the case of people with depression
who have not responded to a first SSRI antidepressant after six
to eight weeks of adequate treatment, switching to an alternative
antidepressant may be considered. Initially, this may be a different
SSRI or a better-tolerated newer-generation antidepressant. Sub-
sequently, an antidepressant of a different pharmacological class
may be chosen, although this may be less well tolerated, for ex-
ample venlafaxine, a tricyclic antidepressant (TCA) or an MAOI
(NICE 2009).
S-Adenosyl methionine (SAMe) was originally discovered in Italy
in 1952 (Cantoni 1952), where it is commonly used in clini-
cal practice. SAMe has been marketed in some European coun-
tries since the mid-1980s for the treatment of depression and for
other medical conditions such as osteoarthritis, fibromyalgia, liver
disease and migraine headaches (Chavez 2000; Di Rocco 2000;
Papakostas 2003; Shippy 2004). However, SAMe is not formally
approved in the UK for the treatment of depression. In the USA,
it has not been classified as a drug but is available as a non-pre-
scription (over-the-counter) dietary supplement under theDietary
Health and Supplement Act of 1999 (Papakostas 2003).
SAMe occurs naturally in the human body. It may be synthesised
from adenosine triphosphate and the alpha-amino acid methio-
nine. Cantoni discovered it to be an active cofactor in biological
methylation reactions (Kresge 2005). As a physiological donor of
methyl groups, it is involved in many cellular functions including
the synthesis and metabolism of neurotransmitters (Gören 2004),
and its potential epigenetic effects have been highlighted (Sugden
2006).
Recommended daily doses of SAMe range from 200 mg to 1600
mg taken in divided doses, depending upon the condition for
which it is being taken and its severity, and upon the route of
administration (Chavez 2000; Delle Chiaie 2002; Morelli 2000).
Exogenous, orally administered SAMe has a short half-life, under-
going first-pass effects and rapid metabolism. However, oral doses
of SAMe at 1600 mg/day are significantly bioavailable and non-
toxic (Gören 2004). Because SAMe is best absorbed on an empty
stomach, it should be administered 30 to 60 minutes before meals
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or two hours after meals; people should be instructed to adhere
strictly to these directions. It may also be administered parenter-
ally, using intramuscular or intravenous routes (Williams 2005).
With regard to possible adverse effects, SAMe is reported to in-
duce mania in some cases (Carney 1989; Lipinski 1984). In one
open study, nine of 11 people with bipolar disorder experienced
a switch to an ’elevated mood state’ (hypomania, mania or eu-
phoria) (Carney 1989). Reports of induced mania and hypoma-
nia were found even in cases with no prior suggestion of bipolar
disorder (Kagan 1990). A transient mixed manic episode with sui-
cidal ideation was reported in a person with no previous psychi-
atric history on SAMe; recovery followed discontinuation (Gören
2004). These findings must be interpreted with caution as bipolar
II disorder (diagnosed by the presence of a hypomanic episode)
is sometimes misdiagnosed as major depressive disorder when hy-
pomanic episodes are overlooked.
There is a theoretical possibility of hyperhomocysteinaemia, a con-
dition associated with cardiac and renal complications in the long
term. However, in their four-week study of SAMe treatment of
healthy participants, Gören 2004 found no elevation in homocys-
teine levels. Mild gastrointestinal disturbance and headache have
been reported (Gören 2004; Lipinski 1984). One Cochrane re-
view on SAMe in the treatment of alcoholic liver disease found no
significant increase in adverse or serious adverse effects (Rambaldi
2006).
The cost of SAMe seems comparable in different countries. In the
USA, one local national chain sells 36 SAMe 400 mg tablets for
USD 42.99 (Craig Nelson 2010). In Italy, the price of 20 SAMe
400 mg tablets amounts to EUR 25.63, whereas in the UK, one
local national chain sells 30 SAMe 400 mg tablets for GBP 26.71.
The mean cost per tablet in these three countries is EUR 1.08.
In some countries such as Italy, Germany and Russia, pharmaceu-
tical grade SAMe is available on physician prescription only. As
of 2016, the cheapest antidepressant drugs available in the UK
are fluoxetine and citalopram with an approximately comparable
price, the net price of a 30-capsules pack of fluoxetine 20 mg is
GBP 1.11, the net price of a 28-tablet pack of citalopram 20 mg
is GBP 1.02 (BNF 2016). Although SAMe seems more expen-
sive, considering its adverse-effect profile and its rapidity of onset
of the antidepressant effect, it may have a specific impact on the
use of resources in terms of drug acquisition, treatment duration
and dosage, inpatient and outpatient care, treatment of adverse
events, management of people who discontinue therapy and time
off work.
How the intervention might work
The mechanism of any antidepressant effect of SAMe is unclear.
It may enhance the activity of the monoamine systems strongly
associated with the aetiology and treatment of depression. Animal
studies demonstrated an association between SAMe treatment and
increased brain concentrations of noradrenaline (norepinephrine)
and serotonin (5-HT) (Algeri 1979; Curcio 1978; Otero-Losado
1989a; Otero-Losado 1989b). In humans, treatment is reported
to increase cerebrospinal fluid concentrations of 5-hydroxyindole
acetic acid (the main metabolite of serotonin) (Agnoli 1976).
In addition, through stimulation of phospholipid methylation,
SAMe may increase the fluidity of cell membranes that is linked
to an increase in β-adrenoreceptor and muscarinic (M1) receptor
density (Bottiglieri 2002). Further, SAMe may influence the ex-
pression of key genes in the brain affecting behaviour, memory,
learning and cognition (Sugden 2006).
Why it is important to do this review
Given the extent of the burden of depression, the prevalence of
treatment resistance described above, and the substantial economic
cost associated with ineffective depression management compared
with successfully treated depression (Byford 2011), there is an ur-
gent need to examine less well recognised approaches to its phar-
macological management. SAMe may be an important addition
to the armamentarium of antidepressant agents. There is evidence
that SAMe has antidepressant efficacy. Existing meta-analyses of
randomised controlled trials (RCT) of SAMe in depression have
shown superior efficacy to placebo and efficacy equivalent toTCAs
(Bressa 1994; Williams 2005), a long-established category of an-
tidepressant (Arroll 2009). In addition, SAMe is well established
and widely used in some countries, such as Italy. Despite the clear
need for new treatments for depression and the apparent evidence
for its efficacy, SAMe is not formally approved or widely used as
an antidepressant treatment in many countries. It is imperative
that the potential role of this agent in depression should be rigor-
ously examined. Further, it is important to consider whether use
of SAMe is advantageous in the management of depression given
the incremental costs (resource use) and benefits (effects) that may
be associated with the intervention.
O B J E C T I V E S
To assess the effects of SAMe in comparison with placebo or an-
tidepressants for the treatment of depression in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs and considered published and unpublished
trials.
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We included cross-over trials in the review; however, as SAMe
treatment may have a lasting effect on depressive symptoms, we
only included data from the first phase of cross-over studies.
We planned to include cluster RCTs, with assessment of their
potential for unit of analysis errors (Higgins 2011a). However, we
found no studies of this design.
We planned to include full economic evaluations, cost analyses and
comparative resource utilisation studies conducted in the context
of an RCT. However, we identified no trials providing economic
analyses.
Types of participants
Participant characteristics
Men and women aged from 18 to 80 years.
Diagnosis
Participants with a diagnosis of major depression, with or with-
out psychotic symptoms, according to Diagnostic and Statistical
Manual of Mental Disorders (DSM)-III/II-R (APA 1980), DSM-
IV/IV-TR (APA 1980; APA 2000), or International Classification
of Diseases (ICD)-9, ICD-10 (WHO 1978; WHO 1992).
Subset data
We included trials examining a particular subgroup of partici-
pants with major depression in the meta-analysis, such as people
with psychotic features, anxiety symptoms, treatment resistance or
atypical depression. We also analysed these subgroups separately.
Comorbidities
We excluded participants with bipolar depression or schizoaffec-
tive disorder. Where studies used heterogeneous groups of par-
ticipants, we excluded these data unless data from those partici-
pants with ’unipolar’ depression could be extracted separately. If
there was any doubt regarding the diagnosis of participants, we
approached the authors to obtain clarification. We excluded cy-
clothymia and dysthymia.
We excluded people with DSM-IV Axis I and II and physical
comorbidities.
Types of interventions
Experimental intervention
S-adenosyl methionine (SAMe) as monotherapy or as an adjunct.
Comparator intervention
1. Placebo.
2. Alternative pharmacological treatment, limited to
antidepressants.
We organised antidepressants into classes for the purposes of this
review, as follows.
1. Tricyclic antidepressants (TCAs): amitriptyline,
imipramine, trimipramine, doxepin, desipramine, protriptyline,
nortriptyline, clomipramine, dothiepin, lofepramine.
2. Heterocyclic antidepressants: mianserin, trazodone,
amoxapine, maprotiline.
3. Selective serotonin reuptake inhibitors (SSRIs):
fluvoxamine, fluoxetine, paroxetine, sertraline, citalopram,
escitalopram.
4. Monoamine oxidase inhibitors (MAOIs), irreversible:
phenelzine, tranylcypromine, isocarboxazid; reversible:
brofaramine, moclobemide, tyrima.
5. Other antidepressants, noradrenaline reuptake inhibitors
(NARIs): reboxetine, atomoxetine; noradrenaline-dopamine
reuptake inhibitors (NDRIs): amineptine, bupropion; serotonin-
noradrenaline reuptake inhibitors (SNRIs): venlafaxine,
milnacipram, duloxetine; noradrenergic and specific serotonergic
antidepressants (NASSAs): mirtazapine; serotonin antagonist
and reuptake inhibitor (SARIs): trazodone; unclassified:
agomelatine, vilazodone.
Acute treatment was treatment instituted specifically to alleviate
symptoms of an existing episode of depression. We considered tri-
als in which SAMe was used as an adjunctive treatment separately.
When trials combined acute treatment and maintenance phases,
we analysed acute treatment data separately. When this was not
possible, we excluded the study from the review.We excluded stud-
ies with treatment durations of less than one week. We excluded
discontinuation trials in which participants received SAMe prior
to randomisation.
Types of outcome measures
Primary outcomes
Efficacy
1. *Change in mean scores from baseline to end of treatment on
the depression rating scale used, such as the Hamilton Depression
Rating Scale (HAM-D; Hamilton 1960) and the Montgomery-
Åsberg Depression Rating Scale (MADRS; Montgomery 1979).
Acceptability
2. *Participants dropping out of treatment during study period for
any reason.
3. Participants dropping out of the treatment during study period
because of adverse effects.
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Secondary outcomes
Efficacy
4. *Response to treatment, defined as a 50% reduction or greater
in depression score from baseline to end of treatment.
5. *Remission, defined as a depression rating scale score within
normal range at end of the study.
We used data according to the definitions of the trialists (docu-
mented in the ’Outcomes’ section of the Description of studies).
The definitions were overall homogeneous.
Acceptability
6. *Participants experiencing troublesome adverse effects of any
nature.
7. Specific adverse effects: mania or hypomania, headache, diar-
rhoea, flatulence, nausea, hyperhomocysteinaemia, emergent sui-
cidal ideation or behaviours, completed suicide and attempted sui-
cide, mortality excluding suicide, and verdicts of undetermined
death and mortality due to iatrogenic causes; the numbers of par-
ticipants experiencing these adverse events were presented in tab-
ular form.
8. Participants dropping out for any reasons other than adverse
effects.
*Outcomes to be reported in the ’Summary of findings’ tables.
Economic data
1. Mean total direct medical cost per participant, including
medication costs, consultant fees and inpatient treatment costs.
2. Direct resources use associated with complications of
treatment.
3. Time to onset of antidepressant effect measured as change
in depression score (days).
4. Time to return to work (days).
5. Incremental cost per disability-adjusted life year (DALY).
Timing of outcome assessment
Outcomes were categorised as short-term (up to six months from
the beginning of treatment), medium-term (six to 12 months) or
long-term (longer than 12months). We considered the short-term
as our primary time point.
Hierarchy of outcome measures
If data on more than one efficacy of treatment measure were pro-
vided for a trial, we extracted the data according to the following
hierarchy.
1. HAM-D.
2. MADRS.
3. Other outcome measure of efficacy with depression rating
scales.
Search methods for identification of studies
We used a comprehensive search strategy to identify all relevant
studies regardless of language or publication status.
The literature search was last updated in February 2016.
Electronic searches
1. The Cochrane Common Mental Disorders Group’s Spe-
cialised Register (CCMDCTR)
The Cochrane Common Mental Disorders Group maintains a
specialised register of randomized controlled trials, the CCMD-
CTR. This register contains over 40,000 reference records (reports
of RCTs) for anxiety disorders, depression, bipolar disorder, eating
disorders, self-harm and other mental disorders within the scope
of this Group. The CCMDCTR is a partially studies based reg-
ister with >50% of reference records tagged to c12,500 individu-
ally PICO coded study records. Reports of trials for inclusion in
the register are collated from (weekly) generic searches of Med-
line (1950-), Embase (1974-) and PsycINFO (1967-), quarterly
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) and review specific searches of additional databases.
Reports of trials are also sourced from international trial registries,
drug companies, the hand-searching of key journals, conference
proceedings and other (non-Cochrane) systematic reviews and
meta-analyses. Details of CCMD’s core search strategies (used to
identify RCTs) can be found on the Group’s website with an ex-
ample of the core Medline search displayed in Appendix 1.
We searched theCCMDCTR (Studies and Reference Registers) to
5 February 2016 using the following free-text terms: (*adenosyl*
or SAM-e or Samyr)
2. Biomedical databases
The original search of MEDLINE, EMBASE and PsycINFO was
conducted in May 2012 (Appendix 2). As the CCMDCTR in-
cludes these databases, further searches to February 2016 were
conducted on the CCMDCTR alone.
3. International trial registries were searched in February 2016
via ClinicalTrials.gov and the WHO trials portal (ICTRP) for
additional unpublished or ongoing studies.
We did not apply any restrictions on date, language or publication
status to the searches.
Searching other resources
Reference checking
We checked the reference lists of all identified RCTs, other rel-
evant papers, and major English, German and Italian textbooks
of affective disorders. We searched the reference lists of identified
studies for additional RCTs and health economics studies.
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Handsearching
Wehandsearched the annual conference proceedings of the Ameri-
can Psychiatric Association, the British Association of Psychophar-
macology, the Congress of the International College of Neuropsy-
chopharmacology, the European College of Neuropsychopharma-
cology and the National Congress of the Italian Psychiatric Asso-
ciation to June 2014.
Personal communications
We identified the authors of significant papers since 2011 from
authorship lists. We contacted them and other experts in the field
and asked if they had knowledge of other studies, published or
unpublished, relevant to the review. We requested pharmaceuti-
cal companies marketing SAMe products to provide relevant pub-
lished and unpublished data.
Data collection and analysis
Selection of studies
Two authors (IG and LO) screened the results of the search using
an over-inclusive approach to construct a list of all papers that were
potentially relevant. The two authors independently screened the
abstracts for inclusion. We obtained the full-texts of papers when-
ever there was any doubt about the relevance of an article or where
the abstract and title looked relevant. Two authors (IG and LO)
independently reviewed all the full-text papers.We applied the full
inclusion criteria to generate a list of studies to be considered for
inclusion.
Two authors (IG and LO) independently reviewed the list of stud-
ies to see whether they met the previously defined inclusion crite-
ria. We planned to resolve disagreements by consensus or discus-
sions with a third member of the review team (AY) and report this
in the final review.Wedidnot calculate a kappa statistic formeasur-
ing the agreement between the two authors as the authors agreed.
We documented the selection process was documented through
the completion of a PRISMA flow chart (Figure 1). We described
excluded studies in the Characteristics of excluded studies table.
We listed multiple publications of the same study.
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Data extraction and management
For trials that met the inclusion criteria of the review, two review
authors (IG and LO) independently extracted data concerning
participant characteristics, intervention details and outcome mea-
sures using a previously piloted data collection form. We planned
to solve any disagreements by consensus or discussions with a third
member of the review team (AY). However, a kappa statistic for
measuring the agreement between the two authors was not calcu-
lated as the authors agreed.
We extracted data on the following comparisons:
1. SAMe versus placebo as monotherapy;
2. SAMe versus a TCA as monotherapy;
3. SAMe versus SSRI as monotherapy;
4. SAMe versus placebo as adjunctive treatment.
We also planned to extract data on the comparison SAMe versus an
active antidepressant agent as an adjunctive treatment; however,
we found no studies.
We planned to develop a data collection form for use with health
economic studies, based on the template used to produce UK
National Health Service Economic Evaluation Database (NHS
EED) structured abstracts (Craig 2007).
Assessment of risk of bias in included studies
Two review authors (KM and AY) independently assessed the
risk of bias using the tool described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011a). This tool
gives special consideration to the generation of randomisation se-
quences, allocation concealment, blinding procedures, the com-
pleteness of final data sets and selective reporting. We planned to
solve any disagreements by consensus or discussion with a third
member of the review team (GM). A kappa statistic for measuring
the agreement between the two authors was not calculated as the
authors agreed.
Where inadequate details of randomisation and other character-
istics of trials were provided, we contacted the trial authors for
clarification. For studies considered to be at high risk of bias due to
the method of sequence generation, the inadequate concealment
of sequence allocation, the absence of double blinding or for any
other reason, we identified the key mechanism of bias. Where this
mechanism was likely to influence a particular outcome measure,
we investigated the effect of including the study in the relevant
meta-analysis using a sensitivity analysis. Sensitivity analyses were
also conducted on studies where the risk of bias remained unclear,
despite contact with the study authors. We recorded the source of
information for each risk of bias judgement, including judgements
based on unpublished information.
For included health economic studies, we planned to assess the
risk of bias and methodological quality using the Cochrane tool
for assessing risk of bias (Higgins 2011b), and the BMJ Checklist
(Drummond 1996).
We used the five GRADE considerations to assess the body of ev-
idence for each outcome (Higgins 2011a). We justified and doc-
umented all such assessments.
Measures of treatment effect
Continuous data
For continuously distributed outcomes, we calculated the mean
difference (MD) between the groups. Where measures were re-
ported using different scales, we used the standardised mean dif-
ference (SMD), if this was clinically appropriate. We also reported
95% confidence intervals (CI).
Data would be checked for skew by calculation of the observed
mean minus the lowest possible value minus (and by calculating
the highest possible value minus the observed mean) and dividing
this by the standard deviation. A ratio less than 2 suggests skew
(Altman 1996a; Higgins 2011a). If the ratio is less than 1, there is
strong evidence of a skewed distribution. When this was the case,
we planned to exclude data from the analysis (Altman 1996a). In
studies in which the ratio was between 1 and 2, suggesting less
marked skew, we planned to subject data to a sensitivity analysis.
Studies with more than 200 participants were exempt from these
processes as skewed data were less problematic in large studies.
Dichotomous data
For dichotomous outcomes, we calculated the risk ratio (RR) of
reported response, with 95% CI. We preferred the RR measure as
the odds ratio is more difficult to interpret (Sackett 1996; Sinclair
1994).
Unit of analysis issues
Cluster-randomised trials
Cluster-randomised studies are at risk of a ’unit of analysis’ error
(Divine 1992) and Type I errors (Bland 1997). Where clustering
was suspected, we contacted the authors with a request that they
supplied intra-class correlation coefficients of their clustered data
and adjust for this using methods described by Gulliford 1999. If
clustering was incorporated, we planned to present the data in the
form of a parallel-group randomised study, with adjustments for
clustering effects. If cluster studies were appropriately analysed, we
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planned to conduct synthesis with other studies using the generic
inverse variance technique.
Cross-over trials
For cross-over studies, we considered only results from the first
randomised portion. Data from the second phase of such studies
are potentially subject to the confounding influences of discon-
tinuation effects and persistent treatment effects.
Studies with multiple treatment groups
When a study had more than two intervention arms, we included
only those intervention and control arms meeting the inclusion
criteria of the review. We entered all relevant intervention groups
of a multi-intervention study in the Characteristics of included
studies table and assessed these studies for any risk of bias. In
particular, we sought reporting biases, such as the combining of
groups on different doses of medication or the presentation of
different outcomes in the comparison of different groups. Where
appropriate, we combined data from all relevant experimental in-
tervention groups of the study into a single group, and combined
data from all relevant control intervention groups into a single
control group (Higgins 2011a).
Dealing with missing data
We analysed all data on an intention-to-treat (ITT) basis. If it was
not clear why data were missing, we contacted trialists to either
provide the data or to explain why it was missing. However, we
were unable to obtain any additional data. Careful consideration
was given to the reason why data were missing, and whether the
data were missing at random or their absence was in some way
related to the outcome measure. We documented this where pos-
sible.
We considered the impact of missing data separately for different
key outcomes. Where participants had withdrawn from the trial
before reaching the end of the study period, we planned to assume
that their condition would have remained unaltered had they con-
tinued to the end, that we would use the last observation carried
forward (LOCF). However, it must be noted that ITT and LOCF
methods have some limitations and can lead to bias as the means
are likely to be distorted (Higgins 2011a). In the event, we were
unable to use the LOCF method as, in all cases, individual raw
participant data were not available. We addressed the missing data
as follows:
1. For continuous efficacy outcomes, we imputed missing data
using the conservative approach of assuming that these
participants had no change in their mean score on the HAM-D
from baseline to the endpoint. As we did not have access to the
raw participant baseline scores, we used the mean baseline score
of all participants. To assess the robustness of the assumptions,
we carried out sensitivity analyses where the participants were
assumed to have had the same mean change as the other
participants.
2. For dichotomous outcomes, we imputed missing data based
on the consideration of a ’worst-case’ scenario. To assess the
robustness of the assumption, we carried out sensitivity analyses
based on a ’best-case’ scenario.
Variation in the degree of missing data was considered as a source
of heterogeneity. We investigated the impact of these assumptions
by undertaking a sensitivity analysis (Alderson 2004).Where stan-
dard error data were presented, we calculated standard deviations
from the standard error (Altman 1996b). In the absence of any
such data, we imputed standard deviations (Furukawa 2006), and
undertook sensitivity analyses to assess the validity of this process.
For a detailed description of the procedures see Appendix 3 (Deal-
ing with missing data).
Assessment of heterogeneity
We assessed heterogeneity using the I2 statistic. We used a P value
of 0.10 as an indication of significant heterogeneity in meta-analy-
ses of small studies, as theChi2 testmay be underpowered to detect
heterogeneity in these circumstances. According to the Cochrane
Handbook for Systematic Reviews of Interventions, the bands of in-
terpretation for I2 are as follows: 0% to 40%:may be unimportant;
30%to60%:may representmoderate heterogeneity; 50%to 90%:
may represent substantial heterogeneity and 75% to 100%: may
have considerable heterogeneity (Higgins 2011a). We took values
above 30% to indicate moderate heterogeneity (Higgins 2011a),
and sought sources of heterogeneity. We considered studies with
heterogeneity greater than 75% too heterogeneous to combine
in a meta-analysis. Where we detected moderate or greater het-
erogeneity, we sought possible causes including the diagnosis, the
demographic profile of the participants, the dose of agents used
and the duration of treatment.We also considered variation in the
degree of missing data as a source of heterogeneity.
Assessment of reporting biases
Where there were more than 10 studies contributing to an out-
come, we planned to construct funnel plots to examine the data
for small-study effects (Higgins 2011a). In addition to publica-
tion bias, such effects may have been due to selective reporting,
poor methodological quality leading to spuriously inflated effects
in smaller studies, true heterogeneity of effect, artefact and chance
(Higgins 2011a). We considered selective outcome reporting as
part of the quality assessment procedure and reported any in-
stances.
Data synthesis
Data from trials were combined in the meta-analyses only if this
was appropriate, that was the participants, interventions, compar-
isons and outcomes were sufficiently similar. The assessment of
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heterogeneity acted as a test of these judgements. We used a ran-
dom-effects model as it assumes that studies estimate different but
related effects (DerSimonian 1986). We considered a random-ef-
fects model appropriate because changes in the depression rating
scales may measure similar but different effects. For instance, a
change in total score may reflect improvements in physical symp-
toms of depression (e.g. sleep disturbance, appetite, lassitude),
while in another study it may reflect a change in psychological
symptoms such as feelings of guilt or hopelessness. Two authors
(IG and LO) entered data into the Review Manager 5 (RevMan
2014).
Subgroup analysis and investigation of heterogeneity
As discussed in the introduction, participants with certain sub-
types of depression may respond differently to SAMe and to other
treatments.We planned to undertake the following subgroup anal-
yses, to examine the contribution of potential effect modifiers to
heterogeneity.
1. Data from parenteral and oral administration of SAMe:
different methods of administration may affect efficacy and the
placebo response.
2. Depression with and without psychotic features: psychotic
features are associated with more severe episodes of depression
and they may respond differently to mild-moderate depression
or to non-psychotic episodes of similar severity.
3. Treatment-resistant depression: participants with this
category of depression, by definition, will have failed to respond
to at least two adequate trials of antidepressants and may respond
differently to trial medications.
4. Atypical depression: participants with this category of
depression characteristically respond optimally to MAOIs and
may respond differently to trial medications.
5. Anxiety: anxiety detrimentally affects treatment outcome.
It is recognised that any findings from these analyses are hypoth-
esis-forming.
Sensitivity analysis
We planned to perform the following sensitivity analyses.
1. Studies where methodological factors may be sources of bias
and likely to impact on the particular outcome under
investigation. For instance, studies with inadequate blinding
procedures may be liable to bias because of the effects of
participants’ and observers’ expectations regarding their allocated
treatment.
2. Studies with high levels of missing data (i.e. more than
30%). In studies with high drop-out rates, the assumptions
involved in the use of the LOCF approach may introduce
considerable bias.
3. Studies using cluster randomisation. This method
introduces the risk of bias in several ways. These include the
possibility of recruitment bias, baseline imbalance and incorrect
analysis (Higgins 2011a). There is also the question of how
comparable these studies are with individually randomised trials.
The influence of these potential sources of bias on the outcome
measures identified in a review are difficult to predict. However,
as there is a possibility of bias, we planned to investigate it
routinely.
It is recognised that any findings from these analyses are hypoth-
esis-forming.
Economics issues
We planned to summarised characteristics and results of included
economic evaluations using additional tables, supplemented by
a narrative summary that would compare and evaluate methods
used and principal results between studies.
In addition, we planned to tabulate unit cost data, when available.
’Summary of findings’ tables
We constructed a ’Summary of findings’ table according to the
recommendations of theCochraneHandbook for Systematic Reviews
of Interventions for each of the comparisons (Higgins 2011a). For
each comparison, the table described the form of intervention,
details of scales and time frames, the number of participants and
studies for each outcome, a measure of the typical burden of non-
response to treatment (i.e. the assumed risks for non-response,
summary of the intervention effect: indices of absolute and relative
magnitudes) and the quality of the body of evidence for each
outcome.
Included outcomes were:
1. change in the mean score in the specified depression rating
scores from baseline to end of treatment;
2. proportions of participants responding to treatment;
3. proportions of participants achieving remission;
4. participants dropping out of treatment during the study
period for any reason;
5. participants experiencing troublesome adverse effects of any
nature.
Notes on the ’Summary of findings’ table
The ’Summary of findings’ table presented the main group com-
parisons only.
For dichotomous outcomes, the table provided both a relative
measure (the RR) of non-response and the absolute risk reduction
(ARR). For continuous data, the table presented theMDor SMD.
We presented typical assumed risks for non-response in the con-
trol group and cited the sources of this information. Participants
in the included studies were experiencing depression, and so the
baseline assumed risk of non-response for a median control group
seemed the most helpful information to present. We cited the in-
formation on which this information was based. We calculated
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a corresponding intervention risk from the RR and the assumed
control risk.
We used the GRADE approach to assessing the quality of the
body of evidence. We adhered to the standard methods for the
preparation and presentation of results outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
R E S U L T S
Description of studies
Results of the search
We identified 650 references: 82 through CCMDCTR, 528
through other electronic databases and 40 through additional re-
sources. After we excluded 221 duplicates, we read the abstracts
and excluded a further 362 references. We considered 67 refer-
ences relevant for our review and tried to retrieve full-text copies
to assess their eligibility. Some studies that were possibly eligible
reported heterogeneous groups of participants without the pos-
sibility to separate out data from those participants with ’unipo-
lar’ depression (Alvarez 1984; De Leo 1987; Delle Chiaie 1999;
Janicak 1988; Kufferle 1982; Salmaggi 1991). We approached the
authors in order to obtain original unpublished data but unsuc-
cessfully and we excluded them. We also contacted Prof M. Fava
to achieve clarification on randomisation in his study (Fava 1992);
his answer did not permit us to include the study in our review.
Finally, eight studies met inclusion criteria for our review and we
included them in the qualitative and quantitative analysis. We cat-
egorised three studies as ongoing, nine references and one study
awaiting classification and excluded the remaining studies for var-
ious reasons (see Figure 1 for PRISMA flow diagram).
We identified no RCTs providing economic analyses.
Included studies
This systematic review included eight studies with 934 partici-
pants. Although we contacted the authors of the included studies
and received a response in some cases, attempts to obtain addi-
tional unpublished data and information regarding missing data
were almost always unsuccessful.
See Characteristics of included studies table.
Study design
All the included studies were RCTs and were reported to be dou-
ble blind. Two studies were multicentre (Delle Chiaie 2000a;
Delle Chiaie 2000b). One study was three-armed with SAMe, an
alternative pharmacological treatment and placebo (Mischoulon
2014). Two studies were two-armed with SAMe versus placebo as
monotherapy (Kagan 1990) or as adjunctive therapy (Papakostas
2010a). The remaining five studies were two-armed with SAMe
versus an alternative pharmacological treatment (Bell 1988; Bell
1994; Delle Chiaie 2000a; Delle Chiaie 2000b; De Vanna 1992).
The Mischoulon 2014 study included a cross-over phase in its
design, though the report included in our review was focused on
the data for the first phase of treatment.
There were no trials comparing SAMe with an active antidepres-
sant as an adjunctive therapy.
Sample size
Overall, the review included 934 participants. Five studies re-
cruited fewer than 100 participants (Bell 1988; Bell 1994; De
Vanna 1992; Kagan 1990; Papakostas 2010a), and only three
studies recruited more than 200 participants overall (Delle Chiaie
2000a; Delle Chiaie 2000b; Mischoulon 2014).
The mean sample size per arm was 55 participants (range 11 to
148).
Participants
Two studies enrolled only inpatients (Bell 1988; Kagan 1990),
four studies only outpatients (Delle Chiaie 2000a; Delle Chiaie
2000b; Papakostas 2010a; Mischoulon 2014). One study enrolled
both inpatients and outpatients (Bell 1994), and for the remaining
trial the setting was unclear (De Vanna 1992). All studies enrolled
people with a diagnosis of major depression, according to DSM-
III (Bell 1988; Kagan 1990), DSM-III-R (Bell 1994; De Vanna
1992), or DSM-IV (Delle Chiaie 2000a; Delle Chiaie 2000b;
Mischoulon 2014; Papakostas 2010a). All but one study (Kagan
1990, only men) recruited both women and men. Three studies
provided participants over the age range of our review, including
people aged 18 to 80 years (De Vanna 1992; Mischoulon 2014;
Papakostas 2010a). Our protocol restricted the age range to 18 to
70 years (Galizia 2014). We decided to include these studies after
consideration of the mean age of the participants.
Bell 1988 reported a past episode of mania in one participant in
the comparison group. As per protocol, we should have excluded
participants with bipolar depression. We decided to include this
study because it was only one participant and nothing in the text
showed that he reported different response to treatment or had a
manic switch during the trial.
Only one study examined a particular subgroup of participants
with major depression, namely SSRI non-responders (Papakostas
2010a). We analysed this subgroup separately. Two studies ex-
cluded participants with history of resistance to TCA treatment
(Bell 1988; Bell 1994).
Six studied excluded people who had psychotic symptoms (Delle
Chiaie 2000a; Delle Chiaie 2000b; De Vanna 1992; Kagan 1990;
Mischoulon 2014; Papakostas 2010a).
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Intervention/comparisons
Studies used SAMe as monotherapy (Bell 1988; Bell 1994; Delle
Chiaie 2000a; Delle Chiaie 2000b; De Vanna 1992; Kagan 1990;
Mischoulon 2014) or as an adjunctive therapy (Papakostas 2010a).
Specifically, SAMe was adjunct to SSRIs (Papakostas 2010a).
The mean duration of treatment was 5.3 weeks (range 2 to 12
weeks).
The administration of SAMe was oral at a target dose of 1600
mg/day (Bell 1994; Delle Chiaie 2000a; De Vanna 1992; Kagan
1990; Papakostas 2010a) or parenteral at a dose of 200 mg/day to
400 mg/day (intravenous Bell 1988, intramuscularly Delle Chiaie
2000b). According to our protocol, we undertook a subgroup
analysis to examine data from parenteral and oral administration
of SAMe (Galizia 2014). In one study, for participants who com-
plained of adverse effects the drug, dose could be reduced from
the third week on, down to a minimal dose of imipramine of 100
mg/day and SAMe of 1200 mg/day; the study excluded partici-
pants who tolerated this dose poorly from the study (Delle Chiaie
2000a). The Papakostas 2010a trial withdrew participants who
were unable to tolerate the study medications, per protocol. One
study allowed a dose increase to 3200 mg/day for non-responders
(Mischoulon 2014); they allowed participants who experienced
intolerable adverse effects at the higher dose to decrease the dose
to the previous level. Four studies specified the exact formula-
tion of the SAMe used in the trial: 1,4-butanedisulphonate-SAMe
(Delle Chiaie 2000a; Delle Chiaie 2000b), and SAMe tosylate
(Mischoulon 2014; Papakostas 2010a).
Two studies compared SAMe with placebo (Kagan 1990;
Papakostas 2010a), four studies SAMe with imipramine (Bell
1988; Delle Chiaie 2000a; Delle Chiaie 2000b; De Vanna 1992),
and one study SAMe with desipramine (Bell 1994). Three cases
titrated imipramine up to 150 mg/day (Bell 1988; Delle Chiaie
2000a;DelleChiaie 2000b), while in theDeVanna 1992 trial, par-
ticipants received a dose of 140 mg/day; desipramine was titrated
up to 250 mg/day. One study was three-armed comparing SAMe
with escitalopram 10-20 mg/day and placebo (Mischoulon 2014).
Some studies allowed the use of benzodiazepine as a hypnotic
(Delle Chiaie 2000a; Delle Chiaie 2000b; De Vanna 1992). How-
ever, none of the studies analysed whether the use of benzodi-
azepines could have somehow affected the outcomes.
Outcomes
We categorised all outcomes in this review as short-term, as the
maximum endpoint of the included studies was 12 weeks.
Primary outcomes
All included studies evaluated the efficacy of treatment by admin-
istration of the Hamilton Depression Scale (HAM-D). However,
they used different versions of this rating scale: 31-item HAM-
D in Bell 1988; and Bell 1994; 17-item HAM-D in Bell 1994;
Mischoulon 2014; and Papakostas 2010a; 21-item HAM-D in
Delle Chiaie 2000a; Delle Chiaie 2000b; De Vanna 1992; and
Kagan 1990. In our analysis, we applied the SMD in order to
measure the treatment efficacy.
The efficacy assessments also included the Beck Depression In-
ventory in two studies (Bell 1988; Bell 1994), and the 14-item
Hamilton Rating Scale for Anxiety and 20-item Zung’s Self-Rat-
ing Scale for Depression in one study (De Vanna 1992). Two
studies evaluated the MADRS (De Vanna 1992; Delle Chiaie
2000a; Delle Chiaie 2000b). Other scales included the Clini-
cal Global Impression scale (Delle Chiaie 2000a; Delle Chiaie
2000b), the Clinical Global Impression - Severity (Mischoulon
2014; Papakostas 2010a), Clinical Global Impression - Improve-
ment versions (Mischoulon 2014; Papakostas 2010a). Further, sec-
ondary measures of efficacy included the Inventory of Depressive
Symptomatology - Clinician Rating and the Inventory of Depres-
sive Symptomatology - Self Report in theMischoulon 2014 study,
the Carroll Rating Scale for Depression in the Kagan 1990 study.
According to the hierarchy of outcome measures of this review, we
prioritised the data from the HAM-D.
In one study, the primary outcome was the correlation between
plasma SAMe levels and the degree of clinical improvement; blood
samples for the analysis of plasma SAMe levels were collected (Bell
1994).
In the De Vanna 1992 trial, we extrapolated data regarding the
efficacy of the treatment from the figure reported in the paper, as
no other information was available. To check the accuracy of our
calculations, we verified if the extrapolated MDs matched with
the per cent improvement in the mean scores shown in the paper.
We conducted a sensitivity analysis to assess the robustness of this
assumption.
We could extract data for the analysis of the outcome “Efficacy.
Change in mean scores from baseline to end of treatment on the
depression rating scale” in all but one study (Bell 1994).
The ’Risk of bias’ table of the Characteristics of included studies
table states the drop-out rates of individual trials, the distribution
of drop-outs among trials arms and the reasons for drop-out.
We could extract data for the analysis of the acceptability outcomes
related to the drop-outs in all but two studies (Delle Chiaie 2000a;
DelleChiaie 2000b).However, theBell1994 study didnot provide
data for the quantitative evaluation of the drop-outs reasons.
Secondary outcomes
Response to treatment was defined as a reduction of more than
50% on HAM-D (Bell 1988; Bell 1994; Mischoulon 2014) or at
least 50% (Delle Chiaie 2000a; Delle Chiaie 2000b; Papakostas
2010a). Treatment-responders were also defined those participants
who had a Clinical Global Impression score of 2 or less at the
end of the study (Delle Chiaie 2000a; Delle Chiaie 2000b) or a
Clinical Global Impression - Improvement score of less than 3 at
endpoint (Papakostas 2010a).
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All but one study (De Vanna 1992) provided data for the analysis
of the outcome “Efficacy. Response to treatment”.
Remission was determined as a final HAM-D score of less than 7
(Mischoulon 2014) or 7 or less (Papakostas 2010a). In addition,
Papakostas 2010a considered remission as a Clinical Global Im-
pression - Severity score of 1 at endpoint. Only data from these
two studies could be extracted to evaluate the remission rates.
All studies evaluated the tolerability and safety of the treatment
by reporting adverse effects. Some studies applied instruments,
such as the Somatic Symptom Checklist (Bell 1988), Systematic
Assessment for Treatment Emergent Events (Bell 1994), and the
Systematic Assessment for Treatment of Emergent Events-Specific
Inquiry (Mischoulon 2014). Almost all studies performed labora-
tory tests, electrocardiogram (ECG) and assessment of vital signs.
Three studies provided the rates of adverse effects of any nature
experienced by participants (Delle Chiaie 2000a; Delle Chiaie
2000b; De Vanna 1992).
Most studies did not provide enough detailed data regarding spe-
cific adverse effects to carry out complete quantitative analyses.
Excluded studies
Twenty-eight studies initially considered for potential inclusion in
the review and retrieved as full-articles did not meet our inclu-
sion criteria and were excluded for different reasons, as follows:
inappropriate diagnosis, presence of comorbidity, inappropriate
outcomes, inappropriate intervention, inappropriate comparator,
unsuitable study design, methodological issues and heterogeneous
group of participants.
See the Characteristics of excluded studies table for details of the
respective reasons for excluding each study.
Studies awaiting classification
We identified nine additional references by screening reference
lists; it is unclear as to whether these are reports of RCTs already
included (e.g. Bell (personal communication)) or otherwise. As
we could identify no abstract or full-text reference to ascertain
study characteristics, we have currently listed these as additional
references (see Alvarez 1987; Bell (personal communication); Bell
1987; Di Padova 2000: Fazio 1974; Macher (in press); Macher
2000; Pancheri 1997; Pinzello 1972).
One additional study identified from the CCMDCTR search was
a handsearch record submitted by the Iberoamerican Cochrane
Centre in the 1980s (Quiros 1982, CENTRAL ID: CN-
00711163).
For further details of these studies see Characteristics of studies
awaiting classification table.
Ongoing studies
We identified three ongoing studies, all described as double-blind,
randomised, placebo-controlled trials involving adults with a di-
agnosis of major depressive disorder. Two studies were three-
armed with SAMe plus cofactors folinic acid and vitamin B12, en-
hanced SAMe combinationnutraceutical formulation andplacebo
(ACTRN12613001299796; ACTRN12613001300763), while
the other study compared adjunctive SAMe as adjunctive therapy
versus adjunctive placebo (NCT01912196).
Risk of bias in included studies
Detailed assessment of risk of bias across all studies is presented
in the Characteristics of included studies table and Figure 2 and
Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
18S-adenosyl methionine (SAMe) for depression in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
Only two studies were at low risk of bias for random sequence
generation, as the investigators sufficiently described the random
component in the sequence generation process (Kagan 1990;
Mischoulon 2014). The remaining studies were rated as having
unclear risk of bias, since the methods of randomisation were not
described in sufficient details.
Allocation concealment
Three studies were at low risk of bias for allocation concealment,
as the investigators used a conceal allocation methods that did
not allow participants and investigators enrolling participants to
foresee assignment (Kagan 1990; Mischoulon 2014; Papakostas
2010a). The remaining studies were rated as unclear as the meth-
ods of concealment were not described in sufficient detail.
Blinding
Blinding of participants and personnel (performance bias)
With regard to the risk of performance bias, four studies were
at low risk of bias as they ensured blinding of participants and
personnel, and it was unlikely that the blinding could have been
broken (Bell 1994; Kagan 1990; Mischoulon 2014; Papakostas
2010a).
The other studies were at unclear risk of performance bias, because
the methods to secure the blinding were not fully described (Bell
1988; Delle Chiaie 2000a; Delle Chiaie 2000b; De Vanna 1992).
In addition, the allocation concealment was unclear.
Blinding of outcome assessment (detection bias)
With regard to the risk of detection bias, four studies were at low
risk of bias as they ensured blinding of outcome assessment, and it
was unlikely that the blinding could have been broken (Bell 1994;
Kagan 1990; Mischoulon 2014; Papakostas 2010a).
The other studies were at unclear risk of detection bias, because
the methods to secure the blinding were not fully described (Bell
1988; Delle Chiaie 2000a; Delle Chiaie 2000b; De Vanna 1992).
In addition, the allocation concealment was unclear.
Incomplete outcome data
Three studies were at low risk of attrition bias. In the Bell 1988
and Kagan 1990 trials, missing outcomes were too few to impact
on the observed effect size. In both cases, the reason for drop-outs
were stated. In the Papakostas 2010a study, an ITT analysis was
available and all non-completers were mentioned with reasons for
drop-out.
One study was at high risk of attrition bias because they used
only data on completers and did not state the reason for missing
participants (Bell 1994).
The remaining four studies were at unclear risk of attrition bias.
It was unclear whether De Vanna 1992 used an ITT analysis.
Although Delle Chiaie 2000a and Delle Chiaie 2000b carried
out an ITT analysis, they did not fully describe non-completers.
Mischoulon 2014 had a very large proportion of drop-outs (almost
50%).
Selective reporting
Across all the studies, the risk of reporting bias was low. This was
given careful consideration, as no study protocols were available.
However, all expected outcomes, including those that were pre-
specified in the protocol section of the final reports, were included
in the results.
Other potential sources of bias
The risk of other bias was low as we identified no other potential
sources of bias.
Effects of interventions
See: Summary of findings for the main comparison S-adenosyl
methionine as monotherapy compared to placebo asmonotherapy
for depression in adults; Summary of findings 2 S-adenosyl
methionine as monotherapy compared to tricyclic antidepressant
agent as monotherapy for depression in adults; Summary of
findings 3 S-adenosyl methionine as monotherapy compared
to SSRI antidepressant agent as monotherapy for depression
in adults; Summary of findings 4 S-adenosyl methionine as
adjunctive treatment compared to placebo as add-on to SSRI for
depression in adults
We extracted data on the following comparisons:
1. SAMe versus placebo as monotherapy;
2. SAMe versus a TCA as monotherapy;
3. SAMe versus SSRI as monotherapy;
4. SAMe versus placebo as adjunctive treatment.
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Where published data were not sufficient to evaluate our out-
comes, we contacted the authors in order to obtain unpublished
data; however, we received no responses.
Comparison 1: S-adenosyl methionine versus placebo
as monotherapy
Two studies were eligible for this comparison (Kagan 1990;
Mischoulon 2014). See Summary of findings for the main
comparison. The Kagan 1990 study was at low risk of selection,
performance, detection, attrition, reporting and other bias. The
Mischoulon 2014 study was at unclear risk of attrition bias and at
low risk of bias in the other domains.
Primary outcomes
1.1 Efficacy. Change in mean scores from baseline to end of
treatment on depression rating scale
In this analysis, a reduction in depression rating scale score (indi-
cated by a negative sign) represents an improvement.
Overall, there was no strong evidence of a difference between
SAMe and placebo as monotherapy in terms of efficacy in the
treatment of depression, measured as change in the mean scores
on depression rating scale (SMD -0.54, 95% CI -1.54 to 0.46; P
= 0.29; 142 participants; 2 studies) (Analysis 1.1). The evidence
contributing to this outcome was very low quality.
The studies showed a high level of heterogeneity (I2 = 72%; P =
0.06), which has been investigated in the Discussion.
1.2 Acceptability. Participants dropping out of treatment
during study period for any reason
There was no strong evidence of a difference between the two arms
with regard to the level of drop-outs (RR 0.88, 95% CI 0.61 to
1.29; P = 0.52; 142 participants; 2 studies; I2 = 0%) (Analysis
1.2). The evidence contributing to this outcome was low quality.
1.3 Acceptability. Participants dropping out of treatment
during study period because of adverse effects
There was no strong evidence of a difference between SAMe and
placebo as monotherapy in terms of drop-outs due to adverse
effects (RR 0.70, 95%CI 0.16 to 3.01; P = 0.64; 142 participants;
2 studies; I2 = 0%) (Analysis 1.3).
Secondary outcomes
1.4 Efficacy. Response to treatment, defined as a 50%
reduction or greater in depression score from baseline to end
of treatment
In this analysis, an increase of RR represents a positive outcome
indicating response to treatment in the SAMe group.
There was no evidence that SAMe was superior to placebo as
monotherapy in terms of response to treatment (RR 1.77, 95%
CI 0.51 to 6.13; P = 0.37; 142 participants; 2 studies) (Analysis
1.4). The evidence contributing to this outcome was low quality.
The two studies included in this analysis showed a non-significant
heterogeneity (I2 = 49%; P = 0.16).
1.5 Efficacy. Remission, defined as a depression rating scale
score within the normal range at end of study
In this analysis, an increase of RR represents a positive outcome
indicating response to treatment in the SAMe group.
Only the Mischoulon 2014 study contributed to this outcome.
There was no evidence of a difference between the two treatment
arms with regard to remission (RR 1.69, 95% CI 0.85 to 3.36;
P = 0.14; 124 participants; 1 study) (Analysis 1.5). The evidence
contributing to this outcome was low quality.
1.6 Acceptability. Participants experiencing troublesome
adverse effects of any nature
There were no available data to conduct this analysis.
1.7 Acceptability. Participants experiencing specific adverse
effects identified in protocol
One study detailed the adverse effects (Kagan 1990). In the SAMe
group, one participant experiencedmanic symptoms andheadache
(Analysis 1.6; Analysis 1.7); in the placebo group, two participants
reported flatulence (Analysis 1.8). The conducted analyses showed
no strong evidence of a difference between the two treatment arms
(Analysis 1.6: RR 2.10, 95% CI 0.10 to 44.40; P = 0.63; 15
participants; 1 study; Analysis 1.7: RR 2.10, 95% CI 0.10 to
44.40; P = 0.63; 15 participants; 1 study; Analysis 1.8: RR 0.14,
95% CI 0.01 to 2.49; P = 0.18; 15 participants; 1 study).
The participant who experienced manic symptoms, on day 19 of
treatment with SAMe, was noted to be energetic, talkative, irrita-
ble, grandiose and hyperkinetic; his clinical ratings had improved
dramatically, but he was noting the return of insomnia and de-
creased appetite. This 65-year-old white man completed the three-
week long trial and subsequently developed a manic episode char-
acterised by pressured speech, flight of ideas, poor judgement, ex-
tensive travel, insomnia, decreased appetite, weight loss and expen-
diture of large sums of money. His manic episode persisted even
though SAMe treatment had been discontinued three months ear-
lier. The participant’s history revealed only one prior depressive
episode (responsive to doxepin), no prior history of mania on hy-
pomania and a family history of depression but not mania.
In both studies, there were no explicit reports of mortality during
the treatment period (Kagan 1990; Mischoulon 2014). Overall,
the trials did not systematically assess risk for suicidal ideation and
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behaviours. Neither study mentioned measurement of homocys-
teinaemia.
1.8 Acceptability. Participants dropping out for any reasons
other than adverse effects
There was no evidence of a difference between SAMe and placebo
as monotherapy in terms of drop-outs for any reason other than
adverse effects (RR 0.91, 95% CI 0.60 to 1.38; P = 0.66; 142
participants; 2 studies; I2 = 0%) (Analysis 1.9).
Comparison 2: S-adenosyl methionine versus tricyclic
antidepressant as monotherapy
Five studieswere eligible for this comparison (Bell 1988; Bell 1994;
Delle Chiaie 2000a; Delle Chiaie 2000b; De Vanna 1992). See
Summary of findings 2.
The Bell 1988 study was at unclear risk of selection, performance
and detection bias and at low risk of attrition, reporting and other
bias. The Bell 1994 study was at high risk of attrition bias, at un-
clear risk of selection bias and at low risk of bias in the remain-
ing domains. Three studies were at unclear risk of selection, per-
formance, detection and attrition bias, and at low risk of report-
ing and other bias (Delle Chiaie 2000a; Delle Chiaie 2000b; De
Vanna 1992).
The antidepressant used as comparators in the included studies
were imipramine and desipramine.
Primary outcomes
2.1 Efficacy. Change in mean scores from baseline to end of
treatment on depression rating scale
In this analysis, a reduction of depression rating scale score (indi-
cated by a negative sign) represents an improvement.
The overall analysis showed that the efficacy of SAMe asmonother-
apy in the treatment of depression was not different from that of
imipramine (SMD -0.04, 95% CI -0.34 to 0.27; P = 0.82; 619
participants; 4 studies; I2 = 57%) (Analysis 2.1). The evidence
contributing to this outcome was low quality.
One study favoured SAMe over the active antidepressant
(imipramine) and was likely responsible for the heterogeneity be-
tween the studies (I2 = 57%; P = 0.07) (Bell 1988).
2.2 Acceptability. Participants dropping out of treatment
during study period for any reason
There was no evidence of a difference between SAMe and TCAs
(imipramine and desipramine) with regard to drop-outs during
the study period for any reason (RR 0.61, 95% CI 0.28 to 1.31;
P = 0.2; 78 participants; 3 studies; I2 = 0%) (Analysis 2.2). The
evidence contributing to this outcome was very low quality.
2.3 Acceptability. Participants dropping out of treatment
during study period because of adverse effects
There was no evidence of a difference identified between drop-
outs because of adverse effects with SAMe as monotherapy versus
imipramine (RR 0.75, 95% CI 0.20 to 2.79; P = 0.67; 52 partic-
ipants; 2 studies; I2 = 0%) (Analysis 2.3).
Secondary outcomes
2.4 Efficacy. Response to treatment, defined as a 50%
reduction or greater in depression score from baseline to end
of treatment
In this analysis, an increase of RR represents a response to treat-
ment in the SAMe group.
There was no strong evidence of a difference in the response rate
between SAMe and a TCA agent (imipramine and desipramine)
as monotherapy (RR 1.14, 95% CI 0.83 to 1.56; P = 0.42; 622
participants; 4 studies; I2 = 58%) (Analysis 2.4). The evidence
contributing to this outcome was very low quality.
We identified moderate heterogeneity among the studies (I2 =
58%; P = 0.07), which has been investigated in the Discussion.
2.5 Efficacy. Remission, defined as a depression rating scale
score within the normal range at end of study
There were no available data.
One study provided details on remission for the four participants
with psychotic features: the two participants in the experimental
group were fully recovered by the end of the study, both having
a HAM-D score of less than 10; however, the two participants in
the control group did not show remission (Bell 1988).
2.6 Acceptability. Participants experiencing troublesome
adverse effects of any nature
There was evidence of low quality that, compared to imipramine,
treatment with SAMe decreased the risk of experiencing trouble-
some adverse effects of any nature by 30% (RR 0.68, 95%CI 0.52
to 0.88; P = 0.004; 604 participants; 3 studies) (Analysis 2.5).
We identified moderate heterogeneity (I2 = 32%) between the
studies that was not significant (P = 0.23) and was probably due
to the De Vanna 1992 trial, which was the only one with the CI
including ’no effect’. This study has a considerably smaller sample
size than the other two; its removal from the analysis resulted in
the elimination of the heterogeneity.
2.7 Acceptability. Participants experiencing specific adverse
effects identified in protocol
Only one study detailed adverse effects (De Vanna 1992). In the
Bell 1988 study, it was just reported that none of the participants
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became manic during the trial. The De Vanna 1992 study re-
ported nausea and vomiting in six of the 15 participants in the
SAMe group and in one of the 15 participants in the imipramine
group, but we could not use these data in the analysis as these two
symptoms were not reported separately. None of the participants
reported headache, diarrhoea or flatulence. One participant ex-
hibited hypomania in the SAMe arm (RR 3.00, 95% CI 0.13 to
68.26; P = 0.49; 48 participants; 2 studies) (Analysis 2.6).
In all studies, there were no explicit reports of mortality. Over-
all, the trials did not systematically assess and report the risk for
suicidal ideation and behaviours. None of the studies mentioned
measurement of homocysteinaemia.
2.8 Acceptability. Participants dropping out for any reasons
other than adverse effects
There was no evidence that SAMe as monotherapy was more ac-
ceptable than a treatment with imipramine in terms of drop-outs
due to any reasons other than adverse effects (RR 1.00, 95% CI
0.17 to 5.89; P = 1; 52 participants; 2 studies; I2 = 0%) (Analysis
2.7).
Comparison 3: S-adenosyl methionine versus
selective serotonin reuptake inhibitor as
monotherapy
One study was eligible for this comparison (Mischoulon 2014).
See Summary of findings 3.
The included study was at unclear risk of attrition bias and at low
risk of bias in the other domains.
The antidepressant used as comparator was escitalopram.
Primary outcomes
3.1 Efficacy. Change in mean scores from baseline to end of
treatment on depression rating scale
In this analysis, lowering of a depression rating scale score (indi-
cated by a negative sign) represents an improvement.
The analysis showed that there was no evidence of a difference in
mean depression rating change scores between SAMe and escitalo-
pram, both as monotherapy (MD 0.12, 95% CI -2.75 to 2.99;
P = 0.93; 129 participants; 1 study) (Analysis 3.1). The evidence
contributing to this outcome was low quality.
3.2 Acceptability. Participants dropping out of treatment
during study period for any reason
There was no evidence of a difference between SAMe and esci-
talopram with regard to drop-outs during the study period for any
reason (RR 0.81, 95% CI 0.57 to 1.16; P = 0.26; 129 partici-
pants; 1 study) (Analysis 3.2). The evidence contributing to this
outcome was low quality.
3.3 Acceptability. Participants dropping out of treatment
during study period because of adverse effects
There was no evidence of a difference identified between drop-
outs because of adverse effects with SAMe as monotherapy versus
escitalopram (RR 0.38, 95% CI 0.11 to 1.37; P = 0.14; 129 par-
ticipants; 1 study) (Analysis 3.3).
Secondary outcomes
3.4 Efficacy. Response to treatment, defined as a 50%
reduction or greater in depression score from baseline to end
of treatment
In this analysis, an increase of RR represents a positive outcome
indicating response to treatment in the SAMe group.
There was no evidence of a difference in the response rate between
SAMe and escitalopram as monotherapy (RR 1.06, 95% CI 0.66
to 1.70; P = 0.8; 129 participants; 1 study) (Analysis 3.4). The
evidence contributing to this outcome was low quality.
3.5 Efficacy. Remission, defined as a depression rating scale
score within the normal range at end of study
In this analysis, an increase of RR represents a positive outcome
indicating response to treatment in the SAMe group.
There was no evidence that SAMe was more efficacious than an
active antidepressant agent in reaching the remission from depres-
sion (RR 1.02, 95% CI 0.58 to 1.77; P = 0.96; 129 participants; 1
studies) (Analysis 3.5). The evidence contributing to this outcome
was low quality.
3.6 Acceptability. Participants experiencing troublesome
adverse effects of any nature
There were no available data for this outcome.
3.7 Acceptability. Participants experiencing specific adverse
effects identified in protocol
There were no available data for this outcome. There were no ex-
plicit reports of mortality reported. The study did not systemati-
cally assess and report the risk for suicidal ideation and behaviours.
The study did not mention measurement of homocysteinaemia.
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3.8 Acceptability. Participants dropping out for any reasons
other than adverse effects
There was no evidence that SAMe as monotherapy was more ac-
ceptable than a treatment with a SSRI antidepressant (escitalo-
pram), in terms of drop-outs due to any reasons other than adverse
effects (RR 0.94, 95%CI 0.62 to 1.43; P = 0.77; 129 participants;
1 study) (Analysis 3.6).
Comparison 4: S-adenosyl methionine versus placebo
as adjunctive treatment
One study compared SAMe with placebo as an adjunctive treat-
ment to their existing SSRI treatment (Papakostas 2010a). See
Summary of findings 4. The study was at unclear risk of bias for
random sequence generation and at low risk of bias in the other
categories.
This study examined a particular subgroup of participants with
major depression, namely SSRI non-responders. We planned to
analyse this subgroup separately. However, as it was the only study
in this comparison, this was not necessary.
Primary outcomes
4.1 Efficacy. Change in mean scores from baseline to end of
treatment on depression rating scale
In this analysis, lowering of a depression rating scale score (indi-
cated by a negative sign) represents an improvement.
There was low quality evidence that SAMewas superior to placebo
as add-on to SSRIs in terms of change in depressive symptoms
from baseline to end of treatment (MD -3.90, 95% CI -6.93 to -
0.87; P = 0.01; 73 participants; 1 study) (Analysis 4.1).
4.2 Acceptability. Participants dropping out of treatment
during study period for any reason
There was no evidence of a difference between SAMe and placebo
as adjunctive therapy with regard to drop-outs during the study
period for any reason (RR 0.70, 95%CI 0.31 to 1.56; P = 0.38; 73
participants; 1 study) (Analysis 4.2). The evidence contributing
to this outcome was very low quality.
4.3 Acceptability. Participants dropping out of treatment
during study period because of adverse effects
There was no evidence of a difference between SAMe and placebo
as adjunctive therapy with regard to drop-outs during the study
period because of adverse effects (RR 0.58, 95% CI 0.10 to 3.28;
P = 0.54; 73 participants; 1 study) (Analysis 4.3).
Secondary outcomes
4.4 Efficacy. Response to treatment, defined as a 50%
reduction or greater in depression score from baseline to end
of treatment
In this analysis, positive RR represents a positive outcome indi-
cating response to treatment in the SAMe group.
We found evidence that the number of participants in the SAMe
arm who obtained a reduction of 50% or greater in depression
score was significantly higher than in the placebo arm (RR 2.62,
95% CI 1.17 to 5.83; P = 0.02; 73 participants; 1 study) (Analysis
4.4). The evidence contributing to this outcome was low quality.
4.5 Efficacy. Remission, defined as a depression rating scale
score within the normal range at end of study
In this analysis, an increase of RR represents a positive outcome
indicating response to treatment in the SAMe group.
For every person in the placebo group that achieved remission,
three people in the SSRI/SAMe achieved remission although obvi-
ously alongside the caveat that this is based on only study that was
low quality due to indirectness and imprecision (RR 3.05, 95%
CI 1.11 to 8.39; P = 0.03; 73 participants; 1 study) (Analysis 4.5).
4.6 Acceptability. Participants experiencing troublesome
adverse effects of any nature
There was no available data for this outcome.
4.7 Acceptability. Participants experiencing specific adverse
effects identified in protocol
The authors of the study reported only those adverse effects experi-
enced by at least two participants, and so we could not include the
study in the quantitative analysis of the all specific adverse effects.
The study reported headache and diarrhoea; neither were signifi-
cantly different compared with the placebo group (headache: RR
1.74, 95% CI 0.34 to 8.93; P = 0.50; 73 participants; 1 study;
Analysis 4.6; diarrhoea: RR 1.22, 95% CI 0.43 to 3.49; P = 0.71;
73 participants; 1 study; Analysis 4.7).
Therewere no explicit reports ofmortality during the study period.
Overall, the trials did not systematically assess and report risk
for suicidal ideation and behaviours. The study did not mention
measurement of homocysteinaemia.
4.8 Acceptability. Participants dropping out for any reasons
other than adverse effects
The number of drop-outs for any reasons other than adverse effects
was not significantly different between the two arms (RR 0.75,
95% CI 0.28 to 2.01; P = 0.56; 73 participants; 1 study) (Analysis
4.8).
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Subgroup analyses
We conducted subgroup analyses only on data from parenteral
and oral administration of SAMe.
We planned to perform other subgroup analyses but it was not
possible, as explained below.
One study described psychotic symptoms in four participants (two
in each treatment group) (Bell 1988); however, because it was
impossible to separate data from these participants, a subgroup
analysis was not undertaken. The authors commented that the two
participants in the SAMe groupwho experiencedmajor depression
with psychotic features (somatic/nihilistic delusions) were fully
recovered by the end of the study and each had a HAM-D score
of less than 10; both of the participants treated with imipramine
with psychotic features did not respond to imipramine only. Six
studies excluded participants who had psychotic symptoms (Delle
Chiaie 2000a; Delle Chiaie 2000b; De Vanna 1992; Kagan 1990;
Mischoulon 2014; Papakostas 2010a).
No studies provided data regarding a specific group of partici-
pants with atypical depression or with anxiety symptoms. How-
ever, one study used the augmented 31-itemHAM-D (Bell 1988).
This scale added items that identified atypical depressive symp-
toms such as hyperphagia; hypersomnia; psychomotor retarda-
tion; and feelings of helplessness, hopelessness and worthlessness;
in addition, the individual item anxiety on the same depression
scale was pointed out. The authors commented that between-
group comparison of scores for individual items on the HAM-
D at the endpoint demonstrated a significantly greater improve-
ment for participants treated with SAMe than participants treated
with imipramine on items concerning psychic anxiety, helpless-
ness, worthlessness and hypersomnia. One study evaluated partic-
ipants using the 14-item Hamilton Rating Scale for Anxiety (De
Vanna 1992); the authors commented that at the endpoint, there
was a significant difference versus baseline values on this scale in
both treatment groups.
One study examined a particular subgroup of participants with
major depression, namely SSRI non-responders (Papakostas
2010a).We planned to analyse this subgroup separately. However,
as it was the only study under the appropriate comparison, we did
not perform a subgroup analysis.
Comparison: S-adenosyl methionine versus tricyclic
antidepressant as monotherapy
Primary outcomes
5.1 Efficacy. Change in mean scores from baseline to end of
treatment on depression rating scale
The subgroup analyses on data from oral and parenteral admin-
istration of SAMe yielded similar results (oral: SMD 0.06, 95%
CI -0.17 to 0.28; P = 0.62; 303 participants; 2 studies; I2 = 0%;
Analysis 6.1; parenteral: SMD -0.46, 95% CI -1.68 to 0.75; P =
0.45; 316 participants; 2 studies; I2 = 85%; Analysis 6.2).
5.2 Acceptability. Participants dropping out of treatment
during study period for any reason
Consideringdata fromoral andparenteral administration of SAMe
separately, the lack of significant difference between SAMe and
active antidepressant persisted (oral: RR 0.54, 95% CI 0.23 to
1.27; P = 0.16; 56 participants; 2 studies; I2 = 0%; Analysis 6.3;
parenteral: RR 1.00, 95% CI 0.17 to 5.89; P = 1; 22 participants;
1 study; I2 = 0%; Analysis 6.4). We noted that in Bell 1988, of
the 11 participants treated with intravenous SAMe, two refused to
continue the study because of the discomfort of the intravenous
procedure.
5.3 Acceptability. Participants dropping out of treatment
during study period because of adverse effects
The subgroup analyses on data from oral and parenteral admin-
istration of SAMe did not change the results and neither of the
methods of administration differed from the two combined (oral:
RR 0.75, 95% CI 0.20 to 2.79; P = 0.67; 30 participants; 1 study;
I2 = 0%; Analysis 6.5; parenteral: no events; Analysis 6.6).
Secondary outcomes
5.4 Efficacy. Response to treatment, defined as a 50%
reduction or greater in depression score from baseline to end
of treatment
When we conducted the subgroup analysis separating data from
oral and parenteral administration, the outcome was not affected
(oral: RR 1.35, 95% CI 0.44 to 4.09; P = 0.6; 306 participants; 2
studies; I2 = 64%; Analysis 6.7; parenteral: RR 1.46, 95% CI 0.66
to 3.26; P = 0.35; 316 participants; 2 studies; I2 = 46%; Analysis
6.8), and neither of the methods of administration differed from
the two combined.
5.5 Acceptability. Participants experiencing troublesome
adverse effects of any nature
When we considered separately data from oral and parenteral ad-
ministration of SAMe, we found evidence for better acceptability
was found only for the parenteral administration (RR 0.59, 95%
CI 0.44 to 0.78; P = 0.0002; 294 participants; 1 study; I2 = 0%;
Analysis 6.9). The analysis of the data regarding the oral adminis-
tration of SAMe showed no significant difference between the two
groups (RR 0.80, 95%CI 0.50 to 1.27; P = 0.34; 310 participants;
2 studies; I2 = 40%; Analysis 6.10). In this last case, one out of the
two studies contributing to the outcome, only one favoured SAMe
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in terms of acceptability. The two studies were heterogeneous in
terms of sample size (180 participants Delle Chiaie 2000a; 30
participants De Vanna 1992). Further, in the Delle Chiaie 2000a
study, in participants who complained of adverse effects, the drug
dose could be reduced from the third week onward, to a mini-
mum dose of imipramine 100 mg/day and SAMe 1200 mg/day.
This could mean that a dose reduction of SAMe may minimise
the risk of experiencing adverse effects more than a reduction of
imipramine.
5.6 Acceptability. Participants dropping out for any reasons
other than adverse effects
When we considered data from oral and parenteral administration
of SAMe separately, the outcome was not affected and neither of
the methods of administration differed from the two combined
(oral: no events; Analysis 6.11; parenteral: RR 1.00, 95% CI 0.17
to 5.89; P = 1; 22 participants; 1 study; I2 = 0%; Analysis 6.12).
Sensitivity analyses
In the De Vanna 1992 study, we extrapolated the data regarding
the efficacy of treatment from the figure reported in the paper,
as no other information was available. To check the correctness
of our calculations, we verified if the extrapolated MD matched
with the per cent improvement in the mean scores shown in the
paper. In addition, the authors did not specify how they dealt
with missing data. We attempted to contact them in order to
obtain clarification, but were unsuccessful. As they did not indicate
whether they had or not conducted an ITT analysis, we decided
to use only the reported data without any imputation, in order to
be themost conservative possible. To assess the robustness of these
assumptions, we conducted a sensitivity analysis.
We identified two studies withmore than 30% ofmissing data and
carried out a sensitivity analysis (Bell 1994; Mischoulon 2014).
Further, as two studies provided no drop-outs rates, we decided
to exclude these studies in this sensitivity analysis (Delle Chiaie
2000a; Delle Chiaie 2000b).
The Bell 1994 studywas at high risk of attrition bias; we performed
a sensitivity analysis excluding this study.
Further, we conducted a sensitivity analysis where we had imputed
missing data and standard deviations.
Comparison 1: S-adenosyl methionine versus placebo as
monotherapy
Primary outcomes
6.1 Efficacy. Change in mean scores from baseline to end of
treatment on depression rating scale
When we performed a sensitivity analysis excluding the
Mischoulon 2014 trial (more than 30% missing data), the results
with the remaining data from Kagan 1990 were significantly dif-
ferent (Analysis 5.4). However, it is important to remember that
the Kagan 1990 study had a very small sample size (18 partici-
pants).
Otherwise, the other conducted sensitivity analyses did not affect
the results (sensitivity analysis for the imputation of continuous
efficacy data with the assumption that missing participants had
the same mean change as the other participants, Analysis 5.1;
sensitivity analysis for the imputation of standard deviations, using
correlation coefficient of 0.4, Analysis 5.3).
6.2 Acceptability. Participants dropping out of treatment
during study period for any reason
The sensitivity analysis excluding the study with high levels of
missing data (Mischoulon 2014) did not change the result, al-
though only one study remained (Kagan 1990) (Analysis 5.5).
Secondary outcomes
6.3 Efficacy. Response to treatment, defined as a 50%
reduction or greater in depression score from baseline to end
of treatment
We performed two sensitivity analyses: sensitivity analysis for the
imputationof dichotomous datawith the assumption of ’best-case’
scenario (Analysis 5.2), and sensitivity analysis excluding study
with high levels of missing data (Analysis 5.6). In both cases, the
results were not affected.
6.4 Acceptability. Participants dropping out for any reasons
other than adverse effects
The sensitivity analysis excluding Mischoulon 2014 (high level of
missing data) had only one study and did not affect the results
(Analysis 5.7).
Comparison 2: S-adenosyl methionine versus tricyclic
antidepressant as monotherapy
Primary outcomes
7.1 Efficacy. Change in mean scores from baseline to end of
treatment on depression rating scale
We conducted the following sensitivity analyses, which did not af-
fect the results: sensitivity analysis for the imputation of continu-
ous efficacy datawith the assumption thatmissing participants had
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the same mean change as the other participants (Analysis 6.13);
sensitivity analysis for the imputation of standard deviations using
correlation coefficient of 0.4 (Analysis 6.15); sensitivity analysis
excluding studies with high levels of missing data (Delle Chiaie
2000a; Delle Chiaie 2000b) (Analysis 6.16); sensitivity analysis
excluding the De Vanna 1992 study (Analysis 6.20).
7.2 Acceptability. Participants dropping out of treatment
during study period for any reason
The sensitivity analysis excluding studies with high levels of miss-
ing data (Bell 1994) (Analysis 6.17) and the sensitivity analysis
excluding the Bell 1994 study that was at high risk of attrition bias
(Analysis 6.21) did not change the results.
Secondary outcomes
7.3 Efficacy. Response to treatment, defined as a 50%
reduction or greater in depression score from baseline to end
of treatment
We carried out the sensitivity analyses as per protocol: sensitiv-
ity analysis for the imputation of dichotomous data with the as-
sumption of ’best-case’ scenario (Analysis 6.14); sensitivity analy-
sis excluding studies with high levels of missing data (Bell 1994;
Delle Chiaie 2000a; Delle Chiaie 2000b) (Analysis 6.18); sensi-
tivity analysis excluding the Bell 1994 study that was at high risk
of attrition bias (Analysis 6.22). This did not change the results.
7.4 Acceptability. Participants experiencing troublesome
adverse effects of any nature
When we performed a sensitivity analysis excluding studies with
high levels of missing data (Delle Chiaie 2000a; Delle Chiaie
2000b), only the De Vanna 1992 study remained. The results
changed and we found no evidence of SAMe superiority (Analysis
6.19).
Comparison 3: S-adenosyl methionine versus selective
serotonin reuptake inhibitor as monotherapy
Primary outcomes
8.1 Efficacy. Change in mean scores from baseline to end of
treatment on depression rating scale
We conducted a sensitivity analysis for the imputation of standard
deviations using correlation coefficient of 0.4, which did not affect
the results (Analysis 7.1).
Comparison 4: S-adenosyl methionine versus placebo as
adjunctive treatment
Primary outcomes
9.1 Efficacy. Change in mean scores from baseline to end of
treatment on depression rating scale
We performed a sensitivity analysis to assess the robustness of the
imputation of standard deviations using a correlation coefficient
of 0.4 (Analysis 8.1). The outcome was not affected.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
S-adenosyl methionine compared to tricyclic antidepressant agent as monotherapy for depression in adults
Patient or population: adults with depression
Settings: inpat ient and outpat ient
Intervention: SAMe as monotherapy
Comparison: TCA as monotherapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control SAM e vs. TCA as
monotherapy
Efficacy. Change in
scores from baseline to
end of treatment on the
depression rating scale
A larger negat ive SMD
indicates greater im-
provement in the SAMe
group
Follow-up: 2 to 6 weeks
- The mean change in
scores f rom baseline to
end of treatment on the
depression rat ing scale
in the SAMe group was
0.04 standard devi-
ations greater (0.34
lower to 0.27 higher), in-
dicat ing more improve-
ment. However, this
was not stat ist ically
signif icant
- 619
(4 studies)
⊕⊕©©
low1,2
SMD -0.04 (95% CI -0.
34 to 0.27)
Acceptability
Part icipants dropping
out of treatment during
the study period for any
reason
Follow-up: 2 to 6 weeks
Study population RR 0.61
(0.28 to 1.31)
not stat ist ically signif i-
cant
78
(3 studies)
⊕©©©
very low3,4,5
-
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33 per 100 20 per 100
(9 to 44)
M oderate
27 per 100 16 per 100
(7 to 35)
Proportions of partic-
ipants responding to
treatment
≥ 50% reduct ion in
depression score f rom
baseline to end of treat-
ment
A larger RR indicates
greater response to
treatment in the SAMe
group
Follow-up: 2 to 6 weeks
Study population RR 1.14
(0.83 to 1.56)
not stat ist ically signif i-
cant
622
(4 studies)
⊕©©©
very
low5,6,7
-
50 per 100 57 per 100
(42 to 79)
M oderate
34 per 100 39 per 100
(28 to 54)
Proportions of partici-
pants achieving remis-
sion
Depression rat ing scale
score within the normal
range at the end of the
study
No data - - - - -
Acceptability. Partic-
ipants experiencing
troublesome adverse
effects of any nature
Follow-up: 4 to 6 weeks
Study population RR 0.68
(0.52 to 0.88)
stat ist ically signif icant
604
(3 studies)
⊕⊕©©
low4,8
-
49 per 100 33 per 100
(25 to 43)
M oderate
2
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47 per 100 32 per 100
(24 to 41)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io; SAM e: S-adenosyl methionine; SM D: standardised mean dif ference; TCA: t ricyclic ant idepressant.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 downgraded one point because of risk of bias: the Bell 1988 study was at unclear risk of select ion, performance and
detect ion bias; three studies were at unclear risk of select ion, performance, detect ion and attrit ion bias (Delle Chiaie 2000a;
Delle Chiaie 2000b; De Vanna 1992).
2 downgraded one point because of inconsistency caused by signif icant heterogeneity between the studies (I2 = 57%; P =
0.07). It was due to one study that favoured SAMe over the act ive ant idepressant (im ipramine) (Bell 1988). The dif ferent
result of the Bell 1988 study could be due to its shorter durat ion (two weeks) and to the fact that the therapeut ic act ions
of im ipramine usually are not immediate, but of ten delayed by two to four weeks. This could suggest a more rapid onset of
act ion of the SAMe. Also, the doses and routes of administrat ion of SAMe among the studies were heterogeneous. However,
when subgroup analysis was conducted separat ing data regarding oral and parenteral administrat ion of SAMe, the outcome
was not af fected.
3 downgraded one point because of risk of bias: the Bell 1988 study was at unclear risk of select ion, performance and
detect ion bias; the Bell 1994 study was at high risk of attrit ion bias and at unclear risk of select ion bias; the De Vanna 1992
study was at unclear risk of select ion, performance, detect ion and attrit ion bias.
4 downgraded one point because of imprecision caused by a total number of events that was fewer than 300.
5 downgraded one point because of imprecision caused by a 95% conf idence interval that includes both no ef fect and
appreciable benef it and appreciable harm (the threshold for ’appreciable benef it ’ or ’appreciable harm’ was a relat ive risk
reduct ion (RRR) or relat ive risk increase (RRI) greater than 25%).
6 downgraded one point because of risk of bias: the Bell 1988 study was at unclear risk of select ion, performance and
detect ion bias; the Bell 1994 study was at high risk of attrit ion bias and at unclear risk of select ion bias; two studies were at
unclear risk of select ion, performance, detect ion and attrit ion bias (Delle Chiaie 2000a; Delle Chiaie 2000b).
7 downgraded one point because of inconsistency caused by signif icant heterogeneity among the studies (I2 = 58%, P =
0.07). It could be caused by the dif ferent durat ions of the treatment. Then, the studies dif fered in terms of ant idepressants
compared to the intervent ion, but it did not explain the heterogeneity. Also, the doses and routes of administrat ion of SAMe
among the studies were heterogeneous. However, when we conducted subgroup analysis separat ing data regarding oral and
parenteral administrat ion of SAMe, the outcome was not af fected.3
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8 downgraded one point because of risk of bias: the three studies were at unclear risk of select ion, performance, detect ion
and attrit ion bias (Delle Chiaie 2000a; Delle Chiaie 2000b; De Vanna 1992).
9 downgraded one point because of risk of bias: the Bell 1988 study was at unclear risk of select ion, performance and
detect ion bias; the De Vanna 1992 study was at unclear risk of select ion, performance, detect ion and attrit ion bias.
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S-adenosyl methionine compared to SSRI antidepressant agent as monotherapy for depression in adults
Patient or population: adults with depression
Settings: outpat ients
Intervention: SAMe as monotherapy
Comparison: SSRI ant idepressant agent as monotherapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control SAM e vs. SSRI an-
tidepressant agent as
monotherapy
Efficacy. Change in
scores from baseline to
end of treatment on the
depression rating scale
A larger negat ive MD
indicates greater im-
provement in the SAMe
group
Follow-up: 12 weeks
- The mean change in
scores f rom baseline to
end of treatment on the
depression rat ing scale
in the SAMe group was
0.12 standard devia-
tions lower (2.75 lower
to 2.99 higher), indicat-
ing less improvement.
However, this was not
stat ist ically signif icant
- 129
(1 study)
⊕⊕©©
low1,2
MD 0.12 (95% CI -2.75
to 2.99)
Acceptability
Part icipants dropping
out of treatment during
the study period for any
reason
Follow-up: 12 weeks
Study population RR 0.81
(0.57 to 1.16)
not stat ist ically signif i-
cant
129
(1 study)
⊕⊕©©
low3,4
-
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54 per 100 44 per 100
(31 to 62)
M oderate
54 per 100 44 per 100
(31 to 63)
Proportions of partic-
ipants responding to
treatment
≥ 50% reduct ion in
depression score f rom
baseline to end of treat-
ment
A larger RR indicates
greater response to
treatment in the SAMe
group
Follow-up: 12 weeks
Study population RR 1.06
(0.66 to 1.7)
not stat ist ically signif i-
cant
129
(1 study)
⊕⊕©©
low3,4
-
34 per 100 36 per 100
(22 to 58)
M oderate
34 per 100 36 per 100
(22 to 58)
Proportions of partici-
pants achieving remis-
sion
depression rat ing scale
score within the normal
range at the end of the
study
A larger RR indicates
greater response to
treatment in the SAMe
group
Follow-up: 12 weeks
Study population RR 1.02
(0.58 to 1.77)
not stat ist ically signif i-
cant
129
(1 study)
⊕⊕©©
low3,4
-
28 per 100 28 per 100
(16 to 49)
M oderate
28 per 100 28 per 100
(16 to 49)
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Acceptability. Partic-
ipants experiencing
troublesome adverse
effects of any nature
No data - - - - -
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; M D: mean dif ference; RR: risk rat io; SAM e: S-adenosyl methionine; SSRI: select ive serotonin reuptake inhibitor.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 downgraded one point because of imprecision caused by small sample size, fewer than 400.
2 downgraded one point because of imprecision caused by a 95% conf idence interval that included no ef fect and the upper
and lower conf idence lim it crossed an ef fect size of 0.5 in either direct ion.
3 downgraded one point because of imprecision caused by a total number of events that was fewer than 300.
4 downgraded one point because of imprecision caused by a 95% conf idence interval that includes both no ef fect and
appreciable benef it and appreciable harm (the threshold for ’appreciable benef it ’ or ’appreciable harm’ was a relat ive risk
reduct ion (RRR) or relat ive risk increase (RRI) greater than 25%).
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S-adenosyl methionine as adjunctive treatment compared to placebo as add-on for depression in adults
Patient or population: adults with depression
Settings: outpat ients
Intervention: SAMe as adjunct ive treatment to SSRI
Comparison: placebo as adjunct ive treatment to SSRI
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo as add-on SAM e as adjunctive
treatment
Efficacy. Change in
scores from baseline to
end of treatment on the
depression rating scale
A larger negat ive MD
indicates greater im-
provement in the SAMe
group
Follow-up: 6 weeks
- The mean change in
scores f rom baseline to
end of treatment on the
depression rat ing scale
in the SAMe group was
3.9 greater (6.93 to
0.87 lower), indicat-
ing more improvement.
This was stat ist ically
signif icant
- 73
(1 study)
⊕⊕©©
low1,2
MD -3.90 (-6.93 to -0.
87)
Acceptability
Part icipants dropping
out of treatment during
the study period for any
reason
Follow-up: 6 weeks
M oderate RR 0.7
(0.31 to 1.56)
not stat ist ically signif i-
cant
73
(1 study)
⊕©©©
very low2,3,4
-
29 per 100 21 per 100
(9 to 46)
Proportions of partic-
ipants responding to
treatment
≥ 50% reduct ion in
M oderate RR 2.62
(1.17 to 5.83)
stat ist ically signif icant
73
(1 study)
⊕⊕©©
low2,4
-
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depression score f rom
baseline to end of treat-
ment
A larger RR indicates
greater response to
treatment in the SAMe
group
Follow-up: 6 weeks
18 per 100 46 per 100
(21 to 100)
Proportions of partici-
pants achieving remis-
sion
depression rat ing scale
score within the normal
range at the end of the
study
A larger RR indicates
greater response to
treatment in the SAMe
group
Follow-up: 6 weeks
M oderate RR 3.05
(1.11 to 8.39)
stat ist ically signif icant
73
(1 study)
⊕⊕©©
low2,4
-
12 per 100 36 per 100
(13 to 99)
Acceptability. Partic-
ipants experiencing
troublesome adverse
effects of any nature
No data - - - - -
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; M D: mean dif ference; RR: risk rat io; SAM e: S-adenosyl methionine; SSRI: select ive serotonin reuptake inhibitor.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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1 downgraded one point because of imprecision caused by small sample size, fewer than 400.
2 downgraded one point because of indirectness caused by a populat ion restricted to SSRI non-responders
3 downgraded one point because of imprecision caused by a 95% conf idence interval that included both no ef fect and
appreciable benef it and appreciable harm (the threshold for ’appreciable benef it ’ or ’appreciable harm’ was a relat ive risk
reduct ion (RRR) or relat ive risk increase (RRI) greater than 25%.
4 downgraded one point because of imprecision caused by a total number of events that was fewer than 300.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
This systematic review included eight trials and 934 participants.
The quality of the evidence, reflected in the GRADE analysis,
ranged from low to very low. This limits the applicability of the
findings and the interpretation of the treatment effects should be
made with caution.
We did not find that SAMe was more efficacious than placebo
in monotherapy, reflected in mean change data in depression rat-
ing scale and in response and remission findings; there were two
studies in the first two analyses and one study in the last analy-
sis. These results should be interpreted with caution. The quality
of the evidence contributing to these outcomes was low to very
low. The result of these analyses were determined by data from
a large three-arm trial in which neither SAMe nor escitalopram
were superior to placebo. Further, in Analysis 1.1 (change in mean
scores from baseline to end of treatment on the depression rating
scale) the studies showed a high level of heterogeneity (I2 = 72%;
P = 0.06). The Kagan 1990 study favoured SAMe over placebo
in terms of efficacy (SMD -1.18; CI -2.21, -0.15; P = 0.02), but
the Mischoulon 2014 study reported no evidence that the active
treatment was more efficacious than placebo (SMD -0.13; CI -
0.48 to 0.22; P = 0.46). This heterogeneity could be related to
the different duration of the trials (three weeks, Kagan 1990; 12
weeks, Mischoulon 2014). As the risk of spontaneous improve-
ment is cumulative (Posternak 2000), it could be maximised in
a 12-week trial, increasing the placebo response. However, it is
noted that in the Mischoulon 2014 study, there was significant
separation between SAMe and placebo on the depression rating
scale only at treatment at weeks eight and 10, not at week three
and dose increase was allowed for non-responders at week six. It
is also noted that in Mischoulon 2014, a three-armed study com-
paring placebo, SAMe and escitalopram, at the endpoint, all three
treatments arms demonstrated a significant improvement in the
depression rating scale but there was no significant difference be-
tween any of the treatments. Another potential source of hetero-
geneity could be that different formulations of SAMe may have
been used: Mischoulon 2014 used SAMe tosylate, while Kagan
1990 did not specify the formulation. Another source of hetero-
geneity could be that participants in Kagan 1990 trial were all in-
patients while in Mischoulon 2014 trial they were all outpatients;
this could suggest a different severity of the disease. In addition,
one study recruited only men (Kagan 1990), while Mischoulon
2014 recruited both men and women, raising the issue of a possi-
ble gender effect of SAMe (Sarris 2015a). In addition, it is relevant
that the two studies were highly diverged in terms of sample size:
Mischoulon 2014 had the largest number of participants (124),
but also had a high level of missing data.
SAMe was more efficacious than placebo as an adjunctive treat-
ment, using mean change data and in terms of response and re-
mission. The quality of this evidence was low. Only one small
study contributed to these outcomes, only SSRIs were tested as
an add-on therapy and the data regarded a specific subgroup of
participants (SSRI non-responders).
We did not find the efficacy of SAMe as monotherapy to be differ-
ent from that of TCA and SSRI antidepressants in the treatment of
depression, using mean change data and response/remission find-
ings; four studies were in the comparison SAMe versus TCAs and
one study in the comparison SAMe versus SSRI. There was a very
small selection of antidepressants tested: the TCAs imipramine
anddesipramine, and the SSRI escitalopram. In addition, the qual-
ity of the evidence contributing to outcomes was low or very low.
Under the comparison of SAMe versus a TCA for themean change
score outcome, the studies involved in the analysis were hetero-
geneous (I2 = 57%; P = 0.07). One study favoured SAMe over
imipramine (Bell 1988). This could be due to its shorter duration
(two weeks). In addition, the therapeutic action of imipramine is
often delayed by two to four weeks, and these results may sug-
gest a more rapid onset of action of the SAMe. Another poten-
tial source of heterogeneity could be that different formulations
of SAMe could have been used: the Delle Chiaie 2000a and Delle
Chiaie 2000b studies used butanedisulphonate-SAMe, while the
other trials did not specify formulations. In addition, the doses
and routes of administration of SAMe among the studies varied.
However, when we conducted subgroup analyses separating data
regarding oral and parenteral administration of SAMe, neither of
the methods of administration differed from the two combined
and the outcome was not affected. Under the same comparison
examining response, we identified moderate heterogeneity among
the studies (I2 = 58%; P = 0.07). The reasons above could explain
this heterogeneity as well as the different comparator antidepres-
sants used (even if there was no pattern of efficacy to explain the
heterogeneity).
Overall, the quality of the evidence related to acceptability out-
comes was low or very low.
We did not find any evidence that SAMe was more acceptable
than antidepressant agents in terms of drop-outs. For the com-
parison SAMe versus TCA, there were three studies in the anal-
ysis ’Participants dropping out of treatment during the study pe-
riod for any reason’ and two studies in the analysis ’Participants
dropping out of the treatment during the study period because
of adverse effects’; for the comparison SAMe versus SSRI, there
was only one study. Interestingly, there was no strong evidence
of a difference in rates of drop-outs between SAMe and placebo;
there were two studies in the analyses where SAMe and placebo
were used as monotherapy, and one study in the analyses where
SAMe and placebo were used as an adjunctive treatment.With the
exception of the De Vanna 1992 study where all drop-outs were
caused by adverse effects, withdrawals were generally due to other
causes such as clinical worsening, non-adherence and scheduling.
With regard to tolerability in terms of number of participants
experiencing troublesome adverse effects of any nature, we found
38S-adenosyl methionine (SAMe) for depression in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
parenteral SAMe to be more tolerable than imipramine (three
studies in this analysis).Data regarding tolerability of SAMe for the
other comparison were not available; however, the studies reported
in the text that SAMe was overall safe and well-tolerated.
Most studies did not detail the specific adverse effects or they
were often described with considerable heterogeneity, precluding a
complete quantitative analysis of these data. Therefore, no defini-
tive conclusions can be drawn on this issue. Using the available
data, we found no evidence of a difference between SAMe and the
comparisonswith regard to the specific adverse effects of headache,
diarrhoea and flatulence (only one study and a very small num-
ber of participants were included in each analyses). With regard
to mania/hypomania, the analyses involved two studies: in one
study, one participant exhibited hypomania and in another study,
one participant with no prior history of mania experienced manic
symptoms, both while taking SAMe. There were no explicit re-
ports of mortality. Overall, the trials did not systematically assess
and report risk for suicidal ideation and behaviours.
The parenteral and oral administration of SAMe seemed to be
comparable. Trials used lower doses for parenteral administration
than oral. This probably reflects the better bioavailability of SAMe
when given parenterally (Stramentinoli 1979). However, the spe-
cific dose equivalence between the oral and parenteral routes of
administration of SAMe is not established yet.
Overall completeness and applicability of
evidence
1. This systematic review included only RCTs and they were
similar in design. They differed in duration of treatment, routes
of administration and sample size. The assessment of the quality
of the trials was often hindered by the lack of detail regarding key
methodological issues, such as randomisation, allocation
concealment, blinding and missing data.
2. The number of included studies, the number of trials used
in each comparison, and, in general, the number of participants
in those studies were small. Although all the objectives of the
review were addressed (see Objectives), not all studies provided
appropriate data for all the outcomes we considered. In addition,
for some outcomes the CIs were large. These factors limit the
applicability of the findings and the interpretation of the
treatment effects.
3. The use of SAMe in the included studies reflects its use in
practice. Trials tested standard doses and both oral and parenteral
routes. However, in the clinical practice lower doses of SAMe are
also administered for the oral route (800 mg/day to 1200 mg/
day as per leaflet of the commercialised drug).
4. Studies analysed both men and women with a diagnosis of
major depression according to DSM-III or DSM-IV criteria, the
population of interest for this review. However, with the
exception of one study examining a particular subgroup of
participants with major depression (SSRI non-responders), we
could not obtain data from other subgroup of participants such
as with atypical depression or anxiety symptoms or psychotic
symptoms or with treatment resistance. Therefore, we could not
investigate if participants with certain subtypes of depression
may respond differently to SAMe. We also excluded participants
with bipolar depression, schizoaffective disorder, cyclothymia
and dysthymia; therefore, the results cannot be generalised to
depressive episodes occurring in these contexts. Overall, it is
accepted that one of the main limitations of efficacy trials is to
include participants far from “real world” (Rothwell 2005). In
clinical practice, patients are usually very heterogeneous, even
among groups of people with the same diagnosis. Similarly, in
clinical practice a large proportion of people with depression
have physical comorbidities. As we excluded studies of
participants with physical comorbidities, this further limits the
generalisability of the findings. This issue may be considered in a
future version of this review.
5. We found SAMe to be more efficacious than placebo as an
adjunctive treatment. However, the applicability of this evidence
is limited. Only one trial contributed to the outcome,
participants were only SSRI non-responders and SAMe was
added only to one category of antidepressant (the SSRI). Further,
under the comparisons of SAMe versus an active treatment,
overall studies included only three antidepressant agents
(imipramine, escitalopram and desipramine), limiting the
applicability of the evidence.
6. The economic case for the use of SAMe in clinical practice
cannot be made as the trials did not provide information on the
comparative costs of the treatments.
Quality of the evidence
We assessed the quality of evidence and constructed the ’Summary
of findings’ tables for each comparison. See Summary of findings
for the main comparison; Summary of findings 2; Summary of
findings 3; Summary of findings 4.
From the GRADE evaluation documented in the ’Summary of
findings’ tables, this systematic review found no evidence of high
or moderate quality. The quality of the evidence for SAMe was
generally low/very low.
It is concluded that higher quality evidence from further research
would be required to increase our confidence in the estimate of
the effect of this intervention. We rated the quality of the body of
evidence for the outcomes accounting the following factors: risk
of bias, inconsistency, indirectness, imprecision and publication
bias.
All included studies were RCTs. However, often, we were unable
to assess the quality of the trials because of the lack of information
regarding randomisation, allocation concealment, blinding and
missing data (Bell 1988; Delle Chiaie 2000a; Delle Chiaie 2000b;
De Vanna 1992). On addition, one of the included studies had
a high risk of attrition bias (Bell 1994). We downgraded, for risk
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of bias, the quality of evidence by one level for the outcomes
determined by these studies.
We downgraded, for inconsistency, the evidence for the outcomes
where the contributing studies showed a significant heterogeneity
(P < 0.1).
We downgraded the evidence for the outcomes where the
Papakostas 2010a study was a contributor, because of indirectness.
This trial examined a particular subgroup of participants with ma-
jor depression, namely SSRI non-responders.
In most outcomes, we downgraded the quality of evidence for
imprecision because the sample size was small, the number of
relevant events was small and the CIs were wide and included ’no
effect’.
In accordance with the protocol, we did not formally assess pub-
lication bias by funnel plot analyses, because the review included
fewer than 10 studies (Galizia 2014).
Potential biases in the review process
Some limitations and biases could be noted in the review process.
1. We performed a broad and thorough literature search,
exploring all sources detailed in the protocol (Galizia 2014).
Therefore, it is likely that we identified all relevant studies.
However, it is possible that we missed studies that are still
unpublished or are currently being conducted and plan to
include these in future updates of the review. Then, although we
made exhaustive attempts to retrieve as much data as possible, by
asking pharmaceutical companies and study authors to supply all
available information, data from some trials are still lacking.
Further, this review lists a number of references and one study
classified as ’awaiting classification’, apparently published but
proved unretrievable.
2. All included studies were RCTs. However, the assessment of
the trial quality was often complicated by the lack of information
regarding randomisation, allocation concealment, blinding and
missing data. Further, some of the older included studies did not
reflect current methodological practice.
3. Overall, the included studies did not always report the data
we needed to assess all our outcomes. For example, only a few
studies reported detailed data on the specific adverse effects
occurring during the trials as well as the rates of adverse effects of
any nature experienced by participants.
4. The meta-analyses often combined data from studies of
different durations and routes of medication administration.
Where identified, we investigated heterogeneity and conducted
subgroup analyses if possible.
5. In the case of missing data, we analysed data on an ITT
basis. Some of the studies included data from ’completer’ data-
sets only. Although we contacted the trialists, attempts to obtain
additional unpublished data and information regarding missing
data were almost always unsuccessful. We were unable to use the
LOCF approach for dealing with missing data, as individual raw
participant data were not available. Therefore, where needed, we
imputed the missing data as well as the standard deviations.
Although the sensitivity analyses conducted to assess the
robustness of the assumptions yielded similar results, the
imputation may have led to biases.
6. Although all included studies evaluated the efficacy of
treatment by administration of the HAM-D, they used different
versions of this rating scale. Therefore, we had to apply the SMD
in order to measure the treatment efficacy and this could have
led to some biases.
7. We evaluated both the rates of response to treatment and
the remission. ’Treatment response’ describes an improvement in
the person’s condition of sufficient quality to result in a reduction
of at least 50% in depressive symptomatology. However, what is
clinically relevant is achieving remission, which correlates with
better longer-term functional recovery and lower risk of relapse.
Only two studies in this review reported remission rates.
8. Three studies provided participants over the age range of
our review, including participants aged 18 to 80 years (De Vanna
1992; Mischoulon 2014; Papakostas 2010a). Our protocol
restricted the age range to 18 to 70 years but did not stipulate
methods for how to deal with this issue (Galizia 2014). We
decided to include these studies after consideration of the mean
age of the participants.
9. One study was not designed to test efficacy of SAMe as a
primary outcome, but focused on the correlation between plasma
SAMe levels and the degree of clinical improvement (Bell 1994).
In this study, a subset of participants from a previously reported
double-blind study comparing oral SAMe and desipramine
participated in the trial. Therefore, though the study included
data for efficacy and tolerability, it may not have been sufficiently
powered to detect differences in depressive symptoms.
10. Another potential bias in the review process could come
from the method in which data were obtained from the De
Vanna 1992 study. We extrapolated data regarding the efficacy of
treatment from the figure reported in the paper, as no other
information was available. We checked the correctness of our
calculations verifying that the extrapolated MDs matched the per
cent improvement in the mean scores cited in the paper. In
addition, the authors of this study did not specify how they dealt
with missing data. We attempted to contact authors to obtain
clarification but were unsuccessful. As they did not indicate
whether they had conducted an ITT analysis, we decided to use
the reported data without any imputation. These factors could
have led to bias, although the sensitivity analysis conducted
yielded similar results.
11. Some studies allowed the use of benzodiazepines as a
hypnotic, but in none of the studies did the authors analyse its
potential confounding effects. This could have led to bias in the
included studies and so in this review.
12. In the present review no RCTs reported economic
outcomes. This represents a limit for the applicability of findings
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as comprehensive economic estimates of antidepressant
treatment effect would better inform healthcare policy.
Agreements and disagreements with other
studies or reviews
Meta-analyses (Bressa 1994; Hardy 2002) and systematic reviews
(Carpenter 2011; Mischoulon 2002; Papakostas 2003; Williams
2005) have consistently concluded that SAMe is effective for treat-
ing depression, with an efficacy superior to placebo and equivalent
to the conventional antidepressants. Further, when used in com-
bination with conventional antidepressants, it has been reported
that SAMe seems to have the potential to enhance response or
limit adverse effects, by allowing lower doses of the conventional
antidepressant to be prescribed (Sarris 2010).
In our review, we found that the efficacy of SAMe for the treat-
ment of depression was not different from TCA and SSRI an-
tidepressants and higher than placebo as an adjunctive treatment,
though the comparisons with SSRI antidepressants and placebo
as an adjunctive treatment included only one study. In contrast
to the findings of other reviews, we did not demonstrate superior
efficacy of SAMe in comparison with placebo in monotherapy. In
our review, this analysis was undermined by a high level of hetero-
geneity and included only two studies.
With regard to acceptability, SAMe has generally reported to be
safe andwell-toleratedwith amore favourable adverse effect profile
than conventional antidepressants (Carpenter 2011; Hardy 2002;
Rambaldi 2006). In our review, SAM-e was not found to be dif-
ferent from either placebo or established antidepressants.
SAMe has been reported to be associated (in rare instances) with
induction of mania (Carney 1989; Carpenter 2011; Gören 2004;
Lipinski 1984) - similarly to conventional antidepressants. Two
studies in our review reported one participant each who presented
with manic/hypomanic symptoms in the SAMe arm.
Where our findings differ from results of previous reviews, it could
be considered that the quality and the methodological rigour of
many of the individual studies included in the previous reviews
is questionable. Most of these studies were older, had a hetero-
geneous population of participants with a diagnosis not necessar-
ily restricted to major depression. Many of the studies exhibited
methodological flaws, had a small sample size and a short duration
of treatment. Often they include data from ’completer’ data-sets
only and exclude participants dropping out for any reason from
the efficacy analysis.
We strictly adhered to the inclusion criteria of our protocol, aiming
to improve the quality of the body of the evidence (Galizia 2014).
This was probably the reason we have included fewer studies in
this review than other reviews. Nevertheless, we met the same lim-
itations of the previous reviews. Some studies were methodologi-
cally dated, lacked information on methodological key issues, had
an inadequate sample size, included data from completers partic-
ipants only, did not report data in an extractable way or a combi-
nation of these.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Given the absence of high quality evidence and the inconsistency
of our findings, we are unable to draw firm conclusions about
the use of S-adenosyl methionine (SAMe) for the treatment of
depression in adults. It should be investigated further by additional
larger high quality randomised controlled trials.
There were two reports of mania/hypomania in a review of 441
participants in the SAMe arm. Although this adverse effect was
not commonly found in our analysis, it is an important factor to
be considered in clinical settings.
Implications for research
Further research of high methodological quality is required to es-
tablish the efficacy and acceptability of SAMe confidently. Dou-
ble-blind randomised controlled trials should be conducted. Spe-
cific attention should be paid to the process of randomisation, al-
location concealment, blinding and handling of missing data.
In addition, the following methodological issues should be con-
sidered.
1. The population studied. Future studies should include
people with a diagnosis of major depression of both sexes; aged
18 years and over; of all ethnicities; and in inpatient, outpatient
and primary care settings. Data from particular subgroups of
participants with major depression, such as those with psychotic
features, mixed features, anxiety symptoms, treatment resistance
or atypical depression should be analysed separately.
2. The nature of the intervention. SAMe should be studied in
monotherapy and as an adjunctive therapy to antidepressant
medication. A dose of 800 mg/day to 1600 mg/day for oral
administration and 200 mg/day to 400 mg/day for parenteral
administration should be used. There is little available
information about the comparability of oral and parenteral doses
of SAMe. Clearly, it would be important to establish this in
studies where oral and parenteral SAMe are directly compared.
Because SAMe is best absorbed on an empty stomach, it should
be administered 30 to 60 minutes before meals or two hours
after meals; future studies should instruct the participants and
monitor for compliance with these instructions. In addition, as
the stability of different formulae and of the tablets varies, in
future studies the formulation of SAMe should be reported in
detail. Trials should also be of at least eight weeks’ duration.
Comparison interventions should include placebo and alternative
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antidepressants or adjunctive agents from all classes. The
antidepressants tested should not be limited to TCAs and SSRI.
3. Relevant outcome measures. Detailed and complete
information should be provided on depression rating scale scores,
remission and response rates, drop-outs with the reasons why
and accounts of specific adverse events. It would be desirable if
these were documented for each participant. Reports of mania
and hypomania are important, particularly with regard to the
safety of prescribing this treatment in people with depression at
high risk of later developing a bipolar illness.
Hyperhomocysteinaemia is also of interest. It would be
worthwhile to investigate specific adverse effects that can limit
the participants’ compliance, such as sexual adverse effects and
weight gain; SAMe could potentially have an advantage with
regard to adverse effects that are commonly caused by recognised
antidepressants. Outcome measures of relevance to participants
and their carers should also be included. Further, there could be
a gender effect with regard to response to SAMe; this has been
reported previously (Sarris 2015a), and may have been a possible
explanation for the heterogeneity between the Kagan 1990 and
Mischoulon 2014 studies. Therefore, it would be interesting to
conduct analyses by the subgroup gender in order to investigate a
possible gender effect.
4. Data on the comparative costs of treatment should be
included in future studies, to allow economic analyses.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bell 1988
Methods Double-blind, randomised, controlled study
Participants 22 inpatients included and treated
Age (years): range 20 to 65 (mean ± SD age of the 18 participants who completed the
study 43 ± 13)
Sex: 5 men, 13 women
Diagnosis: DSM-III diagnosis of major depression and a score at baseline > 23 on an
augmented 31-item version of the HAM-D
Exclusion criteria: histories of major medical illness, personality disorder or substance or
alcohol abuse in the 6months preceding the study; refusal to given written informed con-
sent; history of failure to respond to the equivalent of 150 mg/day or more of imipramine
given for 4 weeks
Interventions SAMe: 11 participants; increasing doses of SAMe iv, from 200 mg/day to 400 mg/day
iv, over 3 days and then were maintained at 400 mg/day throughout the rest of the study
Imipramine: 11 participants; imipramine titrated up to 150mg/day (capsules) in divided
doses over 4 days and then received that dose through the rest of the trial. Also given iv
saline infusions each day
Duration of treatment: 14 days, preceded by 2-day baseline evaluation and medication
washout
Outcomes Efficacy of treatment evaluated by 31-item HAM-D assessed daily and BDI completed
by the participants at baseline and on the last day of study. A reduction of more than
50% on HAM-D was considered a successful treatment response
Tolerability of treatment evaluated by performing CBC, SMA-18, urinalysis, thyroid
function tests, ECG, and DST, at baseline and on the last day of the study; vital signs,
including blood pressure, pulse, and respiration, recorded at baseline evaluation and on
each study day 15, 30 and 60 minutes after the infusion was started
Somatic Symptom Checklist assessed daily
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients randomly assigned”. Method not
described
Allocation concealment (selection bias) Unclear risk Identical tablets and saline infusions. No
other measures described
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Bell 1988 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Nursing staff, raters and participants blind
to the type of infusions.Not specified about
tablets. Allocation concealment was not de-
scribed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Raters blind to type of infusions. Concern
since allocation concealment not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcomes not enough to have clin-
ically relevant impact on observed effect
size. Reason for drop-outs stated
22 participants included and treated. 4 par-
ticipants (2 in each drug treatment group)
did not complete the study; 1 withdrawn
after receiving a diagnosis of antisocial per-
sonality disorder, 2 refused to continue be-
cause of discomfort with the iv procedure,
and 1 withdrawn because results of a test
for syphilis were positive
Selective reporting (reporting bias) Low risk No formal a priori statement of primary
outcome measure, but did report HAM-D
Other bias Low risk
Bell 1994
Methods Double-blind, randomised, controlled study
Participants 26 participants (21 inpatients and 5 outpatients) included and treated
Age (years): range 20 to 70 (mean ± SD age of the 17 participants who completed at
least 2 weeks of active treatment 39 ± 14; 43 ± 16 in SAMe group, 33 ± 8 in desipramine
group)
Sex: 4men, 13women (4men, 7women inSAMegroup; 0men, 6women indesipramine
group)
Diagnosis: DSM-III-R diagnosis of major depression and a baseline score > 20 on 17-
item HAM-D or > 23 on an augmented 31-item HAM-D
Exclusion criteria: history of significant medical illness, personality disorder, substance or
alcohol abuse in the 6months prior to the study, refusal to give written informed consent,
history of failed response to the equivalent of 150 mg/day or more of imipramine for 4
weeks, HAM-D scores fallen to≤ 80% of baseline scores after an initial 3-day evaluation
and medication washout period
Interventions SAMe: 11 participants received 1600 mg/day (tablets) in divided dose every day for the
4 weeks
Desipramine: 6 participants titrated to 250 mg/day (tablets) in divided dose over the
first 5 days and continued, whenever possible, at 250 mg/day until the end of the trial
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Bell 1994 (Continued)
Duration of treatment: 4 weeks, preceded by 3-day evaluation and medication washout
period
Outcomes Relationship between plasma levels of SAMe and clinical response
Efficacy of treatment evaluated by 17-item and 31-item HAM-D, assessed at baseline
andweekly thereafter, as well as by BDI, completed by participants at baseline andweekly
throughout the protocol. A participant classified as a treatment responder if he or she
showed a reduction of > 50% on total HAM-D-17 scores at week 4 from baseline. Blood
samples for the analysis of plasma SAMe levels collected after the washout period and at
the end of study, in order to evaluate the correlation between plasma SAMe levels and
the degree of clinical improvement
Tolerability of treatment was evaluated by Systematic Assessment for Treatment Emer-
gent Events, assessed at baseline and weekly thereafter. In addition, thyroid function,
CBC, SMA-18, urinalysis and ECGmeasured at baseline and on the last day of the study
Vital signs, including blood pressure, pulse and respiration, recorded at baseline and at
each weekly visit
Notes Quote: “A subset of patients fromour previously reported double-blind study comparing
oral SAMe and desipramine in the treatment of major depression participated in this
study”. There was no mention in the literature of this previous study (Bell, American
Journal of Psychiatry). In addition, though we contacted the authors, this did not solve
the issue. Therefore, we have used just this subset
This study was carried out before the US Food and Drug Administration requested that
all US sites conducting clinical investigations on SAMe discontinue their studies until
more information was available from the company making SAMe tablets
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned”. Method not stated
Allocation concealment (selection bias) Unclear risk Method not stated. Pharmacist not blinded
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical tablets. States that nursing staff,
raters and participants were blind to type
of medication
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated that raters were blind to type ofmed-
ication
Incomplete outcome data (attrition bias)
All outcomes
High risk 26 participants randomised. 17 partici-
pants completed ≥ 2 weeks of the study
(11 on SAMe and 6 on desipramine). Only
used data on completers. Reason not stated
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Bell 1994 (Continued)
Selective reporting (reporting bias) Low risk HAM-D was primary outcome measure
(also BDI but not reported)
Other bias Low risk
De Vanna 1992
Methods Double-blind, randomised, controlled study
Participants 30 participants included and treated
Age (years): range 27 to 80 (mean age 48.5 overall; 48.4 in SAMe group; 48.5 in
imipramine group)
Sex: 9 men, 21 women (3 men, 12 women in SAMe group; 6 men, 9 women in
imipramine group)
Diagnosis: DSM-III-R diagnosis of major depression and a score at baseline ≥ 18 on
HAM-D
Exclusion criteria: contraindication to tricyclic antidepressants; suicidal ideation; psy-
chotic episodes; severe liver, renal, cardiovascular, endocrine, or neurological diseases;
pregnant or nursing women; chronic alcohol abusers; drug abusers. Before starting the
trial, participants received placebo during a 7-day drug-free, washout period. Excluded
placebo responders from study
Interventions SAMe: 15 participants received 1600 mg/day (tablets)
Imipramine: 15 participants received 140 mg/day (tablets)
Duration of treatment: 6 weeks
No concomitant medications allowed. In some cases, a sleep-inducing benzodiazepine
(triazolam 0.25 mg) was permitted for not more 2 weekly administrations
Outcomes Efficacy of treatment evaluated by 10-item MADRS, 21-item HAM-D, 14-item HAM-
A, 20-item Zung’s Self-Rating Scale for Depression, assessed at baseline and days 10, 20,
and 42
CBC, blood urea nitrogen, blood sugar, creatinine, transaminases, bilirubin and urinal-
ysis performed at baseline and end of trial. Adverse effects reported
Notes Authors stated that 3 participants in SAMe group and 5 in control group dropped out.
However, incongruity was evident in the paper, because the authors cited elsewhere that
4 participants dropped out in the imipramine group. We attempted to contact the au-
thors to obtain clarification, but were unsuccessful. As the authors quoted also “Twenty-
three patients, 12 in the SAMe group and 11 in the imipramine group, completed the
treatment”, we concluded that 4 participants dropped out in the control group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described, more than “patients were
randomly assigned”
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De Vanna 1992 (Continued)
Allocation concealment (selection bias) Unclear risk Method not described. Called a double-
blind trial
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not fully described. Called a double-blind
trial and indistinguishable tablets used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described. Called a double-blind trial
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 30 enrolled participants. 15 to SAMe
group; 15 to imipramine group. 3 drop-
outs on SAMe (nausea and vomiting), 4
drop-outs on imipramine (1 for nausea and
vomiting, 1 for excessive sweating, 2 for
mouth dryness). Unclear whether LOCF/
ITT used
Selective reporting (reporting bias) Low risk Did not state primary outcome measure.
Did report on all measures they listed
Other bias Low risk
Delle Chiaie 2000a
Methods Multicentre, double-blind, randomised, controlled study
Participants 281 outpatients included and treated
Age (years): range 18 to 70 (mean ± SD: 45.3 ± 11.92 in SAMe group; 44.6 ± 13.2 in
imipramine group)
Sex: 82 men, 196 women (40 men, 103 women in SAMe group; 42 men, 93 women in
imipramine group)
Diagnosis: DSM-IV diagnosis of major depressive episode with a unipolar (depressive)
course and no psychotic symptoms; a score at baseline ≥ 18 on the 21-item HAM-D
with the score on the first item of the scale (depressed mood) being ≥ 2, and a severity
score ≥ 4 on the CGI rating scale. Baseline assessment performed after 1 week, during
which no treatment was administered; at this point, participants who still satisfied the
inclusion and exclusion criteria began the double-blind treatment phase
Interventions SAMe: 143 participants received 1,4-butanedisulphonate-SAMe 1600 mg (tablets)
Imipramine: 138 participants received 150 mg/day (tablets) according to a gradual titra-
tion, and full doses of imipramine reached after 15 days
In participants who complained of adverse effects, the drug dose could be reduced from
the third week on, down to a minimal dose of imipramine 100 mg/day and SAMe 1200
mg/day. Participants who tolerated this dose poorly excluded from study
Duration of treatment: 6 weeks
During the study, only lorazepam (1mg/day to 2.5mg/day orally)was allowed to facilitate
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sleep induction if required
Outcomes Main efficacymeasures wereHAM-D total score at endpoint and percentage of treatment
responders (i.e. those participants who had a CGI score ≤ 2 at end of study)
Secondary efficacy measures were MADRS total score at endpoint and percentage of
treatment responders (i.e. those participants who had a decrease in HAM-D score from
baseline of ≥ 50% at end of study)
21-item version of HAM-D assessed at baseline and at days 14, 28 and 42 to evaluate
depressive symptoms
CGI assessed at baseline and at days 14, 28 and 42 to evaluate severity of illness and
degree of improvement after treatment
MADRS assessed at baseline and at days 14, 28 and 42 to detect the rapidmood variations
occurring during antidepressant therapy
Tolerability and safety of treatment: incidence of adverse events assessed during treatment
period, including changes in laboratory measures. Laboratory analyses, ECG and vital
signs performed at baseline and at final visit
Notes Authors stated, “As is usual in a multicenter clinical study, each center was provided
with a portion of an overrepresented randomisation list, on the basis of the number of
patients the center planned to enrolled. The slight difference in the number of patients
in each group resulted because of a discrepancy between the planned number of patients
and the number actually enrolled in some centers”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description of randomisation. “Ran-
domisation list”
Allocation concealment (selection bias) Unclear risk Use of placebo tablets indistinguishable in
appearance from active compound
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind and dummy
tablets used but allocation concealmentwas
unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as double-blind and dummy
tablets used but allocation concealmentwas
unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 281 participants met criteria. 143 partici-
pants in SAMe group, 138 participants in
imipramine group. 3 in imipramine group
randomised but not included in ITT effi-
cacy analysis because 1 participant received
no treatment and 2 participants received no
postbaseline assessment. ITT analysis car-
ried out, but no other non-completers de-
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Selective reporting (reporting bias) Low risk Primary outcomemeasurewasHAM-Dto-
tal score at endpoint and percentage of re-
sponders on CGI. Reported on these
Other bias Low risk
Delle Chiaie 2000b
Methods Multicentre, double-blind, randomised, controlled study
Participants 295 outpatients included and treated
Age (years): range 18 to 70 (mean ± SD; 48.2 ± 12.2 in SAMe group; 48.8 ± 14.0 in
imipramine group)
Sex: 108 men, 185 women (44 men, 102 women in SAMe group; 64 men, 83 women
in imipramine group)
Diagnosis: DSM-IV diagnosis of major depressive episode with a unipolar (depressive)
course and no psychotic symptoms; a score at baseline ≥ 18 on the 21-item HAM-D,
with the score on the first item of the scale (depressed mood) being ≥ 2, and a severity
score ≥ 4 on the CGI rating scale. Baseline assessment performed after 1 week, during
which no treatment was administered; at this point, participants who still satisfied the
inclusion and exclusion criteria began the double-blind treatment phase
Interventions SAMe: 147 participants received 1,4-butanedisulphonate-SAMe 400 mg/day intramus-
cularly
Imipramine: 148 participants received imipramine 150 mg/day (tablets)
Duration of treatment: 4 weeks
During the study, only lorazepam (1mg/day to 2.5mg/day orally)was allowed to facilitate
sleep induction if required
Outcomes Main efficacymeasures wereHAM-D total score at endpoint and percentage of treatment
responders (i.e. those participants who had a CGI score ≤ 2 at end of study)
Secondary efficacy measures were MADRS total score at endpoint and percentage of
treatment responders (i.e. those participants who had a decrease in HAM-D score from
baseline of ≥ 50% at end of study)
21-item HAM-D assessed at baseline and at days 14 and 28 to evaluate depressive
symptoms
CGI assessed at baseline and at days 14 and 28 to evaluate severity of illness and degree
of improvement after treatment
MADRS assessed at baseline and at days 14 and 28 to detect the rapid mood variations
occurring during antidepressant therapy
Tolerability and safety of treatment: incidence of adverse events assessed during treatment
period, including changes in laboratory measures. Laboratory analyses, ECG and vital
signs performed at baseline and at final visit
Notes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description of randomisation. “Ran-
domisation list”
Allocation concealment (selection bias) Unclear risk Use of placebo tablets indistinguishable in
appearance from active compound
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind and dummy
vials used but allocation concealment was
unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as double-blind and dummy
vials used but allocation concealment was
unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 295 participants met criteria. 147 partici-
pants in SAMe group, 148 participants in
imipramine group. 1 participant in SAMe
group received no postbaseline assessment
and 1 in imipramine group received no
treatment; these 2 participants were ex-
cluded from the ITT efficacy analysis. ITT
analysis carried out but no other non-com-
pleters described
Selective reporting (reporting bias) Low risk Primary outcomemeasurewasHAM-Dto-
tal score at endpoint and percentage of re-
sponders on CGI. Reported on these
Other bias Low risk
Kagan 1990
Methods Double-blind, randomised, placebo-controlled study
Participants 18 inpatients included and treated
Age (years): 18 to 65 (mean ± SD age of 15 participants who completed study 42.2 ±
16.3)
Sex: men
Diagnosis: DSM-III criteria for major depression, unipolar, without psychotic features
and a scores > 20 on the 21-item HAM-D
Exclusion criteria: actively suicidal, bipolar, substance abuse, significant medical prob-
lems, people who would experience undue loss (e.g. financial) from participation in the
trial, major abnormalities in physical examinations, routine laboratory (SMA-18, CBC,
urinalysis, thyroid function tests), and ECGs. All participants underwent 7-day drug-
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free washouts on the ward and were rated again before entering the trial; participants
who no longer met the criteria for the study were excluded
Interventions SAMe: 9 participants received SAMe 1600 mg/day (tablets)
Placebo: 6 participants received placebo tablets
First 5 participants received gradually increasing doses; placebo was given to 2 and SAMe
to 3. Their doses increased from 200 mg/day to 800 mg twice daily by day 7. The dose
remained at 800 mg twice daily for days 8 to 21. Since the oral SAMe was extremely
well tolerated by these first 5 participants, authors decided to eliminate the graduated-
dose phase of the study. The remaining participants received 800 mg twice daily for the
entire trial
Duration of treatment: 21 days
Outcomes Efficacy of treatment evaluated by 21-item HAM-D and Carroll Rating Scale for De-
pression, assessed at baseline and at days 3, 7, 14 and 21
Vital signs recorded each day. Adverse effects reported
Notes Trial initially planned to include 30 participants, but the authors were forced to stop
after 18 participants were enrolled because approval of the SAMe 200-mg tablet was
withdrawn by theUS Food andDrug Administration. This withdrawal was not related to
the clinical performance of SAMe but to technical issues regarding data on the dissolution
of the tablets
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomly assigned by a com-
puter-generated random string of 0s and 1s
Allocation concealment (selection bias) Low risk No participant, families, ward staff or in-
vestigators aware of code and identical
tablets used
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No participant, families, ward staff or in-
vestigators aware of code and identical
tablets used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No participant, families, ward staff or in-
vestigators aware of code and identical
tablets used
Incomplete outcome data (attrition bias)
All outcomes
Low risk 18 participants recruited. 15 participants
completed. 2 in placebo group withdrawn
(1 because of worsening depression, 1 had
hypothyroidism); 1 in SAMe group was
non-compliant and was dropped from the
study. Only reported completers. Missing
outcomes not enough to have clinically rel-
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evant impact on observed effect size
Selective reporting (reporting bias) Low risk Use HAM-D and Carroll Rating for De-
pression. Both reported
Other bias Low risk
Mischoulon 2014
Methods 3-armed, double-blind, randomised, controlled study
Participants 189 outpatients included and treated
Age (years): range 18 to 80 years (mean ± SD 45 ± 15)
Sex: 95 men, 94 women
Diagnosis: DSM-IV diagnosis of major depressive disorder and a score≥ 25 on the IDS-
Clinician Rated
Exclusion criteria: pregnancy or women of childbearing potential who were not using a
medically accepted means of contraception; serious suicidality or homicidality; unstable
medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurolog-
ical or haematological; organic mental disorders; substance- or alcohol-use abusers, active
within the preceding 6months; schizophrenia and other psychotic disorders or psychotic
features; bipolar disorder; acute bereavement; severe borderline or antisocial personality
disorder; current primary diagnoses of panic disorder or obsessive-compulsive disorder;
seizure disorder; concurrent use of other psychotropic drugs; hypothyroidism;≥ 6-week
treatment with escitalopram ≥ 10 mg/day or SAMe ≥ 1200 mg/day during the current
depressive episode; intolerance to SAMe or escitalopram; having taken an investigational
psychotropic drug within the last year; failure to respond to ≥ 2 antidepressant trials
at adequate doses (e.g. fluoxetine ≥ 40 mg/day) and duration (≥ 6 weeks) during the
current depressive episode; any depression-focused ongoing psychotherapy; history of
bleeding diatheses, low platelet counts, gastrointestinal bleeding, or use of medications
that alter bleeding risk; CGI-Improvement scale score of ’much’ or ’verymuch improved’
between the screening and baseline visits or an IDS-Clinician Rated score < 25 at either
the screening or the baseline visit, or both of these
Interventions SAMe: 64 participants received SAMe tosylate 1600 mg/day (tablets) during the first 6
weeks
Escitalopram: 65 participants received escitalopram 10 mg/day (tablets) during the first
6 weeks
Placebo: 60 participants received placebo tablets
Dose increase was allowed for non-responders (participants with a < 50% HAM-D-17
score reduction) at week 6; escitalopram could be increased to 20 mg/day and SAMe to
3200 mg/day for weeks 7 to 12. Participants who experienced intolerable adverse effects
at the higher dose were allowed to decrease the dose to the previous level
Duration of treatment: 12 weeks
Outcomes Primary efficacy measure was change in 17-item HAM-D over 12 weeks. Response
defined as > 50% decrease in the HAM-D -17 items and remission as a final HAM-D <
7
Secondary measures of efficacy included changes in scores on the IDS-Clinician Rated,
59S-adenosyl methionine (SAMe) for depression in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mischoulon 2014 (Continued)
IDS-Self Report, CGI-Severity and CGI-Improvement ratings over time
Adverse events documented with the Systematic Assessment for Treatment of Emergent
Events - Specific Inquiry
Outcomes were assessed at weeks 1, 2, 4, 6, 8, 10 and 12
Notes Study include a cross-over phase in which non-responders to either escitalopram or
SAMe received the combination of the 2 drugs, though this report focused on the main
outcome data for the first 12 weeks of double-blind treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised in a 1:1:1 manner. Randomi-
sation numbers assigned by a biostatisti-
cian, in consecutive order, stratified by site
Allocation concealment (selection bias) Low risk Research pharmacists
at both sites maintained codes/allocations.
All participants, clinicians and research co-
ordinators blinded to intervention
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-dummy design to maintain blind-
ing, and allocation codes kept by pharma-
cists. No information regarding effective-
ness of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors blinded by allocation conceal-
ment. No information regarding effective-
ness of blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ITT analysis, including all participants al-
located to the 3 treatment armswith LOCF
analysis. 189 randomised: 64 in SAMe
group; 65 in escitalopram group; 60 in
placebo group. 92 participants dropped
out. All drop-outs reported in CONSORT
diagram, and reasons for drop-out given
28 participants dropped out in the SAMe
group (3 because of adverse events, 3 for
clinical worsening, 5 because of ineffective-
ness, 1 for scheduling, 4 because of non-
adherence, 4 lost to follow-up and 8 for un-
known reasons)
35 participants dropped out in the escitalo-
pram arm (8 because of adverse events, 4
for clinical worsening, 3 for scheduling, 6
because of non-adherence, 7 lost to follow-
up and7 for unknown/unspecified reasons)
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29 participants discontinued placebo (4 be-
cause of adverse events, 2 for clinical wors-
ening, 4 because of ineffectiveness, 3 be-
cause of non-adherence, 2 lost to follow-up
and 14 for unknown reasons)
A very large proportion of drop-outs oc-
curred
Selective reporting (reporting bias) Low risk Primary outcome measure specified and re-
ported. Some but not all secondary mea-
sures, e.g. not IDS-C
Other bias Low risk
Papakostas 2010a
Methods Double-blind, randomised, placebo-controlled study
Participants 73 participants included and treated
Age (years): range 18 to 80
Sex: 29 men, 44 women (18 men, 21 women in SAMe group, 11 men, 23 women in
placebo group)
Diagnosis: SSRI non-responders with DSM-IV current major depressive disorder and
a score of ≥ 16 on HAM-D; treatment with an SSRI at adequate doses (a minimally
adequate dose was defined as fluoxetine, citalopram or paroxetine at ≥ 20 mg/day; esci-
talopram ≥ 10 mg/day; sertraline ≥ 50 mg/day; duloxetine ≥ 60 mg/day and venlafax-
ine ≥ 150 mg/day; this was defined historically); treatment with SSRIs for an adequate
duration (defined as treatment at an adequate dose for at least 6 weeks). At baseline visit,
participants must have been taking a stable dose of an SSRI for the past 4 weeks
Exclusion criteria: breastfeeding or pregnant women, or women of childbearing potential
who were not using a medically accepted means of contraception; a decrease in depres-
sive symptoms as reflected by the HAM-D total score between the screen and baseline
visits > 15%; serious suicide or homicide risk, unstable medical illness; active alcohol-
or drug-use disorder within the last 6 months; history of mania, hypomania (including
antidepressant-induced), psychotic symptoms, or seizure disorder; clinical evidence of
untreated hypothyroidism; failure to experience sufficient symptom improvement fol-
lowing more than 4 antidepressant trials during the current major depressive episode;
prior course of SAMe or intolerance to SAMe at any dose
Interventions Adjunctive SAMe: 39 participants received 2 SAMe tosylate 400 mg tablets daily
Adjunctive placebo: 34 participants received placebo tablets
All participants had their number of tablets doubled upon completion of 2 weeks of
treatment (target dose of SAMe was 800 mg twice daily)
Participants continued to receive their SSRI treatment at a stable dose throughout the 6-
week trial. Participants who were unable to tolerate the study medications, per protocol,
were withdrawn
Duration of treatment: 6-weeks
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Outcomes Primary outcome measure was defined as difference in response rates, according to 17-
item HAM-D, between the 2 treatment groups. Response according to HAM-D ratings
was defined as a ≥ 50% reduction in scores during treatment (or a final score of ≤ 7)
Secondary outcome measures included continuous change in HAM-D scores and CGI-
Severity ratings during treatment; proportion of participants meeting remission status
according to HAM-D scores (final score of ≤ 7) or CGI-Severity ratings (score of 1 at
endpoint) and response status according to CGI-Improvement ratings (score of < 3 at
endpoint)
Adverse effects were reported
Postbaseline study visits occurred weekly
Notes The authors inadvertently made a calculation error in the results. The quoted percentage
is 36.1% for SAMe + antidepressant treatment among responders, whereas the actual
number of responders indicated on page 945 was 18/39, or 46.1%. Likewise, the quoted
percentage for SAMe + antidepressant treatment among participants who remitted was
25.8%, whereas the actual number of these participants cited on page 945 was 14/39,
or 35.1%. So, 36.1% was given instead of 46.1% and 25.8% instead of 35.8% (Fleisch
2010; Papakostas 2010b)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation process not described -
“randomly assigned”
Allocation concealment (selection bias) Low risk Dummy pills used for placebo
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind trial, but meth-
ods not detailed, except above
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double-blind trial, but meth-
ods not detailed, except above
Incomplete outcome data (attrition bias)
All outcomes
Low risk 73 participants assigned to treatment. 55
completed (31 in SAMe group; 24 in
placebo group). All non-completers were
mentioned, with reasons for drop-out. 4
participants in the control group and 2 in
SAMe group dropped out because of inef-
ficacy; 3 in placebo and 2 in SAMe discon-
tinued because of intolerance; 2 in placebo
and 3 in SAMe discontinued for other rea-
sons; and 1 in each group was lost to fol-
low-up
LOCF used
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Selective reporting (reporting bias) Low risk Primary and secondary outcome measures
not stated, but HAM-D, CGI-Severity and
CGI-Improvement used and reported
Other bias Low risk
BDI: Beck Depression Inventory; CBC: complete blood count; CGI: Clinical Global Impression; DSM: Diagnostic and Statistical
Manual of Mental Disorders; DST: dexamethasone suppression test; ECG: electrocardiogram; HAM-D: Hamilton Depression
Rating Scale; HAM-D: Hamilton Depression Rating Scale; IDS-C: Inventory of Depressive-Symptomatology - Clinician-Rated;
ITT: intention-to-treat; iv: intravenous; LOCF: last observation carried forward; MADRS: Montgomery-Åsberg Depression Rating
Scale; SAMe: S-adenosyl methionine; SD: standard deviation; SMA-18: 18 panel blood test; SSRI: selective serotonin reuptake
inhibitor.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agnoli 1975 Inappropriate diagnosis
Agnoli 1976 Inappropriate diagnosis
Agnoli 1978 Inappropriate diagnosis
Alvarez 1984 Heterogeneous group of participants (depression with both unipolar and bipolar course). Although we ap-
proached the authors to request original data, we obtained no further information and data from those partici-
pants with ’unipolar’ depression could not be separated out
Bambling 2015 Inappropriate comparator
Barberi 1978 Inappropriate diagnosis
Berlanga 1992 The adjunctive treatment (imipramine) was increased during the first week of the trial and the period with a
stable dose of imipramine was limited at only 1 week
Blasi Ras 1985 Inappropriate diagnosis
Bottiglieri 1986 Inappropriate outcomes
Bottiglieri 1990 Inappropriate outcomes
Calandra 1979 Inappropriate diagnosis
Carney 1986 Inappropriate diagnosis
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De Leo 1987 Heterogeneous group of participants (also diagnosis of dysthymia). Although we approached the author to
request original data, we obtained no further information and data from those participants withmajor depression
could not be separated out
Del Vecchio 1978 Inappropriate diagnosis
Delle Chiaie 1999 Heterogeneous group of participants (depression with both unipolar and bipolar course). Although we ap-
proached the author to request original data, we obtained no further information and data from those partici-
pants with ’unipolar’ depression could not be separated out
Di Pierro 2015 Inappropriate intervention
Fava 1992 Initial randomisation of the treated participants not stated
Janicak 1988 Heterogeneous group of participants (depression with both unipolar and bipolar course). Although we approach
the author to request original data, we obtained no further information and data from those participants with
’unipolar’ depression could not be separated out
Kufferle 1982 Heterogeneous group of participants (depression with both unipolar and bipolar course). Although we contacted
the author to request original data, we obtained no further information and data from those participants with
’unipolar’ depression could not be separated out
Lanaia 1977 Inappropriate diagnosis
Mantero 1976 People with comorbidity of skin disease
Muscettola 1982 Inappropriate diagnosis
Rabassini 1979 Inappropriate diagnosis
Salmaggi 1991 Heterogeneous group of participants (also diagnosis of dysthymia). Although we approached the author to
request original data, we obtained no further information and data from those participants withmajor depression
could not be separated out
Sarris 2015b Inappropriate intervention
Scarzella 1978 Inappropriate diagnosis
Schifano 1993 Inappropriate diagnosis
Thomas 1987 Inappropriate diagnosis
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Quiros 1982
Methods
Participants
Interventions
Outcomes
Notes Study not retrievable
Characteristics of ongoing studies [ordered by study ID]
ACTRN12613001299796
Trial name or title Nutraceuticals as Monotherapy Treatments in Major Depressive Disorder: a Double-Blind, Randomised,
Placebo-Controlled Trial
Methods 8 weeks, 3-arm, double-blind, randomised, placebo-controlled trial
Participants Inclusion criteria: aged 18 to 70 years; both men and women; fluent in written and spoken English; has the
capacity to consent to the study and follow its procedures; fulfils the DSM-IV-TR and DSM-V diagnostic
criteria for major depressive disorder on structured interview (MINI-Plus); presents with mild-to-moderate
depression (MADRS 14-25) at time of study entry; meets SAFER 2.0 criteria for a stable episode of depression
Exclusion criteria: currently taking any antidepressant medication (SSRIs, SNRIs, TCAs, MAOIs, mood
stabilisers, etc.); current use of any nutraceutical including a multivitamin, omega-3, or psychotropic herbal
medicine e.g. St John’s wort (a 2-week washout can occur before inclusion); presents with suicidal ideation (> 1
onMADRS suicidal thoughts domain) at time of study entry;≥ 3 failed trials of pharmacotherapy or somatic
therapy (e.g. ECT, TMS) for the current major depressive episode; recently commenced psychotherapy (>
4 weeks of stable treatment acceptable); taking warfarin or phenytoin; diagnosis of bipolar disorder I/II or
schizophrenia on structured interview (MINI-Plus); a primary clinical diagnosis of a substance-/alcohol-
use disorder within the last 12 months on structured interview (MINI-Plus); known or suspected clinically
unstable systemic medical disorder (including cancer, organ failure or serious cardio/cerebrovascular disease)
; pregnancy or breastfeeding; not using medically approved contraception (including abstinence) if women
and of childbearing age; allergy to seafood
Interventions Group A: SAMe 800 mg/day + cofactors folinic acid 500 µg/day and vitamin B12 200 µg/day
Group B: enhanced SAMe combination nutraceutical formulation consisting of SAMe 800 mg/day, omega-
3 concentrate (EPA esters 1000 mg/day, DHA esters 656 mg/day), 5-HTP 200 mg/day, zinc picolinate 30
mg/day + cofactors folinic acid 500 µg/day, vitamin B12 200 µg/day, vitamin B6 200 mg/day, vitamin E 40
IU/day, vitamin C 60 mg/day and magnesium amino acid chelate 40 mg/day)
Group C: placebo tablets and capsules, identical in appearance to the active treatments, made of microcrys-
talline cellulose (an inert plant product) and containing no active ingredients
Outcomes Severity of depressive symptoms measured with MADRS
Anxiety measured with HAM-A
Health-related quality of life measured with SF-12
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Self reported quality of sleep measured with LSEQ
Severity of self reported depressive symptoms measured with the BDI-II
Symptom severity and global improvement measured with CGI-Severity and CGI-Improvement scales
The CORE Assessment of Psychomotor Change
Starting date 21 November 2013
Contact information Dr Jerome Sarris, jerome.sarris@unimelb.edu.au
Ms Jenifer Murphy, NAT-Dstudy@unimelb.edu.au
Notes
ACTRN12613001300763
Trial name or title The Efficacy of S-Adenosyl Methionine (SAMe) and a Combination Nutraceutical as Adjunctive Treatments
in Depression: a Double-Blind, Randomised, Placebo-Controlled Trial
Methods 3-arm, double-blind, randomised, placebo-controlled trial
Participants Men and women aged 18 to 70 years
DSM-IV-TR and DSM-V diagnosis of major depressive disorder with a score≥ 18 onMADRS; meet SAFER
2.0 criteria for a stable episode of depression; not currently suicidal (< 4 on the MADRS suicidal thoughts
domain)
Exclusion criteria: diagnosis of bipolar disorder I/II or schizophrenia; a primary clinical diagnosis of a sub-
stance/alcohol-use disorder within the last 12 months; currently taking MAOIs or TCAs; current use of any
nutraceutical or psychotropic herbal medicine including a multivitamin, omega-3, or St John’s wort (a 2-week
washout can occur before inclusion); ≥ 3 failed trials of pharmacotherapy or somatic therapy (e.g. ECT)
for the current major depressive episode; recently commenced psychotherapy (> 4 weeks of stable treatment
acceptable); taking warfarin or phenytoin; known or suspected clinically unstable systemic medical disorder
(including cancer, organ failure or serious cardio/cerebrovascular disease); pregnancy or breastfeeding; not
using medically approved contraception (including abstinence) if female and of childbearing age; allergy to
seafood; unable to read or understand (or both) English
Interventions Group A: SAMe 800 mg/day + cofactors folinic acid 500 µg/day and vitamin B12 200 µg/day
Group B: enhanced SAMe combination nutraceutical formulation consisting of SAMe 800 mg/day, omega-
3 concentrate (EPA-esters 1000 mg/day, DHA-esters 656 mg/day, 5-HTP 200 mg/day, folinic acid 500 µg/
day, zinc 30 mg/day + cofactors vitamin B6 200 mg/day, vitamin B12 200 µg/day, vitamin E 40 IU/day,
magnesium 40 mg/day and vitamin C 60 mg/day)
Group C: placebo
8-week
Outcomes MADRS, BDI-II, SF-12, CGI-Severity, CGI-Improvement, Anxietymeasuredwith theHAM-A, self reported
quality of sleep measured with the LSEQ: measured at baseline and weeks 2, 4, 6 and 8
CORE Assessment of Psychomotor Change: measured at baseline and week 8
Starting date October 2013
Contact information Dr Jerome Sarris, jsarris@unimelb.edu.au
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Notes
NCT01912196
Trial name or title Add-on Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients with Major Depressive Disorder
(MDD)
Methods Double-blind, randomised, placebo-controlled trial
Participants Men and women aged 21 to 70 years
DSM-IV-TR diagnosis of major depressive disorder with a total score ≥ 16 on the HAM-D17 at screening
and baseline visits, with a score of ≥ 2 on mood item 1, have experienced 1 to 4 prior major depressive
episodes, have failed 1 to 3 treatment regimens in the current depressive episode, have received an adequate
dose and duration of antidepressant therapy (on antidepressant therapy for at least 6 weeks with a stable dose
for at least 3 weeks)
Exclusion criteria: failed ≥ 4 adequate treatment regimens in current episode of depression, significant risk
for suicidal behaviour, intolerance to SAMe, prior use of MSI-195; history of any of the following psychiatric
disorders: eating disorder within 6months, obsessive compulsive disorder, psychotic disorder, bipolar disorder,
mental retardation, dementia or other forms of cognitive impairment at any time or alcohol- or substance-
use abuse; > 3 x ULN alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase; > 1.5 x
ULN total bilirubin; pregnant or lactating women; any history of seizures, excluding febrile seizures; known
positivity for human immunodeficiency virus
Interventions Adjunctive MSI-195: 2 tablets (800 mg) of MSI-195 plus ongoing antidepressant therapy
Adjunctive placebo: 2 tablets placebo plus ongoing antidepressant therapy
8 weeks
Outcomes HAM-D17: assessed from baseline to week 8
MADRS: assessed at baseline, weeks 2, 4, 6, 7 and 8
CGI-Severity: assessed at baseline, weeks 2, 4, 7 and 8
IDS-Self Rated 30: assessed at baseline, weeks 2, 4, 6 and 8
Adverse events: assessed at baseline, weeks 1, 2, 3, 4, 6, 8 and 9 (follow-up)
Columbia Suicide Severity Rating Scale: assessed at baseline, weeks 2, 4, 6 and 8
Starting date October 2013
Contact information Clayton Janik, clayton.janik@ppdi.com; Scott Smith, scott.smith@ppdi.com
Notes
5-HTP: 5-hydroxytryptophan; BDI: Beck Depression Inventory; CGI: Clinical Global Impression; DHA: docosahexaenoic acid;
DSM: Diagnostic and Statistical Manual of Mental Disorders; ECT: electroconvulsive therapy; EPA: eicosapentaenoic acid; HAM-
A: Hamilton Rating Scale for Anxiety; IDS: Inventory of Depressive Symptomatology; IU: international unit; LSEQ: Leeds Sleep
Evaluation Questionnaire; MADRS: Montgomery-Åsberg Depression Rating Scale; MAOI: monoamine oxidase inhibitor; MINI-
Plus: Mini-International Neuropsychiatric Interview; SAFER:Massachusetts General Hospital SAFER interview; SAMe: S-adenosyl
methionine; SF-12: 12-item Short Form; SNRI: serotonin-noradrenaline reuptake inhibitor; SSRI: selective serotonin reuptake
inhibitor; TCA: tricyclic antidepressant; TMS: transcranial magnetic stimulation; ULN: upper limit of normal.
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D A T A A N D A N A L Y S E S
Comparison 1. S-adenosyl methionine versus placebo as monotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Efficacy. Change in mean
scores from baseline to end of
treatment on the depression
rating scale (negative value =
improvement)
2 142 Std. Mean Difference (IV, Random, 95% CI) -0.54 [-1.54, 0.46]
2 Acceptability. Participants
dropping out of treatment
during study period for any
reason
2 142 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.61, 1.29]
3 Acceptability. Participants
dropping out of treatment
during study period because of
adverse effects
2 142 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.16, 3.01]
4 Efficacy. Response to treatment,
defined as a ≥ 50% reduction
in depression score from
baseline to end of treatment
2 142 Risk Ratio (M-H, Random, 95% CI) 1.77 [0.51, 6.13]
5 Efficacy. Remission, defined as
a depression rating scale score
within normal range at end of
study
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Acceptability. Participants
experiencing specific adverse
effects: mania or hypomania
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
7 Acceptability. Participants
experiencing specific adverse
effects: headache
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
8 Acceptability. Participants
experiencing specific adverse
effects: flatulence
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
9 Acceptability. Participants
dropping out for any reasons
other than adverse effects
2 142 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.60, 1.38]
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Comparison 2. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Efficacy. Change in mean
scores from baseline to end
of treatment on depression
rating scale (negative value =
improvement)
4 619 Std. Mean Difference (IV, Random, 95% CI) -0.04 [-0.34, 0.27]
1.1 vs. imipramine 4 619 Std. Mean Difference (IV, Random, 95% CI) -0.04 [-0.34, 0.27]
2 Acceptability. Participants
dropping out of treatment
during study period for any
reason
3 78 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.28, 1.31]
2.1 vs. imipramine 2 52 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.29, 2.39]
2.2 vs. desipramine 1 26 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.14, 1.30]
3 Acceptability. Participants
dropping out of treatment
during study period because of
adverse effects
2 52 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.20, 2.79]
3.1 vs. imipramine 2 52 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.20, 2.79]
4 Efficacy. Response to treatment,
defined as a ≥ 50% reduction
in depression score from
baseline to end of treatment
4 622 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.83, 1.56]
4.1 vs. imipramine 3 596 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.81, 1.44]
4.2 vs. desipramine 1 26 Risk Ratio (M-H, Random, 95% CI) 3.00 [0.74, 12.21]
5 Acceptability. Participants
experiencing troublesome
adverse effects of any nature
3 604 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.52, 0.88]
5.1 vs. imipramine 3 604 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.52, 0.88]
6 Acceptability. Participants
experiencing specific adverse
effects: mania or hypomania
2 48 Risk Ratio (M-H, Random, 95% CI) 3.00 [0.13, 68.26]
6.1 vs. imipramine 2 48 Risk Ratio (M-H, Random, 95% CI) 3.00 [0.13, 68.26]
7 Acceptability. Participants
dropping out for any reasons
other than adverse effects
2 52 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.17, 5.89]
7.1 vs. imipramine 2 52 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.17, 5.89]
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Comparison 3. S-adenosyl methionine versus SSRI antidepressant agent as monotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Efficacy. Change in mean
scores from baseline to end
of treatment on depression
rating scale (negative value =
improvement)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
1.1 vs. escitalopram 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 Acceptability. Participants
dropping out of treatment
during study period for any
reason
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 vs. escitalopram 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Acceptability. Participants
dropping out of treatment
during study period because of
adverse effects
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 vs. escitalopram 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Efficacy. Response to treatment,
defined as a ≥ 50% reduction
in depression score from
baseline to end of treatment
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4.1 vs. escitalopram 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Efficacy. Remission, defined as
a depression rating scale score
within normal range at end of
study
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5.1 vs. escitalopram 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Acceptability. Participants
dropping out for any reasons
other than adverse effects
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6.1 vs. escitalopram 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. S-adenosyl methionine versus placebo as adjunctive treatment to SSRI
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Efficacy. Change in mean
scores from baseline to end
of treatment on depression
rating scale (negative value =
improvement)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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2 Acceptability. Participants
dropping out of treatment
during study period for any
reason
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Acceptability. Participants
dropping out of treatment
during study period because of
adverse effects
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Efficacy. Response to treatment,
defined as a ≥ 50% reduction
in depression score from
baseline to end of treatment
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Efficacy. Remission, defined as
a depression rating scale score
within normal range at end of
study
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Acceptability. Participants
experiencing specific adverse
effects: headache
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
7 Acceptability. Participants
experiencing specific adverse
effects: diarrhoea
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
8 Acceptability. Participants
dropping out for any reasons
other than adverse effects
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 5. Sensitivity analyses. S-adenosyl methionine versus placebo as monotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Sensitivity analysis for
imputation of continuous
efficacy data (assumption:
missing participants had
same mean change as other
participants). Efficacy. Change
in mean scores from baseline
to end of treatment on
the depression rating scale
(negative value = improvement)
2 142 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-1.50, 0.45]
2 Sensitivity analysis for
imputation of dichotomous
data (assumption: ’best-case’
scenario). Efficacy. Response
to treatment, defined as a ≥
50% reduction in depression
score from baseline to end of
treatment
2 142 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.84, 2.06]
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3 Sensitivity analysis for the
imputation of SD (using
correlation coefficient of 0.4).
Efficacy. Change in mean
scores from baseline to end
of treatment on depression
rating scale (negative value =
improvement)
2 142 Std. Mean Difference (IV, Random, 95% CI) -0.55 [-1.53, 0.42]
4 Sensitivity analysis (excluding
studies with high levels of
missing data). Efficacy. Change
in mean scores from baseline to
end of treatment on depression
rating scale (negative value =
improvement)
1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
5 Sensitivity analysis (excluding
studies with high levels of
missing data). Acceptability.
Participants dropping out of
treatment during study period
for any reason
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Sensitivity analysis (excluding
studies with high levels
of missing data). Efficacy.
Response to treatment, defined
as a ≥ 50% reduction in
depression score from baseline
to end of treatment
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
7 Sensitivity analysis (excluding
studies with high levels of
missing data). Acceptability.
Participants dropping out for
any reasons other than adverse
effects
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 6. Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as
monotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Subgroup analysis (oral
administration of SAMe).
Efficacy. Change in mean
scores from baseline to end
of treatment on depression
rating scale (negative value =
improvement)
2 303 Std. Mean Difference (IV, Random, 95% CI) 0.06 [-0.17, 0.28]
1.1 vs. imipramine 2 303 Std. Mean Difference (IV, Random, 95% CI) 0.06 [-0.17, 0.28]
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2 Subgroup analysis (parenteral
administration of SAMe).
Efficacy. Change in mean
scores from baseline to end
of treatment on depression
rating scale (negative value =
improvement)
2 316 Std. Mean Difference (IV, Random, 95% CI) -0.46 [-1.68, 0.75]
2.1 vs. imipramine 2 316 Std. Mean Difference (IV, Random, 95% CI) -0.46 [-1.68, 0.75]
3 Subgroup analysis (oral
administration of SAMe).
Acceptability. Participants
dropping out of treatment
during study period for any
reason
2 56 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.23, 1.27]
3.1 vs. imipramine 1 30 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.20, 2.79]
3.2 vs. desipramine 1 26 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.14, 1.30]
4 Subgroup analysis (parenteral
administration of SAMe).
Acceptability. Participants
dropping out of treatment
during study period for any
reason
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4.1 vs. imipramine 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Subgroup analysis (oral
administration of SAMe).
Acceptability. Participants
dropping out of treatment
during study period because of
adverse effects
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5.1 vs. imipramine 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Subgroup analysis (parenteral
administration of SAMe).
Acceptability. Participants
dropping out of treatment
during study period because of
adverse effects
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6.1 vs. imipramine 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Subgroup analysis (oral
administration of SAMe).
Efficacy. Response to treatment,
defined as a ≥ 50% reduction
in depression score from
baseline to end of treatment
2 306 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.44, 4.09]
7.1 vs. imipramine 1 280 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.73, 1.13]
7.2 vs. desipramine 1 26 Risk Ratio (M-H, Random, 95% CI) 3.00 [0.74, 12.21]
8 Subgroup analysis (parenteral
administration of SAMe).
Efficacy. Response to treatment,
defined as a ≥ 50% reduction
in depression score from
baseline to end of treatment
2 316 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.66, 3.26]
8.1 vs. imipramine 2 316 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.66, 3.26]
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9 Subgroup analysis (parenteral
administration of SAMe).
Acceptability. Participants
experiencing troublesome
adverse effects of any nature
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
9.1 vs. imipramine 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Subgroup analysis (oral
administration of SAMe).
Acceptability. Participants
experiencing troublesome
adverse effects of any nature
2 310 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.50, 1.27]
10.1 vs. imipramine 2 310 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.50, 1.27]
11 Subgroup analysis (oral
administration of SAMe).
Acceptability. Participants
dropping out for any reasons
other than adverse effects
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
11.1 vs. imipramine 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Subgroup analysis (parenteral
administration of SAMe).
Acceptability. Participants
dropping out for any reasons
other than adverse effects
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
12.1 vs. imipramine 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13 Sensitivity analysis for
imputation of continuous
efficacy data (assumption:
missing participants had
same mean change as other
participants). Efficacy. Change
in mean scores from baseline to
end of treatment on depression
rating scale (negative value =
improvement)
4 619 Std. Mean Difference (IV, Random, 95% CI) -0.08 [-0.43, 0.28]
13.1 vs. imipramine 4 619 Std. Mean Difference (IV, Random, 95% CI) -0.08 [-0.43, 0.28]
14 Sensitivity analysis for
imputation of dichotomous
data (assumption: ’best-case’
scenario). Efficacy. Response
to treatment, defined as a ≥
50% reduction in depression
score from baseline to end of
treatment
4 622 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.82, 1.34]
14.1 vs. imipramine 3 596 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.81, 1.47]
14.2 vs. desipramine 1 26 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.51, 1.56]
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15 Sensitivity analysis for
imputation of SD (using
correlation coefficient of 0.4).
Efficacy. Change in mean
scores from baseline to end
of treatment on depression
rating scale (negative value =
improvement)
4 619 Std. Mean Difference (IV, Random, 95% CI) -0.08 [-0.43, 0.28]
15.1 vs. imipramine 4 619 Std. Mean Difference (IV, Random, 95% CI) -0.08 [-0.43, 0.28]
16 Sensitivity analysis (excluding
studies with high levels of
missing data). Efficacy. Change
in mean scores from baseline to
end of treatment on depression
rating scale (negative value =
improvement)
2 45 Std. Mean Difference (IV, Random, 95% CI) -0.46 [-1.83, 0.92]
16.1 vs. imipramine 2 45 Std. Mean Difference (IV, Random, 95% CI) -0.46 [-1.83, 0.92]
17 Sensitivity analysis (excluding
studies with high levels of
missing data). Acceptability.
Participants dropping out of
treatment during study period
for any reason
2 52 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.29, 2.39]
17.1 vs. imipramine 2 52 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.29, 2.39]
18 Sensitivity analysis (excluding
studies with high levels
of missing data). Efficacy.
Response to treatment, defined
as a ≥ 50% reduction in
depression score from baseline
to end of treatment
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
18.1 vs. imipramine 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19 Sensitivity analysis (excluding
studies with high levels of
missing data). Acceptability.
Participants experiencing
troublesome adverse effects of
any nature
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
19.1 vs. imipramine 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
20 Sensitivity analysis (excluding
De Vanna 1992). Efficacy.
Change in mean scores from
baseline to end of treatment
on depression rating scale
(negative value = improvement)
3 596 Std. Mean Difference (IV, Random, 95% CI) -0.09 [-0.44, 0.27]
20.1 vs. imipramine 3 596 Std. Mean Difference (IV, Random, 95% CI) -0.09 [-0.44, 0.27]
21 Sensitivity analysis (excluding
Bell 1994, as at high risk
of bias). Acceptability.
Participants dropping out of
treatment during study period
for any reason
2 52 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.29, 2.39]
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21.1 vs. imipramine 2 52 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.29, 2.39]
22 Sensitivity analysis (excluding
Bell 1994, as at high risk of
bias). Efficacy. Response to
treatment, defined as a ≥
50% reduction in depression
score from baseline to end of
treatment
3 596 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.81, 1.44]
22.1 vs. imipramine 3 596 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.81, 1.44]
Comparison 7. Sensitivity analysis. S-adenosyl methionine versus SSRI antidepressant agent as monotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Sensitivity analysis for
imputation of SD (using
correlation coefficient of 0.4).
Efficacy. Change in mean
scores from baseline to end
of treatment on depression
rating scale (negative value =
improvement)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
1.1 vs. escitalopram 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 8. Sensitivity analysis. S-adenosyl methionine versus placebo as adjunctive treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Sensitivity analysis for
imputation of SD (using
correlation coefficient of 0.4).
Efficacy. Change in mean
scores from baseline to end
of treatment on depression
rating scale (negative value =
improvement)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 S-adenosyl methionine versus placebo as monotherapy, Outcome 1 Efficacy.
Change in mean scores from baseline to end of treatment on the depression rating scale (negative value =
improvement).
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 1 S-adenosyl methionine versus placebo as monotherapy
Outcome: 1 Efficacy. Change in mean scores from baseline to end of treatment on the depression rating scale (negative value = improvement)
Study or subgroup
S-adenosyl
methionine Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kagan 1990 (1) 10 -14.58 (7.3) 8 -5.48 (7.4) 39.0 % -1.18 [ -2.21, -0.15 ]
Mischoulon 2014 (2) 64 -6.19 (8.53) 60 -5.11 (7.67) 61.0 % -0.13 [ -0.48, 0.22 ]
Total (95% CI) 74 68 100.0 % -0.54 [ -1.54, 0.46 ]
Heterogeneity: Tau2 = 0.40; Chi2 = 3.58, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours [S-adenosyl methionine] Favours [placebo]
(1) Oral SAMe 1600 mg; 3-week trial
(2) Oral SAMe 1600 mg/d up to 3200 mg/d; 12-week trial
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Analysis 1.2. Comparison 1 S-adenosyl methionine versus placebo as monotherapy, Outcome 2
Acceptability. Participants dropping out of treatment during study period for any reason.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 1 S-adenosyl methionine versus placebo as monotherapy
Outcome: 2 Acceptability. Participants dropping out of treatment during study period for any reason
Study or subgroup
S-adenosyl
methionine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kagan 1990 (1) 1/10 2/8 2.9 % 0.40 [ 0.04, 3.66 ]
Mischoulon 2014 (2) 28/64 29/60 97.1 % 0.91 [ 0.62, 1.33 ]
Total (95% CI) 74 68 100.0 % 0.88 [ 0.61, 1.29 ]
Total events: 29 (S-adenosyl methionine), 31 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours [S-adenosyl methionine] Favours [placebo]
(1) Oral SAMe 1600 mg; 3-week trial
(2) Oral SAMe 1600 mg/d up to 3200 mg/d; 12-week trial
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Analysis 1.3. Comparison 1 S-adenosyl methionine versus placebo as monotherapy, Outcome 3
Acceptability. Participants dropping out of treatment during study period because of adverse effects.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 1 S-adenosyl methionine versus placebo as monotherapy
Outcome: 3 Acceptability. Participants dropping out of treatment during study period because of adverse effects
Study or subgroup
S-adenosyl
methionine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kagan 1990 (1) 0/10 0/8 Not estimable
Mischoulon 2014 (2) 3/64 4/60 100.0 % 0.70 [ 0.16, 3.01 ]
Total (95% CI) 74 68 100.0 % 0.70 [ 0.16, 3.01 ]
Total events: 3 (S-adenosyl methionine), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [S-adenosyl methionine] Favours [placebo]
(1) Oral SAMe 1600 mg; 3-week trial
(2) Oral SAMe 1600 mg/d up to 3200 mg/d; 12-week trial
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Analysis 1.4. Comparison 1 S-adenosyl methionine versus placebo as monotherapy, Outcome 4 Efficacy.
Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 1 S-adenosyl methionine versus placebo as monotherapy
Outcome: 4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment
Study or subgroup
S-adenosyl
methionine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kagan 1990 (1) 6/10 1/8 28.1 % 4.80 [ 0.72, 32.15 ]
Mischoulon 2014 (2) 23/64 18/60 71.9 % 1.20 [ 0.72, 1.99 ]
Total (95% CI) 74 68 100.0 % 1.77 [ 0.51, 6.13 ]
Total events: 29 (S-adenosyl methionine), 19 (Placebo)
Heterogeneity: Tau2 = 0.49; Chi2 = 1.98, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [placebo] Favours [S-adenosyl methionine]
(1) Oral SAMe 1600 mg; 3-week trial
(2) Oral SAMe 1600 mg/d up to 3200 mg/d; 12-week trial
Analysis 1.5. Comparison 1 S-adenosyl methionine versus placebo as monotherapy, Outcome 5 Efficacy.
Remission, defined as a depression rating scale score within normal range at end of study.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 1 S-adenosyl methionine versus placebo as monotherapy
Outcome: 5 Efficacy. Remission, defined as a depression rating scale score within normal range at end of study
Study or subgroup
S-adenosyl
methionine Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mischoulon 2014 (1) 18/64 10/60 1.69 [ 0.85, 3.36 ]
0.2 0.5 1 2 5
Favours [placebo] Favours [S-adenosyl methionine]
80S-adenosyl methionine (SAMe) for depression in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(1) Oral SAMe 1600 mg/d up to 3200 mg/d; 12-week trial
Analysis 1.6. Comparison 1 S-adenosyl methionine versus placebo as monotherapy, Outcome 6
Acceptability. Participants experiencing specific adverse effects: mania or hypomania.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 1 S-adenosyl methionine versus placebo as monotherapy
Outcome: 6 Acceptability. Participants experiencing specific adverse effects: mania or hypomania
Study or subgroup
S-adenosyl
methionine Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kagan 1990 (1) 1/9 0/6 2.10 [ 0.10, 44.40 ]
0.01 0.1 1 10 100
Favours [S-adenosyl methionine] Favours [placebo]
(1) Oral SAMe 1600 mg; 3-week trial
Analysis 1.7. Comparison 1 S-adenosyl methionine versus placebo as monotherapy, Outcome 7
Acceptability. Participants experiencing specific adverse effects: headache.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 1 S-adenosyl methionine versus placebo as monotherapy
Outcome: 7 Acceptability. Participants experiencing specific adverse effects: headache
Study or subgroup
S-adenosyl
methionine Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kagan 1990 (1) 1/9 0/6 2.10 [ 0.10, 44.40 ]
0.01 0.1 1 10 100
Favours [S-adenosyl methionine] Favours [placebo]
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(1) Oral SAMe 1600 mg; 3-week trial
Analysis 1.8. Comparison 1 S-adenosyl methionine versus placebo as monotherapy, Outcome 8
Acceptability. Participants experiencing specific adverse effects: flatulence.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 1 S-adenosyl methionine versus placebo as monotherapy
Outcome: 8 Acceptability. Participants experiencing specific adverse effects: flatulence
Study or subgroup
S-adenosyl
methionine Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kagan 1990 (1) 0/9 2/6 0.14 [ 0.01, 2.49 ]
0.002 0.1 1 10 500
Favours [S-adenosyl methionine] Favours [placebo]
(1) Oral SAMe 1600 mg; 3-week trial
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Analysis 1.9. Comparison 1 S-adenosyl methionine versus placebo as monotherapy, Outcome 9
Acceptability. Participants dropping out for any reasons other than adverse effects.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 1 S-adenosyl methionine versus placebo as monotherapy
Outcome: 9 Acceptability. Participants dropping out for any reasons other than adverse effects
Study or subgroup
S-adenosyl
methionine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kagan 1990 (1) 1/10 2/8 3.6 % 0.40 [ 0.04, 3.66 ]
Mischoulon 2014 (2) 25/64 25/60 96.4 % 0.94 [ 0.61, 1.44 ]
Total (95% CI) 74 68 100.0 % 0.91 [ 0.60, 1.38 ]
Total events: 26 (S-adenosyl methionine), 27 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [S-adenosyl methionine] Favours [placebo]
(1) Oral SAMe 1600 mg; 3-week trial
(2) Oral SAMe 1600 mg/d up to 3200 mg/d; 12-week trial
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Analysis 2.1. Comparison 2 S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy,
Outcome 1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale
(negative value = improvement).
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 2 S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)
Study or subgroup
S-adenosyl
methionine Antidepressant
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 vs. imipramine
Bell 1988 (1) 11 -20.78 (11.23) 11 -6.38 (12.36) 9.1 % -1.17 [ -2.09, -0.25 ]
De Vanna 1992 (2) 12 -16.4 (9) 11 -18.6 (9.5) 10.9 % 0.23 [ -0.59, 1.05 ]
Delle Chiaie 2000a (3) 143 -12.6 (9) 137 -12.91 (9.5) 39.8 % 0.03 [ -0.20, 0.27 ]
Delle Chiaie 2000b (4) 147 -12.51 (7.3) 147 -13.1 (7.4) 40.3 % 0.08 [ -0.15, 0.31 ]
Total (95% CI) 313 306 100.0 % -0.04 [ -0.34, 0.27 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 6.99, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
(3) Oral SAMe 1600 mg/d vs imipramine 150 mg/d. 6-week trial
(4) i.m. SAMe 400 mg/d vs imipramine 150 mg/d. 4-week trial
84S-adenosyl methionine (SAMe) for depression in adults (Review)
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Analysis 2.2. Comparison 2 S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy,
Outcome 2 Acceptability. Participants dropping out of treatment during study period for any reason.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 2 S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 2 Acceptability. Participants dropping out of treatment during study period for any reason
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
Bell 1988 (1) 2/11 2/11 18.7 % 1.00 [ 0.17, 5.89 ]
De Vanna 1992 (2) 3/15 4/15 33.9 % 0.75 [ 0.20, 2.79 ]
Subtotal (95% CI) 26 26 52.6 % 0.83 [ 0.29, 2.39 ]
Total events: 5 (S-adenosyl methionine), 6 (Antidepressant)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
2 vs. desipramine
Bell 1994 (3) 3/13 7/13 47.4 % 0.43 [ 0.14, 1.30 ]
Subtotal (95% CI) 13 13 47.4 % 0.43 [ 0.14, 1.30 ]
Total events: 3 (S-adenosyl methionine), 7 (Antidepressant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Total (95% CI) 39 39 100.0 % 0.61 [ 0.28, 1.31 ]
Total events: 8 (S-adenosyl methionine), 13 (Antidepressant)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.78, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Chi2 = 0.71, df = 1 (P = 0.40), I2 =0.0%
0.01 0.1 1 10 100
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
(3) Oral SAMe 1600 mg/d vs desipramine 250 mg/d. 4-week trial
85S-adenosyl methionine (SAMe) for depression in adults (Review)
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Analysis 2.3. Comparison 2 S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy,
Outcome 3 Acceptability. Participants dropping out of treatment during study period because of adverse
effects.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 2 S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 3 Acceptability. Participants dropping out of treatment during study period because of adverse effects
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
Bell 1988 (1) 0/11 0/11 Not estimable
De Vanna 1992 (2) 3/15 4/15 100.0 % 0.75 [ 0.20, 2.79 ]
Total (95% CI) 26 26 100.0 % 0.75 [ 0.20, 2.79 ]
Total events: 3 (S-adenosyl methionine), 4 (Antidepressant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
86S-adenosyl methionine (SAMe) for depression in adults (Review)
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Analysis 2.4. Comparison 2 S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy,
Outcome 4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to
end of treatment.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 2 S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
Bell 1988 (1) 6/11 2/11 4.9 % 3.00 [ 0.77, 11.74 ]
Delle Chiaie 2000a (2) 73/143 77/137 44.9 % 0.91 [ 0.73, 1.13 ]
Delle Chiaie 2000b (3) 86/147 74/147 45.6 % 1.16 [ 0.94, 1.43 ]
Subtotal (95% CI) 301 295 95.3 % 1.08 [ 0.81, 1.44 ]
Total events: 165 (S-adenosyl methionine), 153 (Antidepressant)
Heterogeneity: Tau2 = 0.03; Chi2 = 4.88, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 0.50 (P = 0.62)
2 vs. desipramine
Bell 1994 (4) 6/13 2/13 4.7 % 3.00 [ 0.74, 12.21 ]
Subtotal (95% CI) 13 13 4.7 % 3.00 [ 0.74, 12.21 ]
Total events: 6 (S-adenosyl methionine), 2 (Antidepressant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.12)
Total (95% CI) 314 308 100.0 % 1.14 [ 0.83, 1.56 ]
Total events: 171 (S-adenosyl methionine), 155 (Antidepressant)
Heterogeneity: Tau2 = 0.05; Chi2 = 7.08, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 1.97, df = 1 (P = 0.16), I2 =49%
0.002 0.1 1 10 500
Favours [antidepressant] Favours [S-adenosyl methionine]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 150 mg/d. 6-week trial
(3) i.m. SAMe 400 mg/d vs imipramine 150 mg/d. 4-week trial
(4) Oral SAMe 1600 mg/d vs desipramine 250 mg/d. 4-week trial
87S-adenosyl methionine (SAMe) for depression in adults (Review)
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Analysis 2.5. Comparison 2 S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy,
Outcome 5 Acceptability. Participants experiencing troublesome adverse effects of any nature.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 2 S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 5 Acceptability. Participants experiencing troublesome adverse effects of any nature
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
De Vanna 1992 (1) 8/15 7/15 11.9 % 1.14 [ 0.56, 2.35 ]
Delle Chiaie 2000a (2) 42/143 59/137 40.7 % 0.68 [ 0.50, 0.94 ]
Delle Chiaie 2000b (3) 47/147 80/147 47.4 % 0.59 [ 0.44, 0.78 ]
Total (95% CI) 305 299 100.0 % 0.68 [ 0.52, 0.88 ]
Total events: 97 (S-adenosyl methionine), 146 (Antidepressant)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.95, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 150 mg/d. 6-week trial
(3) i.m. SAMe 400 mg/d vs imipramine 150 mg/d. 4-week trial
88S-adenosyl methionine (SAMe) for depression in adults (Review)
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Analysis 2.6. Comparison 2 S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy,
Outcome 6 Acceptability. Participants experiencing specific adverse effects: mania or hypomania.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 2 S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 6 Acceptability. Participants experiencing specific adverse effects: mania or hypomania
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
Bell 1988 (1) 0/9 0/9 Not estimable
De Vanna 1992 (2) 1/15 0/15 100.0 % 3.00 [ 0.13, 68.26 ]
Total (95% CI) 24 24 100.0 % 3.00 [ 0.13, 68.26 ]
Total events: 1 (S-adenosyl methionine), 0 (Antidepressant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
89S-adenosyl methionine (SAMe) for depression in adults (Review)
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Analysis 2.7. Comparison 2 S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy,
Outcome 7 Acceptability. Participants dropping out for any reasons other than adverse effects.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 2 S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 7 Acceptability. Participants dropping out for any reasons other than adverse effects
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
Bell 1988 (1) 2/11 2/11 100.0 % 1.00 [ 0.17, 5.89 ]
De Vanna 1992 (2) 0/15 0/15 Not estimable
Total (95% CI) 26 26 100.0 % 1.00 [ 0.17, 5.89 ]
Total events: 2 (S-adenosyl methionine), 2 (Antidepressant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
90S-adenosyl methionine (SAMe) for depression in adults (Review)
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Analysis 3.1. Comparison 3 S-adenosyl methionine versus SSRI antidepressant agent as monotherapy,
Outcome 1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale
(negative value = improvement).
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 3 S-adenosyl methionine versus SSRI antidepressant agent as monotherapy
Outcome: 1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)
Study or subgroup
S-adenosyl
methionine Antidepressant
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 vs. escitalopram
Mischoulon 2014 (1) 64 -6.19 (8.53) 65 -6.31 (8.11) 0.12 [ -2.75, 2.99 ]
-10 -5 0 5 10
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) Oral SAMe 1600 mg/d up to 3200 mg/d vs escitalopram 10 mg/d up to 20 mg/d. 12-week trial
Analysis 3.2. Comparison 3 S-adenosyl methionine versus SSRI antidepressant agent as monotherapy,
Outcome 2 Acceptability. Participants dropping out of treatment during study period for any reason.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 3 S-adenosyl methionine versus SSRI antidepressant agent as monotherapy
Outcome: 2 Acceptability. Participants dropping out of treatment during study period for any reason
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. escitalopram
Mischoulon 2014 (1) 28/64 35/65 0.81 [ 0.57, 1.16 ]
0.5 0.7 1 1.5 2
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) Oral SAMe 1600 mg/d up to 3200 mg/d vs escitalopram 10 mg/d up to 20 mg/d. 12-week trial
91S-adenosyl methionine (SAMe) for depression in adults (Review)
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Analysis 3.3. Comparison 3 S-adenosyl methionine versus SSRI antidepressant agent as monotherapy,
Outcome 3 Acceptability. Participants dropping out of treatment during study period because of adverse
effects.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 3 S-adenosyl methionine versus SSRI antidepressant agent as monotherapy
Outcome: 3 Acceptability. Participants dropping out of treatment during study period because of adverse effects
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. escitalopram
Mischoulon 2014 (1) 3/64 8/65 0.38 [ 0.11, 1.37 ]
0.05 0.2 1 5 20
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) Oral SAMe 1600 mg/d up to 3200 mg/d vs escitalopram 10 mg/d up to 20 mg/d. 12-week trial
Analysis 3.4. Comparison 3 S-adenosyl methionine versus SSRI antidepressant agent as monotherapy,
Outcome 4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to
end of treatment.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 3 S-adenosyl methionine versus SSRI antidepressant agent as monotherapy
Outcome: 4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. escitalopram
Mischoulon 2014 (1) 23/64 22/65 1.06 [ 0.66, 1.70 ]
0.01 0.1 1 10 100
Favours [antidepressant] Favours [S-adenosyl methionine]
(1) Oral SAMe 1600 mg/d up to 3200 mg/d vs escitalopram 10 mg/d up to 20 mg/d. 12-week trial
92S-adenosyl methionine (SAMe) for depression in adults (Review)
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Analysis 3.5. Comparison 3 S-adenosyl methionine versus SSRI antidepressant agent as monotherapy,
Outcome 5 Efficacy. Remission, defined as a depression rating scale score within normal range at end of study.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 3 S-adenosyl methionine versus SSRI antidepressant agent as monotherapy
Outcome: 5 Efficacy. Remission, defined as a depression rating scale score within normal range at end of study
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. escitalopram
Mischoulon 2014 (1) 18/64 18/65 1.02 [ 0.58, 1.77 ]
0.01 0.1 1 10 100
Favours [antidepressant] Favours [S-adenosyl methionine]
(1) Oral SAMe 1600 mg/d up to 3200 mg/d vs escitalopram 10 mg/d up to 20 mg/d. 12-week trial
Analysis 3.6. Comparison 3 S-adenosyl methionine versus SSRI antidepressant agent as monotherapy,
Outcome 6 Acceptability. Participants dropping out for any reasons other than adverse effects.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 3 S-adenosyl methionine versus SSRI antidepressant agent as monotherapy
Outcome: 6 Acceptability. Participants dropping out for any reasons other than adverse effects
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. escitalopram
Mischoulon 2014 (1) 25/64 27/65 0.94 [ 0.62, 1.43 ]
0.2 0.5 1 2 5
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) Oral SAMe 1600 mg/d up to 3200 mg/d vs escitalopram 10 mg/d up to 20 mg/d. 12-week trial
93S-adenosyl methionine (SAMe) for depression in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.1. Comparison 4 S-adenosyl methionine versus placebo as adjunctive treatment to SSRI,
Outcome 1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale
(negative value = improvement).
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 4 S-adenosyl methionine versus placebo as adjunctive treatment to SSRI
Outcome: 1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)
Study or subgroup SAMe + SSRI Placebo + SSRI
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Papakostas 2010a (1) 39 -8 (6.56) 34 -4.1 (6.61) -3.90 [ -6.93, -0.87 ]
-20 -10 0 10 20
Favours [SAMe + SSRI] Favours [placebo + SSRI]
(1) Oral SAMe 1600 mg/d. 6-week trial. SSRI-nonresponders participants
Analysis 4.2. Comparison 4 S-adenosyl methionine versus placebo as adjunctive treatment to SSRI,
Outcome 2 Acceptability. Participants dropping out of treatment during study period for any reason.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 4 S-adenosyl methionine versus placebo as adjunctive treatment to SSRI
Outcome: 2 Acceptability. Participants dropping out of treatment during study period for any reason
Study or subgroup SAMe + SSRI Placebo + SSRI Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Papakostas 2010a (1) 8/39 10/34 0.70 [ 0.31, 1.56 ]
0.05 0.2 1 5 20
Favours [SAMe + SSRI] Favours [placebo + SSRI]
(1) Oral SAMe 1600 mg/d. 6-week trial. SSRI-nonresponders participants
94S-adenosyl methionine (SAMe) for depression in adults (Review)
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Analysis 4.3. Comparison 4 S-adenosyl methionine versus placebo as adjunctive treatment to SSRI,
Outcome 3 Acceptability. Participants dropping out of treatment during study period because of adverse
effects.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 4 S-adenosyl methionine versus placebo as adjunctive treatment to SSRI
Outcome: 3 Acceptability. Participants dropping out of treatment during study period because of adverse effects
Study or subgroup SAMe + SSRI Placebo + SSRI Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Papakostas 2010a (1) 2/39 3/34 0.58 [ 0.10, 3.28 ]
0.01 0.1 1 10 100
Favours [SAMe + SSRI] Favours [placebo + SSRI]
(1) Oral SAMe 1600 mg/d. 6-week trial. SSRI-nonresponders participants
Analysis 4.4. Comparison 4 S-adenosyl methionine versus placebo as adjunctive treatment to SSRI,
Outcome 4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to
end of treatment.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 4 S-adenosyl methionine versus placebo as adjunctive treatment to SSRI
Outcome: 4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment
Study or subgroup SAMe + SSRI Placebo + SSRI Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Papakostas 2010a (1) 18/39 6/34 2.62 [ 1.17, 5.83 ]
0.02 0.1 1 10 50
Favours [placebo + SSRI] Favours [SAMe + SSRI]
(1) Oral SAMe 1600 mg/d. 6-week trial. SSRI-nonresponders participants
95S-adenosyl methionine (SAMe) for depression in adults (Review)
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Analysis 4.5. Comparison 4 S-adenosyl methionine versus placebo as adjunctive treatment to SSRI,
Outcome 5 Efficacy. Remission, defined as a depression rating scale score within normal range at end of study.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 4 S-adenosyl methionine versus placebo as adjunctive treatment to SSRI
Outcome: 5 Efficacy. Remission, defined as a depression rating scale score within normal range at end of study
Study or subgroup SAMe + SSRI Placebo + SSRI Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Papakostas 2010a (1) 14/39 4/34 3.05 [ 1.11, 8.39 ]
0.01 0.1 1 10 100
Favours [placebo + SSRI] Favours [SAMe + SSRI]
(1) Oral SAMe 1600 mg/d. 6-week trial. SSRI-nonresponders participants
Analysis 4.6. Comparison 4 S-adenosyl methionine versus placebo as adjunctive treatment to SSRI,
Outcome 6 Acceptability. Participants experiencing specific adverse effects: headache.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 4 S-adenosyl methionine versus placebo as adjunctive treatment to SSRI
Outcome: 6 Acceptability. Participants experiencing specific adverse effects: headache
Study or subgroup SAMe + SSRI Placebo + SSRI Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Papakostas 2010a (1) 4/39 2/34 1.74 [ 0.34, 8.93 ]
0.01 0.1 1 10 100
Favours [SAMe + SSRI] Favours [placebo + SSRI]
(1) Oral SAMe 1600 mg/d. 6-week trial. SSRI-nonresponders participants
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Analysis 4.7. Comparison 4 S-adenosyl methionine versus placebo as adjunctive treatment to SSRI,
Outcome 7 Acceptability. Participants experiencing specific adverse effects: diarrhoea.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 4 S-adenosyl methionine versus placebo as adjunctive treatment to SSRI
Outcome: 7 Acceptability. Participants experiencing specific adverse effects: diarrhoea
Study or subgroup SAMe + SSRI Placebo + SSRI Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Papakostas 2010a (1) 7/39 5/34 1.22 [ 0.43, 3.49 ]
0.01 0.1 1 10 100
Favours [SAMe + SSRI] Favours [placebo + SSRI]
(1) Oral SAMe 1600 mg/d. 6-week trial. SSRI-nonresponders participants
Analysis 4.8. Comparison 4 S-adenosyl methionine versus placebo as adjunctive treatment to SSRI,
Outcome 8 Acceptability. Participants dropping out for any reasons other than adverse effects.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 4 S-adenosyl methionine versus placebo as adjunctive treatment to SSRI
Outcome: 8 Acceptability. Participants dropping out for any reasons other than adverse effects
Study or subgroup SAMe + SSRI Placebo + SSRI Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Papakostas 2010a (1) 6/39 7/34 0.75 [ 0.28, 2.01 ]
0.05 0.2 1 5 20
Favours [SAMe + SSRI] Favours [placebo + SSRI]
(1) Oral SAMe 1600 mg/d. 6-week trial. SSRI-nonresponders participants
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Analysis 5.1. Comparison 5 Sensitivity analyses. S-adenosyl methionine versus placebo as monotherapy,
Outcome 1 Sensitivity analysis for imputation of continuous efficacy data (assumption: missing participants
had same mean change as other participants). Efficacy. Change in mean scores from baseline to end of
treatment on the depression rating scale (negative value = improvement).
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 5 Sensitivity analyses. S-adenosyl methionine versus placebo as monotherapy
Outcome: 1 Sensitivity analysis for imputation of continuous efficacy data (assumption: missing participants had same mean change as other participants). Efficacy. Change
in mean scores from baseline to end of treatment on the depression rating scale (negative value = improvement)
Study or subgroup
S-adenosyl
methionine Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kagan 1990 (1) 10 -16.2 (7.3) 8 -7.3 (7.4) 38.5 % -1.15 [ -2.18, -0.13 ]
Mischoulon 2014 (2) 64 -6.19 (8.53) 60 -5.11 (7.67) 61.5 % -0.13 [ -0.48, 0.22 ]
Total (95% CI) 74 68 100.0 % -0.53 [ -1.50, 0.45 ]
Heterogeneity: Tau2 = 0.37; Chi2 = 3.43, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours [S-adenosyl methionine] Favours [placebo]
(1) Oral SAMe 1600 mg; 3-week trial
(2) Oral SAMe 1600 mg/d up to 3200 mg/d; 12-week trial
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Analysis 5.2. Comparison 5 Sensitivity analyses. S-adenosyl methionine versus placebo as monotherapy,
Outcome 2 Sensitivity analysis for imputation of dichotomous data (assumption: ’best-case’ scenario). Efficacy.
Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 5 Sensitivity analyses. S-adenosyl methionine versus placebo as monotherapy
Outcome: 2 Sensitivity analysis for imputation of dichotomous data (assumption: ’best-case’ scenario). Efficacy. Response to treatment, defined as a ≥ 50% reduction
in depression score from baseline to end of treatment
Study or subgroup
S-adenosyl
methionine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kagan 1990 (1) 7/10 3/8 21.0 % 1.87 [ 0.70, 4.99 ]
Mischoulon 2014 (2) 23/64 18/60 79.0 % 1.20 [ 0.72, 1.99 ]
Total (95% CI) 74 68 100.0 % 1.31 [ 0.84, 2.06 ]
Total events: 30 (S-adenosyl methionine), 21 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [placebo] Favours [S-adenosyl methionine]
(1) Oral SAMe 1600 mg; 3-week trial
(2) Oral SAMe 1600 mg/d up to 3200 mg/d; 12-week trial
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Analysis 5.3. Comparison 5 Sensitivity analyses. S-adenosyl methionine versus placebo as monotherapy,
Outcome 3 Sensitivity analysis for the imputation of SD (using correlation coefficient of 0.4). Efficacy. Change
in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement).
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 5 Sensitivity analyses. S-adenosyl methionine versus placebo as monotherapy
Outcome: 3 Sensitivity analysis for the imputation of SD (using correlation coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on
depression rating scale (negative value = improvement)
Study or subgroup
S-adenosyl
methionine Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kagan 1990 (1) 10 -14.58 (7.3) 8 -5.48 (7.4) 38.4 % -1.18 [ -2.21, -0.15 ]
Mischoulon 2014 (2) 64 -6.19 (7.09) 60 -5.11 (6.47) 61.6 % -0.16 [ -0.51, 0.19 ]
Total (95% CI) 74 68 100.0 % -0.55 [ -1.53, 0.42 ]
Heterogeneity: Tau2 = 0.37; Chi2 = 3.40, df = 1 (P = 0.07); I2 =71%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours [S-adenosyl methionine] Favours [placebo]
(1) Oral SAMe 1600 mg; 3-week trial
(2) Oral SAMe 1600 mg/d up to 3200 mg/d; 12-week trial
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Analysis 5.4. Comparison 5 Sensitivity analyses. S-adenosyl methionine versus placebo as monotherapy,
Outcome 4 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Change in mean
scores from baseline to end of treatment on depression rating scale (negative value = improvement).
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 5 Sensitivity analyses. S-adenosyl methionine versus placebo as monotherapy
Outcome: 4 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Change in mean scores from baseline to end of treatment on depression
rating scale (negative value = improvement)
Study or subgroup
S-adenosyl
methionine Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kagan 1990 (1) 10 -14.58 (7.3) 8 -5.48 (7.4) -1.18 [ -2.21, -0.15 ]
-4 -2 0 2 4
Favours [S-adenosyl methionine] Favours [placebo]
(1) Oral SAMe 1600 mg; 3-week trial
Analysis 5.5. Comparison 5 Sensitivity analyses. S-adenosyl methionine versus placebo as monotherapy,
Outcome 5 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants
dropping out of treatment during study period for any reason.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 5 Sensitivity analyses. S-adenosyl methionine versus placebo as monotherapy
Outcome: 5 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants dropping out of treatment during study period for any
reason
Study or subgroup
S-adenosyl
methionine Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kagan 1990 (1) 1/10 2/8 0.40 [ 0.04, 3.66 ]
0.002 0.1 1 10 500
Favours [S-adenosyl methionine] Favours [placebo]
(1) Oral SAMe 1600 mg; 3-week trial
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Analysis 5.6. Comparison 5 Sensitivity analyses. S-adenosyl methionine versus placebo as monotherapy,
Outcome 6 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Response to
treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 5 Sensitivity analyses. S-adenosyl methionine versus placebo as monotherapy
Outcome: 6 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score
from baseline to end of treatment
Study or subgroup
S-adenosyl
methionine Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kagan 1990 (1) 6/10 1/8 4.80 [ 0.72, 32.15 ]
0.002 0.1 1 10 500
Favours [placebo] Favours [S-adenosyl methionine]
(1) Oral SAMe 1600 mg; 3-week trial
Analysis 5.7. Comparison 5 Sensitivity analyses. S-adenosyl methionine versus placebo as monotherapy,
Outcome 7 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants
dropping out for any reasons other than adverse effects.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 5 Sensitivity analyses. S-adenosyl methionine versus placebo as monotherapy
Outcome: 7 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants dropping out for any reasons other than adverse effects
Study or subgroup
S-adenosyl
methionine Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kagan 1990 (1) 1/10 2/8 0.40 [ 0.04, 3.66 ]
0.002 0.1 1 10 500
Favours [S-adenosyl methionine] Favours [placebo]
(1) Oral SAMe 1600 mg; 3-week trial
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Analysis 6.1. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 1 Subgroup analysis (oral administration of SAMe). Efficacy.
Change in mean scores from baseline to end of treatment on depression rating scale (negative value =
improvement).
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 1 Subgroup analysis (oral administration of SAMe). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative
value = improvement)
Study or subgroup
S-adenosyl
methionine Antidepressant
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 vs. imipramine
De Vanna 1992 (1) 12 -16.4 (7.43) 11 -18.6 (4.45) 7.5 % 0.34 [ -0.48, 1.17 ]
Delle Chiaie 2000a (2) 143 -12.6 (9) 137 -12.91 (9.5) 92.5 % 0.03 [ -0.20, 0.27 ]
Total (95% CI) 155 148 100.0 % 0.06 [ -0.17, 0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 150 mg/d. 6-week trial
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Analysis 6.2. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 2 Subgroup analysis (parenteral administration of SAMe).
Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value =
improvement).
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 2 Subgroup analysis (parenteral administration of SAMe). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale
(negative value = improvement)
Study or subgroup
S-adenosyl
methionine Antidepressant
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 vs. imipramine
Bell 1988 (1) 11 -20.78 (11.23) 11 -6.38 (12.36) 43.4 % -1.17 [ -2.09, -0.25 ]
Delle Chiaie 2000b (2) 147 -12.51 (7.3) 147 -13.1 (7.4) 56.6 % 0.08 [ -0.15, 0.31 ]
Total (95% CI) 158 158 100.0 % -0.46 [ -1.68, 0.75 ]
Heterogeneity: Tau2 = 0.67; Chi2 = 6.73, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
(2) i.m. SAMe 400 mg/d vs imipramine 150 mg/d. 4-week trial
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Analysis 6.3. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 3 Subgroup analysis (oral administration of SAMe).
Acceptability. Participants dropping out of treatment during study period for any reason.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 3 Subgroup analysis (oral administration of SAMe). Acceptability. Participants dropping out of treatment during study period for any reason
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
De Vanna 1992 (1) 3/15 4/15 41.7 % 0.75 [ 0.20, 2.79 ]
Subtotal (95% CI) 15 15 41.7 % 0.75 [ 0.20, 2.79 ]
Total events: 3 (S-adenosyl methionine), 4 (Antidepressant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 vs. desipramine
Bell 1994 (2) 3/13 7/13 58.3 % 0.43 [ 0.14, 1.30 ]
Subtotal (95% CI) 13 13 58.3 % 0.43 [ 0.14, 1.30 ]
Total events: 3 (S-adenosyl methionine), 7 (Antidepressant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Total (95% CI) 28 28 100.0 % 0.54 [ 0.23, 1.27 ]
Total events: 6 (S-adenosyl methionine), 11 (Antidepressant)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 0.41, df = 1 (P = 0.52), I2 =0.0%
0.002 0.1 1 10 500
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
(2) Oral SAMe 1600 mg/d vs desipramine 250 mg/d. 4-week trial
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Analysis 6.4. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 4 Subgroup analysis (parenteral administration of SAMe).
Acceptability. Participants dropping out of treatment during study period for any reason.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 4 Subgroup analysis (parenteral administration of SAMe). Acceptability. Participants dropping out of treatment during study period for any reason
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
Bell 1988 (1) 2/11 2/11 1.00 [ 0.17, 5.89 ]
0.005 0.1 1 10 200
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
Analysis 6.5. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 5 Subgroup analysis (oral administration of SAMe).
Acceptability. Participants dropping out of treatment during study period because of adverse effects.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 5 Subgroup analysis (oral administration of SAMe). Acceptability. Participants dropping out of treatment during study period because of adverse effects
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
De Vanna 1992 (1) 3/15 4/15 0.75 [ 0.20, 2.79 ]
0.01 0.1 1 10 100
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
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Analysis 6.6. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 6 Subgroup analysis (parenteral administration of SAMe).
Acceptability. Participants dropping out of treatment during study period because of adverse effects.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 6 Subgroup analysis (parenteral administration of SAMe). Acceptability. Participants dropping out of treatment during study period because of adverse effects
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
Bell 1988 (1) 0/11 0/11 Not estimable
0.02 0.1 1 10 50
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
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Analysis 6.7. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 7 Subgroup analysis (oral administration of SAMe). Efficacy.
Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 7 Subgroup analysis (oral administration of SAMe). Efficacy. Response to treatment, defined as a≥ 50% reduction in depression score from baseline to end
of treatment
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
Delle Chiaie 2000a (1) 73/143 77/137 67.1 % 0.91 [ 0.73, 1.13 ]
Subtotal (95% CI) 143 137 67.1 % 0.91 [ 0.73, 1.13 ]
Total events: 73 (S-adenosyl methionine), 77 (Antidepressant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
2 vs. desipramine
Bell 1994 (2) 6/13 2/13 32.9 % 3.00 [ 0.74, 12.21 ]
Subtotal (95% CI) 13 13 32.9 % 3.00 [ 0.74, 12.21 ]
Total events: 6 (S-adenosyl methionine), 2 (Antidepressant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.12)
Total (95% CI) 156 150 100.0 % 1.35 [ 0.44, 4.09 ]
Total events: 79 (S-adenosyl methionine), 79 (Antidepressant)
Heterogeneity: Tau2 = 0.47; Chi2 = 2.78, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Chi2 = 2.72, df = 1 (P = 0.10), I2 =63%
0.005 0.1 1 10 200
Favours [antidepressant] Favours [S-adenosyl methionine]
(1) Oral SAMe 1600 mg/d vs imipramine 150 mg/d. 6-week trial
(2) Oral SAMe 1600 mg/d vs desipramine 250 mg/d. 4-week trial
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Analysis 6.8. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 8 Subgroup analysis (parenteral administration of SAMe).
Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of
treatment.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 8 Subgroup analysis (parenteral administration of SAMe). Efficacy. Response to treatment, defined as a≥ 50% reduction in depression score from baseline
to end of treatment
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
Bell 1988 (1) 6/11 2/11 24.1 % 3.00 [ 0.77, 11.74 ]
Delle Chiaie 2000b (2) 86/147 74/147 75.9 % 1.16 [ 0.94, 1.43 ]
Total (95% CI) 158 158 100.0 % 1.46 [ 0.66, 3.26 ]
Total events: 92 (S-adenosyl methionine), 76 (Antidepressant)
Heterogeneity: Tau2 = 0.21; Chi2 = 1.84, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours [antidepressant] Favours [S-adenosyl methionine]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
(2) i.m. SAMe 400 mg/d vs imipramine 150 mg/d. 4-week trial
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Analysis 6.9. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 9 Subgroup analysis (parenteral administration of SAMe).
Acceptability. Participants experiencing troublesome adverse effects of any nature.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 9 Subgroup analysis (parenteral administration of SAMe). Acceptability. Participants experiencing troublesome adverse effects of any nature
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
Delle Chiaie 2000b (1) 47/147 80/147 0.59 [ 0.44, 0.78 ]
0.01 0.1 1 10 100
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) i.m. SAMe 400 mg/d vs imipramine 150 mg/d. 4-week trial
Analysis 6.10. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 10 Subgroup analysis (oral administration of SAMe).
Acceptability. Participants experiencing troublesome adverse effects of any nature.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 10 Subgroup analysis (oral administration of SAMe). Acceptability. Participants experiencing troublesome adverse effects of any nature
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
De Vanna 1992 (1) 8/15 7/15 29.9 % 1.14 [ 0.56, 2.35 ]
Delle Chiaie 2000a (2) 42/143 59/137 70.1 % 0.68 [ 0.50, 0.94 ]
Total (95% CI) 158 152 100.0 % 0.80 [ 0.50, 1.27 ]
Total events: 50 (S-adenosyl methionine), 66 (Antidepressant)
Heterogeneity: Tau2 = 0.05; Chi2 = 1.67, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours [S-adenosyl methionine] Favours [antidepressant]
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(1) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 150 mg/d. 6-week trial
Analysis 6.11. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 11 Subgroup analysis (oral administration of SAMe).
Acceptability. Participants dropping out for any reasons other than adverse effects.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 11 Subgroup analysis (oral administration of SAMe). Acceptability. Participants dropping out for any reasons other than adverse effects
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
De Vanna 1992 (1) 0/15 0/15 Not estimable
0.01 0.1 1 10 100
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
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Analysis 6.12. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 12 Subgroup analysis (parenteral administration of SAMe).
Acceptability. Participants dropping out for any reasons other than adverse effects.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 12 Subgroup analysis (parenteral administration of SAMe). Acceptability. Participants dropping out for any reasons other than adverse effects
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
Bell 1988 (1) 2/11 2/11 1.00 [ 0.17, 5.89 ]
0.005 0.1 1 10 200
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
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Analysis 6.13. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 13 Sensitivity analysis for imputation of continuous efficacy
data (assumption: missing participants had same mean change as other participants). Efficacy. Change in
mean scores from baseline to end of treatment on depression rating scale (negative value = improvement).
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 13 Sensitivity analysis for imputation of continuous efficacy data (assumption: missing participants had same mean change as other participants). Efficacy.
Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)
Study or subgroup
S-adenosyl
methionine Antidepressant
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 vs. imipramine
Bell 1988 (1) 11 -25.4 (11.23) 11 -7.8 (12.36) 10.7 % -1.43 [ -2.39, -0.48 ]
De Vanna 1992 (2) 12 -16.4 (9) 11 -18.6 (9.5) 13.4 % 0.23 [ -0.59, 1.05 ]
Delle Chiaie 2000a (3) 143 -12.6 (9) 137 -13.1 (9.5) 37.8 % 0.05 [ -0.18, 0.29 ]
Delle Chiaie 2000b (4) 147 -12.6 (7.3) 147 -13.1 (7.4) 38.1 % 0.07 [ -0.16, 0.30 ]
Total (95% CI) 313 306 100.0 % -0.08 [ -0.43, 0.28 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 9.35, df = 3 (P = 0.03); I2 =68%
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
(3) Oral SAMe 1600 mg/d vs imipramine 150 mg/d. 6-week trial
(4) i.m. SAMe 400 mg/d vs imipramine 150 mg/d. 4-week trial
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Analysis 6.14. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 14 Sensitivity analysis for imputation of dichotomous data
(assumption: ’best-case’ scenario). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression
score from baseline to end of treatment.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 14 Sensitivity analysis for imputation of dichotomous data (assumption: ’best-case’ scenario). Efficacy. Response to treatment, defined as a≥ 50% reduction
in depression score from baseline to end of treatment
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
Bell 1988 (1) 8/11 4/11 7.0 % 2.00 [ 0.85, 4.73 ]
Delle Chiaie 2000a (2) 73/143 79/137 39.1 % 0.89 [ 0.71, 1.10 ]
Delle Chiaie 2000b (3) 87/147 74/147 39.8 % 1.18 [ 0.95, 1.45 ]
Subtotal (95% CI) 301 295 85.9 % 1.09 [ 0.81, 1.47 ]
Total events: 168 (S-adenosyl methionine), 157 (Antidepressant)
Heterogeneity: Tau2 = 0.04; Chi2 = 5.68, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 0.58 (P = 0.56)
2 vs. desipramine
Bell 1994 (4) 8/13 9/13 14.1 % 0.89 [ 0.51, 1.56 ]
Subtotal (95% CI) 13 13 14.1 % 0.89 [ 0.51, 1.56 ]
Total events: 8 (S-adenosyl methionine), 9 (Antidepressant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Total (95% CI) 314 308 100.0 % 1.05 [ 0.82, 1.34 ]
Total events: 176 (S-adenosyl methionine), 166 (Antidepressant)
Heterogeneity: Tau2 = 0.03; Chi2 = 5.98, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Chi2 = 0.40, df = 1 (P = 0.53), I2 =0.0%
0.01 0.1 1 10 100
Favours [antidepressant] Favours [S-adenosyl methionine]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 150 mg/d. 6-week trial
(3) i.m. SAMe 400 mg/d vs imipramine 150 mg/d. 4-week trial
(4) Oral SAMe 1600 mg/d vs desipramine 250 mg/d. 4-week trial
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Analysis 6.15. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 15 Sensitivity analysis for imputation of SD (using correlation
coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on depression rating
scale (negative value = improvement).
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 15 Sensitivity analysis for imputation of SD (using correlation coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on
depression rating scale (negative value = improvement)
Study or subgroup
S-adenosyl
methionine Antidepressant
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 vs. imipramine
Bell 1988 (1) 11 -20.78 (9.24) 11 -6.38 (10.25) 10.6 % -1.42 [ -2.38, -0.46 ]
De Vanna 1992 (2) 12 -16.4 (9) 11 -18.6 (9.5) 13.3 % 0.23 [ -0.59, 1.05 ]
Delle Chiaie 2000a (3) 143 -12.6 (9) 137 -12.91 (9.5) 37.9 % 0.03 [ -0.20, 0.27 ]
Delle Chiaie 2000b (4) 147 -12.51 (7.3) 147 -13.1 (7.4) 38.2 % 0.08 [ -0.15, 0.31 ]
Total (95% CI) 313 306 100.0 % -0.08 [ -0.43, 0.28 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 9.25, df = 3 (P = 0.03); I2 =68%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
(3) Oral SAMe 1600 mg/d vs imipramine 150 mg/d. 6-week trial
(4) i.m. SAMe 400 mg/d vs imipramine 150 mg/d. 4-week trial
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Analysis 6.16. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 16 Sensitivity analysis (excluding studies with high levels of
missing data). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale
(negative value = improvement).
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 16 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Change in mean scores from baseline to end of treatment on depression
rating scale (negative value = improvement)
Study or subgroup
S-adenosyl
methionine Antidepressant
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 vs. imipramine
Bell 1988 (1) 11 -20.78 (11.23) 11 -6.38 (12.36) 48.9 % -1.17 [ -2.09, -0.25 ]
De Vanna 1992 (2) 12 -16.4 (9) 11 -18.6 (9.5) 51.1 % 0.23 [ -0.59, 1.05 ]
Total (95% CI) 23 22 100.0 % -0.46 [ -1.83, 0.92 ]
Heterogeneity: Tau2 = 0.79; Chi2 = 4.97, df = 1 (P = 0.03); I2 =80%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
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Analysis 6.17. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 17 Sensitivity analysis (excluding studies with high levels of
missing data). Acceptability. Participants dropping out of treatment during study period for any reason.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 17 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants dropping out of treatment during study period for any
reason
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
Bell 1988 (1) 2/11 2/11 35.5 % 1.00 [ 0.17, 5.89 ]
De Vanna 1992 (2) 3/15 4/15 64.5 % 0.75 [ 0.20, 2.79 ]
Total (95% CI) 26 26 100.0 % 0.83 [ 0.29, 2.39 ]
Total events: 5 (S-adenosyl methionine), 6 (Antidepressant)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
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Analysis 6.18. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 18 Sensitivity analysis (excluding studies with high levels of
missing data). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline
to end of treatment.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 18 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Response to treatment, defined as a≥ 50% reduction in depression score
from baseline to end of treatment
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
Bell 1988 (1) 6/11 2/11 3.00 [ 0.77, 11.74 ]
0.005 0.1 1 10 200
Favours [antidepressant] Favours [S-adenosyl methionine]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
Analysis 6.19. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 19 Sensitivity analysis (excluding studies with high levels of
missing data). Acceptability. Participants experiencing troublesome adverse effects of any nature.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 19 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants experiencing troublesome adverse effects of any nature
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
De Vanna 1992 (1) 8/15 7/15 1.14 [ 0.56, 2.35 ]
0.005 0.1 1 10 200
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
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Analysis 6.20. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 20 Sensitivity analysis (excluding De Vanna 1992). Efficacy.
Change in mean scores from baseline to end of treatment on depression rating scale (negative value =
improvement).
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 20 Sensitivity analysis (excluding De Vanna 1992). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative
value = improvement)
Study or subgroup
Favours
[S-adenosyl
methionine] Antidepressant
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 vs. imipramine
Bell 1988 (1) 11 -20.78 (11.23) 11 -6.38 (12.36) 11.7 % -1.17 [ -2.09, -0.25 ]
Delle Chiaie 2000a (2) 143 -12.6 (9) 137 -12.91 (9.5) 43.9 % 0.03 [ -0.20, 0.27 ]
Delle Chiaie 2000b (3) 147 -12.51 (7.3) 147 -13.1 (7.4) 44.3 % 0.08 [ -0.15, 0.31 ]
Total (95% CI) 301 295 100.0 % -0.09 [ -0.44, 0.27 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 6.75, df = 2 (P = 0.03); I2 =70%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 150 mg/d. 6-week trial
(3) i.m. SAMe 400 mg/d vs imipramine 150 mg/d. 4-week trial
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Analysis 6.21. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 21 Sensitivity analysis (excluding Bell 1994, as at high risk of
bias). Acceptability. Participants dropping out of treatment during study period for any reason.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 21 Sensitivity analysis (excluding Bell 1994, as at high risk of bias). Acceptability. Participants dropping out of treatment during study period for any reason
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
Bell 1988 (1) 2/11 2/11 35.5 % 1.00 [ 0.17, 5.89 ]
De Vanna 1992 (2) 3/15 4/15 64.5 % 0.75 [ 0.20, 2.79 ]
Total (95% CI) 26 26 100.0 % 0.83 [ 0.29, 2.39 ]
Total events: 5 (S-adenosyl methionine), 6 (Antidepressant)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 140 mg/d. 6-week trial
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Analysis 6.22. Comparison 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic
antidepressant agent as monotherapy, Outcome 22 Sensitivity analysis (excluding Bell 1994, as at high risk of
bias). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end
of treatment.
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 6 Sensitivity and subgroup analyses. S-adenosyl methionine versus tricyclic antidepressant agent as monotherapy
Outcome: 22 Sensitivity analysis (excluding Bell 1994, as at high risk of bias). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from
baseline to end of treatment
Study or subgroup
S-adenosyl
methionine Antidepressant Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 vs. imipramine
Bell 1988 (1) 6/11 2/11 4.2 % 3.00 [ 0.77, 11.74 ]
Delle Chiaie 2000a (2) 73/143 77/137 47.5 % 0.91 [ 0.73, 1.13 ]
Delle Chiaie 2000b (3) 86/147 74/147 48.4 % 1.16 [ 0.94, 1.43 ]
Total (95% CI) 301 295 100.0 % 1.08 [ 0.81, 1.44 ]
Total events: 165 (S-adenosyl methionine), 153 (Antidepressant)
Heterogeneity: Tau2 = 0.03; Chi2 = 4.88, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [antidepressant] Favours [S-adenosyl methionine]
(1) i.v. SAMe 400 mg/d vs imipramine 150 mg/d. 2-week trial
(2) Oral SAMe 1600 mg/d vs imipramine 150 mg/d. 6-week trial
(3) i.m. SAMe 400 mg/d vs imipramine 150 mg/d. 4-week trial
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Analysis 7.1. Comparison 7 Sensitivity analysis. S-adenosyl methionine versus SSRI antidepressant agent as
monotherapy, Outcome 1 Sensitivity analysis for imputation of SD (using correlation coefficient of 0.4).
Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value =
improvement).
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 7 Sensitivity analysis. S-adenosyl methionine versus SSRI antidepressant agent as monotherapy
Outcome: 1 Sensitivity analysis for imputation of SD (using correlation coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on depression
rating scale (negative value = improvement)
Study or subgroup
S-adenosyl
methionine Antidepressant
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 vs. escitalopram
Mischoulon 2014 (1) 64 -6.19 (7.09) 65 -6.31 (6.73) 0.12 [ -2.27, 2.51 ]
-20 -10 0 10 20
Favours [S-adenosyl methionine] Favours [antidepressant]
(1) Oral SAMe 1600 mg/d up to 3200 mg/d vs escitalopram 10 mg/d up to 20 mg/d. 12-week trial
Analysis 8.1. Comparison 8 Sensitivity analysis. S-adenosyl methionine versus placebo as adjunctive
treatment, Outcome 1 Sensitivity analysis for imputation of SD (using correlation coefficient of 0.4). Efficacy.
Change in mean scores from baseline to end of treatment on depression rating scale (negative value =
improvement).
Review: S-adenosyl methionine (SAMe) for depression in adults
Comparison: 8 Sensitivity analysis. S-adenosyl methionine versus placebo as adjunctive treatment
Outcome: 1 Sensitivity analysis for imputation of SD (using correlation coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on depression
rating scale (negative value = improvement)
Study or subgroup SAMe + SSRI Placebo + SSRI
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Papakostas 2010a (1) 39 -8 (5.63) 34 -4.1 (5.71) -3.90 [ -6.51, -1.29 ]
-20 -10 0 10 20
Favours [SAMe + SSRI] Favours [placebo + SSRI]
(1) Oral SAMe 1600 mg/d. 6-week trial. SSRI-nonresponders participants
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A P P E N D I C E S
Appendix 1. Core Ovid MEDLINE search - CCMDCTR
Core Ovid MEDLINE search used to inform the Cochrane Common Mental Disorders Group’s specialised register (CCMDCTR), a
weekly search alert based on condition + RCT filter.
1. [MeSH Headings]:
eating disorders/ or anorexia nervosa/ or binge-eating disorder/ or bulimia nervosa/ or female athlete triad syndrome/ or pica/ or
hyperphagia/ or bulimia/ or self-injurious behavior/ or self mutilation/ or suicide/ or suicidal ideation/ or suicide, attempted/ or
mood disorders/ or affective disorders, psychotic/ or bipolar disorder/ or cyclothymic disorder/ or depressive disorder/ or depression,
postpartum/ or depressive disorder, major/ or depressive disorder, treatment-resistant/ or dysthymic disorder/ or seasonal affective
disorder/ or neurotic disorders/ or depression/ or adjustment disorders/ or exp antidepressive agents/ or anxiety disorders/ or agoraphobia/
or neurocirculatory asthenia/ or obsessive-compulsive disorder/ or obsessive hoarding/ or panic disorder/ or phobic disorders/ or stress
disorders, traumatic/ or combat disorders/ or stress disorders, post-traumatic/ or stress disorders, traumatic, acute/ or anxiety/ or anxiety,
castration/ or koro/ or anxiety, separation/ or panic/ or exp anti-anxiety agents/ or somatoform disorders/ or body dysmorphic disorders/
or conversion disorder/ or hypochondriasis/ or neurasthenia/ or hysteria/ ormunchausen syndrome by proxy/ ormunchausen syndrome/
or fatigue syndrome, chronic/ or obsessive behavior/ or compulsive behavior/ or behavior, addictive/ or impulse control disorders/
or firesetting behavior/ or gambling/ or trichotillomania/ or stress, psychological/ or burnout, professional/ or sexual dysfunctions,
psychological/ or vaginismus/ or Anhedonia/ or Affective Symptoms/ or *Mental Disorders/
2. [Title/ Author Keywords]:
(eating disorder* or anorexia nervosa or bulimi* or binge eat* or (self adj (injur* or mutilat*)) or suicide* or suicidal or parasuicid* or
mood disorder* or affective disorder* or bipolar i or bipolar ii or (bipolar and (affective or disorder*)) or mania or manic or cyclothymic*
or depression or depressive or dysthymi* or neurotic or neurosis or adjustment disorder* or antidepress* or anxiety disorder* or
agoraphobia or obsess* or compulsi* or panic or phobi* or ptsd or posttrauma* or post trauma* or combat or somatoform or somati#
ation or medical* unexplained or body dysmorphi* or conversion disorder or hypochondria* or neurastheni* or hysteria or munchausen
or chronic fatigue* or gambling or trichotillomania or vaginismus or anhedoni* or affective symptoms or mental disorder* or mental
health).ti,kf.
3. [RCT filter]:
(controlled clinical trial.pt. or randomized controlled trial.pt. or (randomi#ed or randomi#ation).ab,ti. or randomly.ab. or (random*
adj3 (administ* or allocat* or assign* or class* or control* or determine* or divide* or distribut* or expose* or fashion or number* or
place* or recruit* or subsitut* or treat*)).ab. or placebo*.ab,ti. or drug therapy.fs. or trial.ab,ti. or groups.ab. or (control* adj3 (trial* or
study or studies)).ab,ti. or ((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or dummy*)).mp. or clinical trial, phase ii/ or
clinical trial, phase iii/ or clinical trial, phase iv/ or randomized controlled trial/ or pragmatic clinical trial/ or (quasi adj (experimental
or random*)).ti,ab. or ((waitlist* or wait* list* or treatment as usual or TAU) adj3 (control or group)).ab.)
4. (1 and 2 and 3)
Records are screened for reports of RCTs within the scope of the Cochrane Common Mental Disorders Group. Secondary reports of
RCTs are tagged to the appropriate study record.
Similar weekly search alerts are also conducted on OVID EMBASE and PsycINFO, using relevant subject headings (controlled
vocabularies) and search syntax, appropriate to each resource.
Appendix 2. MEDLINE, EMBASE and PsycINFO search strategies
Ovid MEDLINE was searched using the following terms (30-May-2012):
1. S-ADENOSYLMETHIONINE/
2. 29908-03-0.rn.
3. (s adenosyl$).tw.
4. (SAM-e or Samyr or Ademetionine or Adomet or Adenosylmethionine or Adenoylmethionine or Adenosyl levo Methionine
or Adenosyl l Methionine or Active Methionine or Acylcarnitine or Methioninyladenylate or Gumbaral or fo 1561 or fo1561).tw.
5. or/1-4
6. exp MOOD DISORDERS/
7. DEPRESSION/
8. (depress$ or dysthymi$ or affective disorder$ or adjustment disorder$ or cyclothym$).tw.
9. or/6-8
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10. randomised controlled trial.pt.
11. controlled clinical trial.pt.
12. randomi#ed.ti,ab.
13. placebo$.tw.
14. drug therapy.fs.
15. trial$.ti,ab.
16. groups.ab.
17. randomly.ab.
18. (clinic$ adj3 (trial$ or study or studies$)).ti,ab.
19. ((singl$ or doubl$ or tripl$) adj (blind$ or mask$ or dummy)).ti,ab.
20. (control$ or prospectiv$ or volunteer$).ti,ab.
21. or/10-20
22. exp animals/ not humans.sh.
23. 21 not 22
24. 23 and 9 and 5
Ovid EMBASE was searched using the following terms (30-May-2012):
1. S ADENOSYLMETHIONINE/
2. (s adenosyl$).tw.
3. (SAM-e or Samyr or Ademetionine or Adomet or Adenosylmethionine or Adenoylmethionine or Adenosyl levo Methionine
or Adenosyl l Methionine or Active Methionine or Acylcarnitine or Methioninyladenylate or Gumbaral or fo 1561 or fo1561).tw.
4. 29908-03-0.rn.
5. or/1-4
6. exp MOOD DISORDER/
7. exp DEPRESSION/
8. exp BIPOLAR DISORDER/
9. ADJUSTMENT DISORDER/
10. (depress$ or dysthymi$ or affective disorder$ or adjustment disorder$ or cyclothym$).tw.
11. or/6-10
12. clinical trial.de.
13. controlled clinical trial.de.
14. randomised controlled trial.de.
15. major clinical study.de.
16. double blind procedure.de.
17. single blind procedure.de.
18. randomization.de.
19. placebo.de.
20. prospective study.de.
21. comparative study.de.
22. follow up.de.
23. (randomi#ed or randomly).ti,ab.
24. ((singl$ or doubl$ or tripl$) adj (blind$ or mask$ or dummy)).ti,ab.
25. placebo$.tw.
26. (clinic$ adj3 (trial$ or study or studies$)).ti,ab.
27. comparative stud$.ti,ab.
28. (control$ or prospectiv$ or volunteer$).ti,ab.
29. or/12-28
30. ((animal or nonhuman) not (human and (animal or nonhuman))).de.
31. 29 not 30
32. 31 and 11 and 5
Ovid PsycINFO was searched using the following terms (30-May-2012):
1. (s adenosyl$).tw.
2. (SAM-e or Samyr or Ademetionine or Adomet or Adenosylmethionine or Adenoylmethionine or Adenosyl levo Methionine
or Adenosyl l Methionine or Active Methionine or Acylcarnitine or Methioninyladenylate or Gumbaral or fo 1561 or fo1561).tw.
124S-adenosyl methionine (SAMe) for depression in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
3. or/1-2
4. exp AFFECTIVE DISORDERS/
5. ADJUSTMENT DISORDERS/
6. (depress$ or dysthymi$ or affective disorder$ or adjustment disorder$ or cyclothym$).tw.
7. or/4-6
8. treatment effectiveness evaluation.de.
9. clinical trials.de.
10. placebo.de.
11. treatment outcomes.de.
12. mental health program evaluation.de.
13. evaluation.de.
14. followup studies.de.
15. random$.ti,ab.
16. placebo$.tw.
17. comparative stud$.ti,ab.
18. (clinical adj3 trial$).ti,ab.
19. (research adj3 design).ti,ab.
20. (evaluat$ adj3 stud$).ti,ab.
21. (prospectiv$ adj3 stud$).ti,ab.
22. ((singl$ or doubl$ or tripl$) adj3 (blind$ or mask$ or dummy)).ti,ab.
23. or/8-22
24. (animal NOT (animal and (human or inpatient or outpatient))).po.
25. 23 not 24
26. 25 and 7 and 3
Appendix 3. Dealing with missing data
We contacted trialists to request information and data on missing participants, but were unable to obtain any additional data.
We analysed data on an intention-to-treat (ITT) basis. We were unable to use the last observation carried forward (LOCF) approach
as, in all cases, individual raw participant data were not available. We addressed the missing data as follows.
1. For continuous efficacy outcomes, we imputed missing data using the conservative approach of assuming that these participants had
no change in their mean score on the Hamilton Depression Rating Scale (HAM-D) from baseline to endpoint. As we did not have
access to the raw participant data for their baseline score, we used the mean baseline score of all participants.
To assess the robustness of the assumptions, we carried out sensitivity analyses: we assumed the participants had the same mean change
as the other participants.
Where present, we kept the same original change-from-baseline standard deviation (SD) (Delle Chiaie 2000a; Delle Chiaie 2000b);
otherwise we imputed them. Where possible, we used the SD from another study in the review sufficiently homogeneous in terms
of measurement scales and time period (Delle Chiaie 2000a to impute SD in De Vanna 1992; Delle Chiaie 2000b to impute SD in
Kagan 1990). Otherwise, we calculated the correlation coefficient from the Delle Chiaie 2000a study (c = 0.1) and imputed the change-
from-baseline SDs in the other studies, making use of this imputed correlation coefficient (Bell 1988; Mischoulon 2014; Papakostas
2010a). We then used the SDs thus calculated for the imputed means in each study.
We undertook a sensitivity analysis trying a different value of the correlation coefficient. We used a value of 0.4, as it was the highest
correlation coefficient obtained from the studies reported in considerable detail to calculate it (correlation coefficient of 0.1 was the
lowest value obtained).
In the De Vanna 1992 study, the authors did not specify how they dealt with missing data. We attempted to contact the authors in
order to obtain clarification, but were unsuccessful. As they did not indicate whether they had or not conducted an ITT analysis, we
decided to use the reported data without any imputation, in order to be the most conservative possible. We conducted a sensitivity
analysis for the efficacy data.
2. For dichotomous outcomes, we imputed missing data based on the consideration of a ’worst-case’ scenario. To assess the robustness
of the assumption, we carried out sensitivity analyses based on a ’best-case’ scenario.
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With regard to the outcome ’Acceptability. Participants experiencing specific adverse effects’, in handling missing data, we departed
from the protocol and performed an available-case analysis (Galizia 2014). Given the restricted number of trials and small number of
events, we did not want to overestimate the specific adverse events, such as manic symptoms, etc., by imputing them.
Four studies provided an ITT analysis, using the LOCF approach (Delle Chiaie 2000a; Delle Chiaie 2000b; Papakostas 2010a
Mischoulon 2014). However, in the Mischoulon 2014 study, there were tolerability data available for 166 participants (59 participants
in SAMe group, 55 in escitalopram group and 52 in placebo group) of the 189 randomised. Through contact with the authors, we
established that for the tolerability analysis they focused on participants who had completed at least one postbaseline visit with adverse
effects recorded.
In the Delle Chiaie 2000a trial, of the 281 randomised participants, they excluded three participants in the control group from the
ITT efficacy analysis because one participant received no treatment and two participants received no postbaseline assessment. In the
Delle Chiaie 2000b trial, of the 295 randomised participants, one in the control group received no treatment and one in the SAMe
group received no postbaseline assessment; these two participants were excluded from the ITT efficacy analysis. In the Delle Chiaie
2000a trial, we imputed missing data for two of the three participants who received treatment. Similarly, in the Delle Chiaie 2000b
trial, we imputed data for one of the two missed participants who received treatment. Instead, in both studies, all treated participants
were included in the safety evaluation.
Overall, we imputed missing data as follows.
For the outcome ’Change in mean score from baseline to end of treatment on depression rating scale’, under the comparison ’S-adenosyl
methionine versus placebo as monotherapy’, we imputed missing data for Kagan 1990; under the comparison ’S-adenosyl methionine
versus an active antidepressant agent as monotherapy’, we imputed missing data for Bell 1988; Delle Chiaie 2000a; Delle Chiaie 2000b;
and De Vanna 1992.
For the outcome ’Efficacy. Response to treatment’, under the comparison ’S-adenosyl methionine versus placebo as monotherapy’,
we imputed missing data for Kagan 1990; under the comparison ’S-adenosyl methionine versus an active antidepressant agent as
monotherapy’, we imputed missing data for Bell 1988; Bell 1994; Delle Chiaie 2000a; and Delle Chiaie 2000b.
For the outcome ’Acceptability. Participants experiencing troublesome adverse effects of any nature’, under the comparison ’S-adenosyl
methionine versus placebo as monotherapy’ we imputed missing data for Kagan 1990.
There was no need to impute missing data in the Papakostas 2010a and Mischoulon 2014 studies, for the analysed outcomes.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Our protocol restricted the age range of participants to 18 to 70 years (Galizia 2014). Three studies provided participants over the
range 18 to 80 years (De Vanna 1992; Mischoulon 2014; Papakostas 2010a). We decided to include these studies after consideration
of the participants mean age.
In the Bell 1988 study, one participant in the comparison group reported a past episode of mania. As per protocol, we should have
excluded participants with bipolar depression.We decided to include this study because this conditionwas limited to only one participant
and nothing in the text showed that he experienced a different response to treatment or had a manic switch during the trial.
As per protocol, we analysed data on an ITT basis. However, we were unable to use the LOCF approach and imputed the missing data
differently (for a full explanation of imputation strategy see Appendix 3). We did not perform any imputation for the De Vanna 1992
study: because the authors did not specify how they dealt with missing data (by ITT or not) and we decided to use only the reported
data, in order to be as conservative as possible. Further, we departed from the protocol in dealing with missing data for the outcome
’Participants experiencing specific adverse effects’. Given the restricted number of trials and events, we performed an available-case
analysis, in order to avoid overestimating the specific adverse events, such as manic symptoms, etc., through the imputation of data.
In the protocol, we defined the outcome ’Response to treatment’ as a 50% reduction or greater in depression score from baseline to end
of treatment where this was clinically meaningful. However, it was difficult to define clinical meaningfulness so we used 50% reduction
only.
Lastly, in the ’Summary of findings’ table, we added the outcome ’Participants experiencing troublesome adverse effects of any nature’
as we found evidence that we considered to be of interest to the reader. In addition, as we exceeded the maximum number of outcomes
for ’Summary of findings’ tables, which is seven, we removed the outcome ’Reported adverse events’; most studies did not detail the
specific adverse effects or were often described with considerable heterogeneity, precluding a complete quantitative analysis of these
data.
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